

Annual Report

The 10th Accounting Period
From January 1, 2020
To December 31, 2020

※ Disclaimer

This document was disclosed voluntarily for foreign investors. The original Korean version of the disclosure can be found on KIND(<http://kind.krx.co.kr>), DART(<http://dart.fss.or.kr>). If and when there is any discrepancy between the English and Korean versions, the Korean text shall prevail. Therefore, it is essential for the investors to consult the Korean text before making investment decisions.

To. Financial Services Commission
Korea Exchange

March 31, 2021

Type of Corporation Subject to Submit	Stock-listed Corporation
Reason for Exemption	Not applicable
Name of Company	Samsung Biologics Co., Ltd.
CEO	Rim John Chongbo
Place of Principal Office	300, Songdo Bio-daero, Yeonsu-gu, Incheon, Korea (Songdo-dong, Samsung Biologics Co., Ltd.) (Tel.) 82-032-455-3114 (Homepage) http://www.samsungbiologics.com
Principal Officer	(Title) Director of Business Support Center (Name) Kim Dongjoong (Tel.) 82-032-455-3114

I. Company Overview

1. Company Overview

A. Legal and commercial name

The Company's name is 'Samsung Biologics Co., Ltd.'

B. Establishment date

Samsung Biologics Co., Ltd. was established on April 22, 2011.

C. Address, telephone number, and homepage

Address of head office: 300, Songdo Bio-daero, Yeonsu-gu, Incheon, South Korea
(Songdo-dong, Samsung Biologics Co., Ltd.)

Telephone number: 82-032-455-3114

Homepage: www.samsungbiologics.com

D. Status of SME

Samsung Biologics Co., Ltd. (hereinafter, the Company) does not fall within small and medium enterprises (SMEs) in accordance with Article 2 of the Framework Act of Small and Medium Enterprises and Article 3 of the Enforcement Decree of the Framework Act on Small and Medium Enterprises as of the date when the report is submitted.

E. Main business

The Company provides CMO (Contract Manufacturing Organization) services that serve other domestic and international pharmaceutical companies on a contract basis to produce high-tech bio-medicines and CDO (Contract Development Organization) services that serve cell line development and process development, CRO (Contract Research Organization) services that serve the exploration of drug candidate materials, biological stability/toxicity analysis in the cell line development, and homogeneity verification and cell storage as of the date when the report is submitted. For the details of business by segment, refer to II. Business Overview.

F. Matters regarding affiliates

The Company is an affiliate of Samsung Group under the Monopoly Regulation and Fair Trade Act, which has 59 domestic affiliates including 16 listed companies and 43 unlisted companies on December 31, 2020.

(As of December 31, 2020)

Category	No. of companies	Name of company	Business registration no.
Listed companies	16	Samsung C&T Corporation	1101110015762
		Samsung Biologics Co., Ltd.	1201110566317
		Samsung Life Insurance Co., Ltd.	1101110005953
		Samsung SDI Co., Ltd.	1101110394174
		Samsung SDS Co., Ltd.	1101110398556
		Samsung Engineering Co., Ltd.	1101110240509
		Samsung Electro-Mechanics Co., Ltd.	1301110001626
		Samsung Electronics Co., Ltd.	1301110006246
		Samsung Heavy Industries Co., Ltd.	1101110168595
		Samsung Securities Co., Ltd.	1101110335649
		Samsung Card Co., Ltd.	1101110346901
		Samsung Fire & Marine Insurance Co., Ltd.	1101110005078
		Multicampus Corporation	1101111960792
		S-1 Corporation	1101110221939
		Cheil Worldwide Inc.	1101110139017
		Hotel Shilla Co., Ltd.	1101110145519
Unlisted companies	43	Samsung Display Co., Ltd.	1345110187812
		Samsung Medison Co., Ltd.	1346110001036
		Samsung Bioepis Co., Ltd.	1201110601501
		Samsung Venture Investment Corporation	1101111785538
		Samsung Life Service Claim Adjustment Co., Ltd.	1101111855414
		Samsung Futures Inc.	1101110894520
		Samsung Active Asset Management Co., Ltd.	1101116277382
		Samsung SRA Asset Management Co., Ltd.	1101115004322
		Samsung Welstory Co., Ltd.	1101115282077
		Samsung Asset Management Co., Ltd.	1701110139833
		Samsung Electronics Logitech Corporation	1301110046797
		Samsung Electronics Service Co., Ltd.	1301110049139
		Samsung Electronics Service CS Co., Ltd	1358110352541
		Samsung Electronics Sales Co., Ltd.	1801110210300
		Samsung Card Customer Service Co., Ltd.	1101115291656
		Samsung Corning Advanced Glass LLC.	1648110138904
		Samsung Hedge Asset Management Co., Ltd.	1101116277390
		Samsung Fire Service Co., Ltd.	1101111237703
		Samsung Claim Adjustment Service Co., Ltd.	1101111595680
		SEMES Co., Ltd.	1615110011795
		Suwon Samsung Football Club Co., Ltd.	1358110160126
		Steel Structure Technologies Co., Ltd. (STECO)	1647110003490

Category	No. of companies	Name of company	Business registration no.
		Shilla Stay Co., Ltd.	1101115433927
		SD Flex Co., Ltd.	1760110039005
		SBTM Co., Ltd.	1101116536556
		S1CRM Corporation	1358110190199
		SUMaterials Co., Ltd.	1648110061337
		S-Core Co., Ltd.	1101113681031
		STM Co., Ltd.	2301110176840
		HDC Shilla Duty Free Ltd.	1101115722916
		Open Hands Co., Ltd.	1311110266146
		Cheil Fashion Retail Co., Ltd.	1101114736934
		Miracom Inc Co., Ltd.	1101111617533
		Samsung Economic Research Institute (SERI)	1101110766670
		Samsung Lions Co., Ltd.	1701110015786
		Samsung Life Financial Service Co., Ltd.	1101115714533
		Samsung Fire & Marine Financial Service Co., Ltd.	1101116002424
		Samwoo Architects & Engineers Co., Ltd.	1101115494151
		Seoul Lake Side Co., Ltd.	1101110504070
		SECUI Co., Ltd.	1101111912503
		CVnet Corporation	1101111931686
		Harman International Korea	1101113145673
		Human TSS Co., Ltd.	1101114272706
Total	59		

※ For the details of domestic and international affiliates, refer to IX. Matters Regarding Affiliates.

G. Overview of the consolidated subsidiaries

(Unit : million won)

Name of Company	Established Date	Address	Main business	Total asset of the last business years	Basis of a dominant-subordinate relationship	Major Subsidiary
Samsung Biologics America, Inc.	2020.01	California, U.S.	Biologics R&D	15,398	Majority ownership of voting rights (K-IFRS 1110)	X

H. Changes in the consolidated subsidiaries

	Subsidiary	Reason
New	Samsung biologics America, Inc.	Established in the current period
	-	-
Exclusion	-	-
	-	-

I. Matters regarding credit rating

Date	Securities	Ratings	Credit Rating Agency (Rating Range)	Note
2018.02.12	Corporate Credit Rating	-	Korea Investors Service (AAA~D)	Initial rating
2018.03.14	Corporate Credit Rating	-	NICE Investors Service (AAA~D)	Initial rating
2018.03.16	Corporate Credit Rating	-	Korea Ratings (AAA~D)	Initial rating
2018.04.23	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Initial rating
2018.04.25	6-1,6-2 Private non-guaranteed bond	-	Korea Investors Service (AAA~D)	Initial rating
2018.05.04	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Non-periodic rating
2018.07.20	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Non-periodic rating
2018.10.19	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Non-periodic rating
2018.11.15	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Non-periodic rating
2019.02.15	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Non-periodic rating
2019.05.15	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Periodic rating
2019.06.18	6-1,6-2 Private non-guaranteed bond	-	Korea Investors Service (AAA~D)	Periodic rating
2019.08.14	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Non-periodic rating
2019.10.07	6-1,6-2 Private non-guaranteed bond	-	Korea Investors Service (AAA~D)	Non-periodic rating
2019.11.15	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Non-periodic rating
2020.02.07	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Non-periodic rating
2020.05.07	6-1,6-2 Private non-guaranteed bond	-	Korea Ratings (AAA~D)	Non-periodic rating
2020.07.15	6-1,6-2 Private non-guaranteed bond	-	Korea Investors Service (AAA~D)	Non-periodic rating

- The credit rating is not entered according to the condition not to be disclosed.

J. Stock listing (or registration/designation) and special technology listing

Listing (or Registration/Designation)	Listing (or Registration/Designation) Date	Technical Listing	Applicable Laws incl. Technical Listing
Listed on KOSPI (securities market)	2016.11.10	Not applicable	Not applicable

2. Company History

A. Place of principal office and its changes

Changes in the place of principal office since the establishment of the Company are as follows:

Date	Address	Remarks
2011.04.22	104-B, Pilot Plant, 7-50, Songdo-dong, Yeonsu-gu, Incheon, South Korea	Establishment
2012.01.26	30-3, Songdo Technopark IT Center M, 172-1, Songdo-dong, Yeonsu-gu, Incheon, South Korea	-
2012.06.26	201-2, Songdo-dong, Yeonsu-gu, Incheon, South Korea	-
2014.01.07	125, Cheomdan-daero, Yeonsu-gu, Incheon, South Korea (Songdo-dong, Samsung Biologics Co., Ltd.)	Replacement with a road name-based address
2016.07.04	300 Songdo Bio-daero, Yeonsu-gu, Incheon, South Korea	Change of the road name-based address

B. Important changes in management executives (change of more than 1/3 including CEO)

On August 10, 2016, Executive director Lee Kyusung resigned from the board, and Kim Dongjoong was newly appointed as Executive director. Other Non-Executive directors Kang Wooyoung and Anand Tharmaratnam resigned. Independent director Jeong Seokwoo, Yoon Byungchol, and Kwon Soonjo were newly appointed. Auditor Kim Yongkwan resigned.

On March 22, 2019, Independent director Yoon Byungchol retired and Heo Guennyong was newly appointed as Independent director.

On March 20, 2020, Executive director John Rim was appointed as the new Chief Executive Officer and Kim Taehan resigned from his position of Chief Executive Director.

As of the reporting date on December 31, 2020, the Company's Board consists of three Executive directors (Kim Taehan, John Rim, and Kim Dongjoong) and four Independent directors (Jeong Seokwoo, Kwon Soonjo, Heo Geunyoung, and Eunice Kim).

C. Changes in the largest shareholder

Date	Before	After	Remarks
2014.07.04	Samsung Everland Inc. Samsung Electronics Co., Ltd.	(Old) Cheil Industries Inc. Samsung Electronics Co., Ltd.	The largest shareholder's company name is changed.

2015.09.02	(Old) Cheil Industries Inc. Samsung Electronics Co., Ltd.	Samsung C&T Corporation	After (Old) Cheil Industries Inc. and (Old) Samsung C&T Corporation were merged, the company name of (Old) Cheil Industries Inc. was changed to Samsung C&T Corporation.
------------	--	-------------------------	--

D. Change of trade name

- Not applicable

E. Details and results in case the Company went through or currently goes through compositions, reorganization proceedings, and other equivalents

- Not applicable

F. Details in case the Company experienced merges

Biogen Therapeutics Inc. has a call option that allows it to purchase up to 50%-1 shares of Samsung Bioepis under an agreement between shareholders on December 6, 2011.

On June 29, 2018, Biogen Therapeutics Inc. exercised the call option, and on November 7, the transfer of shares and payments were completed.

Category	Dates
Contract Between Shareholders	2011.12.06
Evaluation of external evaluation agencies	2018.06.22 ~ 2018.06.29
Key item report submission date	2018.06.29
Transfer of shares and payment date	2018.11.07

G. Type of business or changes in main business

- Not applicable

H. Other important matters related to the management activities

Date	Details
2011.04.22	Established Samsung Biologics Co., Ltd.
2011.04.28	Signed a lease agreement for the plant site in Songdo
2011.05.06	Started the construction of Songdo Plant #1
2012.02.28	Established Samsung Bioepis Co., Ltd.
2013.07.18	Signed a contract with BMS regarding DS manufacturing
2013.09.23	Started the construction of Songdo Plant #2
2013.10.18	Signed a contract with Roche regarding DS manufacturing
2014.04.16	Signed a contract with BMS regarding DS manufacturing enhancement and DP manufacturing
2014.06.23	Established a joint venture, Archigen Biotech Ltd.
2014.07.04	Changed the largest shareholder's company name (Samsung Everland Inc. → Cheil Industries Inc.)

Date	Details
2015.09.02	Changed the largest shareholders (Before: Samsung Electronics Co., Ltd. 46.79%, Cheil Industries Inc. 46.79%, Samsung C&T Corporation 4.25% → After: Samsung C&T Corporation 51.04%, Samsung Electronics Co., Ltd. 46.79%)
2015.11.12	Started the construction of Songdo Plant #3
2015.11.30	Obtained an approval of Songdo Plant #1's manufacturing license from FDA (no observation)
2016.04.01	Signed a contract with Samsung Bioepis regarding biosimilar manufacturing
2016.05.03	Signed a contract with a US pharmaceutical company regarding DP manufacturing
2016.07.29	Obtained an approval of Songdo Plant #1's manufacturing license from EMA
2016.11.10	Became listed on the KOSPI
2016.11.16	Signed a contract with Cilag regarding DS manufacturing
2017.01.24	Signed a contract with a Swiss pharmaceutical company regarding DS manufacturing
2017.07.04	Signed a contract with Sun Pharma regarding DS manufacturing
2017.07.20	Signed a contract with a Europe pharmaceutical company regarding DS manufacturing
2017.09.06	Signed LOI with Ichnos Science regarding DS manufacturing
2017.09.22	Obtained an approval of Songdo Plant #2's manufacturing license from FDA
2017.11.08	Signed a contract with a US pharmaceutical company regarding DS manufacturing
2017.12.21	Obtained an approval of Songdo Plant #2's manufacturing license from EMA
2017.12.21	Signed a contract with UCB regarding DS manufacturing
2018.02.01	Signed an additional contract with a Asia pharmaceutical company regarding DS manufacturing
2018.02.21	Signed a contract with an US pharmaceutical company regarding DS manufacturing
2018.04.30	Signed an additional contract with a Europe pharmaceutical company regarding DS manufacturing
2018.06.01	Signed a contract Ichnos Sciences S.A. regarding DS manufacturing
2018.06.29	Biogen's execution of call option and Stock transfer decision
2018.08.14	Signed a contract with an Asia pharmaceutical company regarding DS manufacturing
2018.09.11	Signed a contract with Immunomedics, Inc. regarding DS manufacturing
2018.11.07	Transfer of 9,226,068 Samsung Bioepis' shares to Biogen Therapeutics Inc.
2019.04.01	Signed a contract with Cytodyn Inc. regarding DS manufacturing
2019.04.26	Signed a contract with an Asia pharmaceutical company regarding DS manufacturing
2019.04.26	Signed a contract with an Asia pharmaceutical company regarding DS manufacturing
2019.05.14	Signed a contract with an Asia pharmaceutical company regarding DS manufacturing
2019.05.17	Signed a contract with UCB regarding DS manufacturing
2019.11.05	Signed an additional contract with Ichnos Sciences S.A. regarding DS manufacturing
2019.11.28	Signed a contract with an Asia pharmaceutical company regarding DS manufacturing
2019.12.03	Signed a contract with an US pharmaceutical company regarding DS manufacturing
2019.12.24	Signed a contract with a Swiss pharmaceutical company regarding DS manufacturing
2020.01.29	Established Samsung Biologics America, Inc.
2020.04.23	Signed an additional contract with Immunomedics regarding DS manufacturing
2020.07.27	Signed a contract with Eli Lilly and Company regarding DS manufacturing
2020.08.05	Signed a contract with GlaxoSmithKline Trading Limited regarding DS manufacturing
2020.08.05	Launched the proprietary cell line technology, S-CHOice
2020.09.21	Signed a contract with AstraZeneca UK Ltd. regarding DS/DP manufacturing
2020.10.29	Established CDO R&D center in San Francisco, U.S.
2020.11.18	Started the construction of Songdo Plant #4

3. Changes in Paid-in Capital

- Status of capital increase (decrease)

(As of December 31, 2020)

(Unit: won, share)

Date of stock issuance (reduction)	Type of issuance (reduction)	Details of issued(reduced) shares				
		Class	Volume	Face value per share	Amount issued(reduced) per share	Remarks
2011.04.22	-	Common stocks	1,500,000	5,000	50,000	Establishment
2011.09.07	Capital increase with consideration by allocation to shareholders	Common stocks	1,500,000	5,000	50,000	Increase rates of 100%
2012.01.18	Capital increase with consideration by allocation to shareholders	Common stocks	1,500,000	5,000	50,000	Increase rates of 50%
2012.02.23	Capital increase with consideration by allocation to shareholders	Common stocks	2,916,567	5,000	48,000	Increase rates of 65%
2012.04.19	Capital increase with consideration by allocation to shareholders	Common stocks	1,500,000	5,000	50,000	Increase rates of 20%
2012.08.21	Capital increase with consideration by allocation to shareholders	Common stocks	1,355,931	5,000	47,200	Increase rates of 15%
2013.02.19	Capital increase with consideration by allocation to shareholders	Common stocks	866,007	5,000	46,189	Increase rates of 8%
2013.08.20	Capital increase with consideration by allocation to shareholders	Common stocks	748,520	5,000	43,345	Increase rates of 7%
2014.02.20	Capital increase with consideration by allocation to shareholders	Common stocks	4,181,064	5,000	40,516	Increase rates of 35%
2014.08.21	Capital increase with consideration by allocation to shareholders	Common stocks	4,298,560	5,000	38,478	Increase rates of 27%
2015.02.24	Capital increase with consideration by allocation to shareholders	Common stocks	3,538,930	5,000	37,695	Increase rates of 17%
2015.08.20	Capital increase with consideration by allocation to shareholders	Common stocks	3,663,142	5,000	36,526	Increase rates of 15%
2016.09.12	Stock split	Common stocks	27,568,721	2,500	-	-
2016.11.07	Capital increase with consideration by ordinary public offering	Common stocks	11,027,558	2,500	136,000	Increase rates of 20%

4. Stock Information

A. Total number of shares

(As of December 31, 2020)

(Unit: share)

Classification		Class			Remarks
		Common stock	Preferred stock	Total	
I . Number of authorized shares		500,000,000	-	500,000,000	-
II. Number of shares issued		66,165,000	-	66,165,000	-
III. Number of shares decreased		-	-	-	-
	1. Capital reduction	-	-	-	-
	2. Number of shares canceled	-	-	-	-
	3. Redemption of redeemable shares	-	-	-	-
	4. Others	-	-	-	-
IV. Number of outstanding shares (II-III)		66,165,000	-	66,165,000	-
V . Treasury shares		-	-	-	-
VI. Number of floating shares (IV- V)		66,165,000	-	66,165,000	-

B. Treasury Shares

- Not applicable

C. Types of Registered Stock

- Not applicable

5. Voting Shares

The Company has 66,165,000 shares of common stock outstanding, which account for 13.23% of the total number of authorized shares (500 million shares). The number of shares available for exercising the voting right is 66,116,300 shares excluding 48,700 shares in a special account of Samsung Life Insurance Co., Ltd. which is a financial affiliate.

(As of December 31, 2020)

(Unit: share)

Classification		Number of shares	Remarks
Number of outstanding shares (A)	Common stock	66,165,000	-
	Preferred stock	-	-
Number of shares with no voting	Common stock	-	-

Classification		Number of shares	Remarks
rights (B)	Preferred stock	-	-
Number of shares with no voting rights according to articles of incorporation (C)	Common stock	-	-
	Preferred stock	-	-
Number of shares with limited voting rights under relevant laws (D)	Common stock	48,700	Special account of Samsung Life Insurance Co., Ltd. excluded in accordance with the Insurance Act
	Preferred stock	-	
Number of shares with revived voting rights(E)	Common stock	-	-
	Preferred stock	-	-
Number of shares with voting rights (F = A - B - C - D + E)	Common stock	66,116,300	-
	Preferred stock	-	-

6. Shareholder Return

A. Matters regarding dividends

Description	Class	2020	2019	2018
Face value per share (won)		2,500	2,500	2,500
(Consolidated) Current net income (million won)		240,975	202,904	224,109
(Separate) Current net income (million won)		250,969	-	-
(Consolidated) Earnings per share (won)		3,642	3,067	3,387
Total cash dividends (million won)		-	-	-
Total stock dividends (million won)		-	-	-
(Consolidated) Cash dividends payout ratio (%)		-	-	-
Cash dividends payout ratio (%)	Common	-	-	-
	Preferred	-	-	-
Stock dividends payout ratio (%)	Common	-	-	-
	Preferred	-	-	-
Cash dividends per share (won)	Common	-	-	-
	Preferred	-	-	-
Stock dividends per share (share)	Common	-	-	-
	Preferred	-	-	-

※ Information provided for 2018 and 2019 is based on separate financial statements, and information for 2020 is based on consolidated financial statements.

B. Dividend History

Number of consecutive dividend payout		Average dividend payout	
Quarterly(Interim) dividend	Annual dividend	3-year	5-year
-	-	-	-

※ The Company has no dividend payout history in the past five years.

7. Matters regarding articles of incorporation

Amendment record

Date of change	Meeting name	Description	Reason
2019.03.22	8 th Annual General Meeting	<p>Article 8 (Classes of Shares and Share Certificates) Section ⑦ - Deleted</p> <p>Article 8-2 (Electronic registration on Rights to be Indicated on Shares and Stock Warrant Certificates) Section ③ - Amended</p> <p>Article 9 (Transfer agent) Section ③ - Amended</p> <p>Article 10 (Shareholders' Obligation to report on address, name and signet or signature) – Deleted</p> <p>Article 17-2 (Electronic registration on Rights to be Indicated on Bonds and Stock Warrant Certificates) - Introduced</p> <p>Article 18 (Applicable Provisions regarding Issuance of Bonds) – Post-amendment Review of Section</p> <p>Article 33 (Duties of Directors) Section ③ - Amended</p> <p>Article 42 (Composition of Audit Committee) ⑦ - Introduced</p> <p>Article 43 (Duties, etc. of Audit Committee) Section ⑥ - Amended</p>	<p>- Amendment/Deletion of relevant articles following the enactment of the Act on Electronic Registration of Stocks, Bonds, etc.</p> <p>- Reflection of flexible operation scheme and exception regulation of BOD following the leave of CEO/Member of Audit committee</p> <p>- Reflection of changes in rights to select an outside independent auditor following the amendment of the Act on External Audit of Stock Companies</p>

※ The latest date of change in the Company's articles of incorporation is March 22, 2019. No change was made at the Company's 10th Annual General Meeting, held on March 19, 2021.

II. Business Overview

1. Business Overview

Samsung Biologics is a global CMO/CDO/CRO provider equipped with a batch production system for biopharmaceuticals. The company is currently specialized in CMO business operation which is focused on manufacturing biopharmaceuticals on a contract basis. The company is also engaged in CDO business by providing services from cell lines to initial clinical trials including cell line development, processes development, and formulation/analysis methodology. The company's CRO business supports the exploration of drug candidate materials, biological stability/toxicity analysis in cell line development, and homogeneity verification and cell storage. The company seeks to become a One-Stop, End-to-End Service Provider through these three business areas. In addition, the company's subsidiary, Samsung Bioepis is a biopharmaceuticals research & development firm that is working on the development and commercialization of biosimilars, and the company has established a subsidiary Samsung Biologics America, Inc. in the United States for stable CDO business orders and overseas base expansion.

A. Industry status

(1) Characteristics of business

(A) Industry trends

The bio contract manufacturing organization (CMO) business is for global pharmaceutical companies that either lack its own production capability or strategically outsource its production to mainly focus on drug R&D and marketing. Bio-pharmaceutical products are expected to lead the growth in the overall pharmaceutical market with its high growth rate of 10.5%(Evaluate Pharma, Jan 2021), and the utilization of CMO by pharmaceutical companies is increasing along with the rapid growth of the bio-pharmaceutical market. The CMO business operation requires competitive manufacturing cost, speed in production and supply, and a stable capability to win contracts based on essential quality control capabilities in the drug manufacturing processes.

Antibody medication, which is SBL's field of focus, requires a large investment in commercial plant construction and is characterized by a project that takes at least three years to prepare for commercialization such as plant design, construction, and validation. In addition, antibody medication requires a high level of quality control capability that conforms to Good Manufacturing Practices (GMP) throughout the entire production processes including cell culture, purification, and filling which all use animal cells. Additionally, it generally takes more than two years for pharmaceutical companies to prepare for the production of commercial bio-pharmaceuticals through CMOs after technology transfer, test production, diverse national pharmaceutical regulatory GMP, and others. Hence, CMO contracts with pharmaceutical companies are usually based on 5 ~ 10-year long-term contracts.

(2) Growth potential

(A) Growth factor of market

Growth factors of the biopharmaceutical CMO market are as follows:

1) Continued development of blockbuster biopharmaceuticals

Blockbuster biopharmaceuticals released around the year 2000 (immunosuppressant drugs, anticancer drugs, antidiabetic drugs, etc.) still show a high level of sales growth, and new promising antibody drugs for hyperlipidemia, Alzheimer's disease, and atopic dermatitis along with immune checkpoint inhibitors continue to be released.

2) Expansion of production outsourcing by global manufacturing companies

Pharmaceutical companies are expanding the areas of production outsourcing to specialized CMOs where massive capital investments are required to minimize the uncertainty in marketing authorization and sales forecasting of drugs. This market change gives a new opportunity to CMOs.

3) Increasing demand for dual sourcing to secure supply stability

Recently, regulatory authorities across the world have strongly recommended pharmaceutical companies to secure a source for stable drug production. The U.S. Food and Drug Administration (FDA) requested pharmaceutical companies to establish a contingency plan, believing that supply stability cannot be guaranteed in case the drug is manufactured in a single site. Accordingly, pharmaceutical companies are making use of CMOs to run multiple manufacturers for a single drug.

4) Drug patent expiration to boost biosimilars market

The biosimilars market is expected to continue enjoying massive growth as most blockbuster biosimilar drugs such as Humira, Herceptin, Remicade, and Lantus are coming off patent. In this way, the biosimilar market expansion is expected to further accelerate an increase in demand for overall biopharmaceutical production.

(B) Market size and forecast

In 2020, the global biopharmaceutical market is valued at USD 285.1 billion, which accounts for 30.1% of the entire pharmaceutical market. The market is expected to increase with an average growth rate of 10.5% and reach USD 481.3 billion by 2025, which accounts for 35.7% of the global pharmaceutical market (EvaluatePharma, Jan 2021).

The global bio-CDMO market is valued at USD 13.3 billion in 2020 and is forecasted to reach USD 25.3 billion by 2025 at an average growth rate of 13.7% for the next five years. (Frost & Sullivan, Oct 2019)



(3) Characteristics of economic fluctuation

- Not applicable

(4) Competition status

The Company runs a bio-CMO business specialized in manufacturing mammalian cell-based antibody drugs, the major component of the biopharmaceutical market. The bio-CMO market is oligopolistic, dominated by a few players with large-scale manufacturing facilities such as Samsung Biologics. Switzerland-based Lonza has 250,000-liter mammalian cell culture facilities while Germany-based Boehringer Ingelheim has 290,000-liter manufacturing plants in Germany and the United States.

Samsung Biologics runs 364,000 liter-production facilities as of the end of 2020 as it kicked off production of 180,000 liters at Plant#3 in 2018 and became the world's top CMO in terms of production capacity by surpassing established vendors.

(5) Raw material sourcing

CMO production is designed to receive manufacturing technologies from customers and produce products that meet the customers' needs. In case a customer supplies raw materials free of charge or a customer designates a supplier, CMOs like the Company separately sign long-term supply contracts with suppliers, which is a system that allows for a stable supply of raw materials.

(6) Related laws or government regulations

Regulatory authorities from all over the world have separate laws on manufacturing license by item and approve the license after verifying the overall system of manufacturing process and quality control of drugs through on-site inspection of new manufacturing facilities. The Company successfully obtained a

total of 7 manufacturing licenses for Plant #1 from the FDA and EMA as of the end of 2016, proving its competitiveness in offering world-class quality.

B. Company Status

(1) Operation and Production

The Company has emerged as a global leader in biologics CMO services by securing a total of 364,000-liter capacity including 360,000-liter production facilities for commercial drugs (Plant#1: 30,000 liters, Plant#2: 150,000 liters, and Plant#3: 180,000 liters) and 4,000-liter production facilities for clinical drugs in the Incheon Free Economic Zone (Songdo). The Company will solidify its global top position after the completion of ongoing Plant#4(256,000 liters) construction by 2023.

(A) Production activities

If the Company signs a CMO contract with a customer, the customer first transfers its manufacturing technologies to the Company which is called 'Tech Transfer.' The most important thing in this process is to minimize the difference between processes by applying the customer's original process into the Company's process. Next, manufacturing stability tests through a series of pilot production such as Engineering Run and Process Validation Run are carried out. If stability is believed to be secured, it is needed to apply for a manufacturing approval for produced products and production process to regulatory authorities (FDA, EMA, etc.).

The Company cultures high-quality cells using a titer appropriate for a customer's product specification through an upstream process and refines active pharmaceutical ingredients through a downstream process. All manufacturing processes need to strictly conform to each country's good manufacturing practice and a customer has a right to request the Company for inspection and necessary measures for the overall manufacturing process. The Company also has to document all procedures and results and submit them to the customer and regulatory authorities.

(B) Biologics manufacturing plants

[SBL Manufacturing plants]

Category	Plant #1	Plant #2	Plant #3	Plant #4
Location	Songdo	Songdo	Songdo	Songdo
Scope	30,000 L (5,000 L x 6 units)	154,000 L (15,000 L x 10 units, 1,000 L x 4 units)	180,000 L (15,000 L x 12 units)	256,000 L (15,000 L x 12 units, 10,000L x 6 units, 2,000L x 8 units)
Construction period	25 months	29 months	35 months	36 months
Construction cost	KRW 350 billion won (USD 300 million)	KRW 700 billion (USD 650 million)	KRW 850 billion (USD 740 million)	KRW 1.74 trillion estimated (USD 1.47 billion)
Status	Commercial production	Commercial production	Commercial production	Construction in progress

※ Construction cost converted to USD was calculated by applying average exchange rate during the applicable plant construction period.

※ Information on Plant#4 is based on the approval from the Board of Directors meeting, held on August 11, 2020.

(C) Sales activities

The Company's global contract sales division is in charge of new business operation and sales activities, and supports the activities for winning new contracts utilizing local manpower in main strongholds in the Eastern and Western states of the United States including San Francisco, Boston, and New Jersey. The sales division regularly holds meetings with global pharmaceutical companies and provides them with information on the Company's CMO services and manufacturing facilities at the meetings. The division also continuously sends sales and marketing representatives to overseas bio-conferences to identify latest technology trends in the market and contact potential customers as part of strategy to maintain a strategic relationship with customers. In addition, the company has established non-face-to-face platforms such as virtual exhibition halls and live virtual tour and inspection systems to minimize the impact of COVID-19 prolonged period, and are strengthening non-face-to-face activities such as video conferencing with customers and Webinar.

(2) Market share

The Company rose to the top in CMO services with a total of 364,000-liter production capacity as Plant#3 with 180,000-liter production capacity began operations in 2018. The Company's facility capacity accounts for 26% of the global CMO capacity (1.40 million liters), ranking with Lonza (Switzerland, 250,000 liters, 18%) and Boehringer Ingelheim (Germany, 290,000 liters, 21%).

(3) Details and prospect of new business

The Company is expanding its business area from CMO(Contract Manufacturing Organization) oriented business to CDO(Contract Development Organization) business to become a global No.1 CMO / CDO / CRO company.

CDO services provide cell line development and process development for small and medium-sized pharmaceutical companies which do not possess the capacity for cell line development and process development. CDO business is expected to confront 10% annual growth rate with an increase in small biotech companies and biosimilar antibody pipelines. In 2020, the Company opened its first global CDO R&D center in the renowned San Francisco Biopharma Cluster and currently plans to widen the scope of the market including Boston, Europe, and China.

Meanwhile, CRO (Contract Research Organization) business based on the capabilities of the existing quality analysis laboratory is underway, and related business capabilities are being strengthened.

2. Matters regarding major product

A. Major products

(Unit: million won)

Business Unit	Type	Item	2020		2019		2018	
			Amount	Share	Amount	Share	Amount	Share
CMO	Goods	Biologics	1,102,593	94.7%	648,375	92.4%	528,228	98.6%
	Services	Others	62,184	5.3%	53,217	7.6%	7,578	1.4%
Total			1,164,777	100.0%	701,592	100.0%	535,806	100.0%

※ Consolidated basis In accordance with K-IFRS.

B. Price fluctuation of major products

The selling prices of products manufactured or to be manufactured by the Company can be adjusted according to contract conditions, for instance being adjusted by the ratio calculated by reflecting the annually-announced CPI (Customer Price index) in the initially-determined selling price or being increased at the fixed rate determined by a contract.

3. Major raw materials

A. Purchase of major raw materials

(Unit: million won)

Business Unit	Type	Item	Amount of purchase	Ratio	Remarks (place of purchase)
CMO	Raw materials	Resin, etc.	278,424	60.3%	- Global Life Sciences Solutions Singapore, Merck Limited, Avanto Performance Material Korea, etc.
	Auxiliary materials	Filter, etc.	183,131	39.7%	- Merck Limited, Sartorius Korea Biotech, etc.
Total			461,555	100.0%	-

- ※ The CMO industry generally gets a full refund of raw/auxiliary materials and handling fees that belong to BOM (Bill of Material) from customers.
- ※ Consolidated basis In accordance with K-IFRS.

B. Raw materials price trends and major components

Quality check of raw materials to be used by the Company for drug production is performed by a customer, or purchase is made through a supplier designated by the customer, and the cost of purchasing raw materials is refunded (ex post settlement) from the customer. Therefore, the risks relating to the purchase of raw materials like price fluctuation due to the contract terms are limited.

Meanwhile, the Company signs a long-term contract with a raw material supplier to get a stable supply of raw materials and applies the inflation rate (about 1~2%) level of raise to a price increase. Therefore, risks relating to price fluctuation due to the contract terms are limited.

4. Matters regarding production and manufacturing facilities

A. Production Capacity, Production Performance and Operating Rate

The Company calculates production capacity based on 330-day operations excluding 30 days out of 60 days of slowdown which is a biennial inspection, by reflecting diverse factors including the number of products produced and batch production intervals according to the characteristics of products (pilot production, production for certification, and commercial production) considering actual production conditions.

(Unit: batch)

	2020	2019	2018
Production capacity	392	418	220
Production performance	237	174	155
Operating rate	60.5%	41.6%	70.5%

※ Production capacity of 2018 reflects the completion of Plant#3 at the end of Oct 2018

B. Mattering regarding manufacturing facilities

(1) Manufacturing facilities

(Unit: million won)

Assets	Beginning of year	Acquisition	Disposal	Depreciation	Other increase/reduction	End of year	Remarks
Land	-	-	-	-	-	-	Note 1)
Building	718,993	-	(1,251)	(19,576)	2,683	700,849	-
Fixtures	9,187	-	-	(259)	495	9,423	-
Machinery	918,900	1,519	(69)	(104,368)	86,072	902,054	-
Vehicles	263	82	(1)	(149)	11	206	-

Others	18,735	1,620	(91)	(7,063)	5,364	18,565	-
Assets under construction	36,715	163,797	-	-	(95,042)	105,470	-
Total	1,702,793	167,018	(1,412)	(131,415)	(417)	1,736,567	-

Note 1) The Company is exempted from paying rental fees as the Company satisfied the requirements for rental fee exemption according to the Ordinance of Common Property Management of the Incheon Metropolitan City by signing a lease agreement with the Incheon Metropolitan City.

Note 2) Market value is excluded as an objective estimation for major tangible assets is difficult.

(2) Investments

(Unit: million won)

Classification	Investment Period	Target assets	2020 Total investment Amount	Note
New, extended, supplemented, etc.	2020.01~2020.12	Manufacturing facilities, etc.	115,932	-

5. Matters regarding sales

A. Sales performance

- Sales performance by Type

(Unit: million won)

Business Unit	Type	Item	2020		2019		2018	
			Amount	Share	Amount	Share	Amount	Share
CMO	Goods	Biologics	1,102,593	94.7%	648,375	92.4%	528,228	98.6%
	Services	Others	62,184	5.3%	53,217	7.6%	7,578	1.4%
Total			1,164,777	100.0%	701,592	100.0%	535,806	100.0%

- Sales performance by Location

(Unit: million won)

Location	2020		2019		2018	
	Amount	Share	Amount	Share	Amount	Share
Korea	296,609	25.5%	207,120	29.5%	227,950	42.6%
Europe	527,493	45.3%	418,234	59.6%	290,010	54.1%
US	289,478	24.8%	62,385	8.9%	16,104	3.0%
Others	51,197	4.4%	13,853	2.0%	1,742	0.3%
Total	1,164,777	100.0%	701,592	100.0%	535,806	100.0%

B. Sales channel

The most important thing for the Company's sales activities is to sign contracts with customers since the CMO business in which the Company is engaged is a contract-based industry. It usually takes 6~12 months to win an order (from the date when a customer's request for proposal was received until the date when a contract is concluded), and is implemented as follows:

[Order-winning process]

Category		Details
Discover a potential customer	Contact the customer	<ul style="list-style-type: none"> Inspect the status of customers (organization, number of products, clinical test progress, capacity, etc.) Contact a customer when participating in exhibitions and introduce CMO services
Request for the customer's CMO(RFP)	Meeting of persons in charge	<ul style="list-style-type: none"> Email, telephone, visit and meeting, etc. Take the minutes of a meeting
	Check the volume to order	<ul style="list-style-type: none"> Sign a confidential agreement, provide corporate profile data (incl. capacity), attract to visit the Songdo site
Submit a proposal	Review risks	<ul style="list-style-type: none"> Review related divisions of each field Financial risk: review differentiated batch prices Legal risk: existing products ordered, noncompetitive review with Samsung Biologics' products
	Review terms and conditions	<ul style="list-style-type: none"> Suggest contract terms in which the customer's conditions for manufacturing process are reflected Consider conditions including contract period, time available to manufacture, price, scope of services, minimum volume guaranteed, capacity reserve, etc.
Select a CMO	Select candidate CMOs	<ul style="list-style-type: none"> A customer selects 2~3 candidate CMOs
	Select a preferred CMO	<ul style="list-style-type: none"> A customer selects a preferred CMO through final evaluation
Consult on contract terms	Review risks	<ul style="list-style-type: none"> Review related divisions of each field Financial risk: minimum volume guaranteed/reserve volume, service sales item, etc. Legal risk: liability scope, noncompetitive clauses, etc.
	Consult on basic contract terms	<ul style="list-style-type: none"> Negotiate on and adjust major conditions Prepare MOU and LOI
	Consult on detailed contract terms	<ul style="list-style-type: none"> Consult on conditions for master service agreement
Win a contract	Exchange a final contract	<ul style="list-style-type: none"> Develop a final contract

After this, the Company recognizes sales at the point of quality release (QR) by a customer for the products manufactured, and delivers the customer's inventory stored in the Company's warehouse to a location designated by the customer (generally a customer's carrier) in accordance with the contract.

Meanwhile, the Company does not have separate sales channels or agencies.

C. Sales method and conditions

The sales method and conditions for biopharmaceutical manufactured by the Company are separately determined by a contract with a customer. According to the contract, annual minimum volume of production is determined, and the volume requested for PO by the customer is manufactured and delivered to the designated location. Sales recognition and billing are implemented at the time when the customer's quality approval is obtained for the products manufactured, and the payment is collected within 30~60 days after billing.

D. Sales strategy

The Company provides company information such as cutting-edge manufacturing facilities, technological competence, and excellent manpower through various methods including homepage, advertisements, press releases, overseas exhibitions/conferences, company presentations, and virtual due diligence and exhibition hall, while striving to raise its profile worldwide as a bio-company of Samsung Group. Despite being a late starter, the Company has a potential opportunity to access more than 100 pharmaceutical companies worldwide since its establishment in 2011 with Samsung's brand image and full support of Samsung Group including Samsung Electronics Co., Ltd. Additionally, the Company has participated every year in the BioPhoru7t5m Group, a conference of executives from global biopharmaceutical manufacturers, since joining in 2012.

The Company will make new contracts and expand existing contracts by constantly communicating about the Company's production capacity, facility expansion progress, and future plans and maintaining relationships with existing/potential customers. The Company also leads strategic sales activities by actively participating in various inner circle meetings to identify demand for biopharmaceutical production and competitors' production plans.

In addition, we are expanding our customer from large pharmaceutical companies to small and medium sized bio-tech companies, and in order to increase orders, we continue to strengthen our marketing capabilities and expand our global network. Besides, we are enhancing our potential customers' confidence in our production and quality control capabilities through thorough track record management.

6. Contracts

Item	Initial commercial production year	Deadline	Case		Total amount of contracts	Delivered amount	Order backlog
Antibody drugs	2015	~2031 *Subject to each contract	Minimum Take or Pay	Amount (\$ Million)	6,087	2,141	3,946
				Production (Liters)	27,856,000	9,863,000	17,993,000
			Expected demand when the customers develop the products	Amount (\$ Million)	10,830	2,141	8,689
				Production (Liters)	44,647,000	9,863,000	34,784,000

Note 1) Total contract amounts may also increase after the consultation depending on the increase in customers' demands.

Note 2) Total contract amounts above exclude raw material revenue from raw materials and supplies that have been put into production and service revenue from production process improvements and additional services such as quality analysis.

7. Market risk and risk control

A. Risk control policy

The Company's risk control policy was established in order to distinguish and analyze the risks faced by the Company, setting the appropriate limit and control of risk, and prevent risk from exceeding the limit. The risk control policy and system are regularly reviewed to reflect the market situation and the changes in the Company's activities. The Company aims to build a strictly controlled structural environment where all employees can understand their roles and obligations through training, standards, and procedures for quality control. The Board of Directors oversees how the consolidated companies follow the risk control policy and procedures and reviews whether the Company's risk control system is appropriate.

B. Credit Risk

Credit risk is the risk that may cause financial loss as the contractual obligations for financial instruments are not fulfilled by customers or partners. The book value of financial assets represents the maximum level of exposure to credit risk. The Company's maximum level of exposure to credit risk in 2020 and 2019 are as follows:

(Unit: thousand won)

Description	End of 2020	End of 2019
Cash and cash equivalents	28,850,121	125,100,653
Short-term financial instruments	300,000,000	320,000,000
Loans	700,000	400,000
Financial assets at fair value through profit or loss	500,046,403	210,040,293
Long-term financial instruments	174,483	7,000
Accounts receivable and other receivables	246,603,866	187,118,116
Derivative assets	-	1,002,990
Guarantee deposits	46,039,821	42,877,973
Total	1,122,414,694	886,547,025

(*) The cash amount held by the Company is excluded.

C. Liquidity risk

Liquidity risk is the risk that may cause the Company to have difficulty in satisfying the obligations related to financial liabilities. The Company's liquidity management policy is to maintain sufficient liquidity to pay off its debts prior to the maturity date without risk of causing unacceptable loss in financially difficult situations or degrading the Company's reputation.

The ultimate responsibility for liquidity risk management lies with the Board of Directors that establishes basic policies to properly take care of the Company's short-, mid-, and long-term financing and liquidity management regulations. The Company manages liquidity risk by regularly forecasting and adjusting funds receipts and disbursement to maintain optimal liquidity.

Contractual maturity dates of financial liabilities as of the end of 2020 and 2019 are as follows. The amount includes interest paid and does not include the effect of netting agreements. The Company does not anticipate that the cash flow occurs significantly earlier or the amount is significantly different.

① End of 2019

(Unit: thousand won)

Description	Book value	Contractual cash flow	In 1 year	1-2 years	2~3 years	More than 3 years
Accounts payable and other payables	148,932,588	148,932,588	144,261,210	4,671,378	-	-
Lease liabilities	22,546,904	24,017,909	7,144,259	1,861,321	9,211,129	5,801,200
Bonds	189,858,358	194,767,095	152,901,425	1,412,800	40,452,870	-
Short-term borrowings	30,000,000	30,027,847	30,027,847	-	-	-
Long-term borrowings	542,500,000	568,396,305	20,892,480	118,209,699	429,294,126	-
Total	933,837,850	966,141,744	355,227,221	126,155,198	478,958,125	5,801,200

② End of 2019

(Unit: thousand won)

Description	Book value	Contractual cash flow	In 1 year	1-2 years	2~3 years	More than 3 years
Accounts payable and other payables	73,018,783	73,018,783	68,251,491	4,767,292	-	-
Lease liabilities	15,889,284	17,330,666	3,756,506	3,539,260	3,292,400	6,742,500
Bonds	189,755,125	200,840,489	6,073,394	152,901,425	1,412,800	40,452,870
Short-term borrowings	150,000,000	152,654,775	152,654,775	-	-	-
Long-term borrowings	298,062,000	307,852,511	258,340,729	13,006,681	1,252,814	35,252,287
Total	726,725,192	751,697,224	489,076,895	174,214,658	5,958,014	82,447,657

D. Foreign exchange risk

The Company is exposed to foreign exchange risk for sales, purchases, and borrowings expressed in currencies other than Korean Won (KRW) which is a functional currency. The main currency used to express these transactions is USD. The Company established a plan to handle foreign exchange risk through foreign exchange forward transaction in case that foreign exchange risk needs to be avoided.

① Exposure to foreign exchange risk

The Company's level of exposure to foreign exchange risk is as follows:

(Unit: thousand won)

Description	End of 2020					End of 2019				
	USD	EUR	CHF	JPY	GBP	USD	EUR	CHF	JPY	GBP
Assets:										
Cashable asset	10,880,000	-	-	-	-	115,780,000	-	-	-	-
Accounts receivable and other receivables	233,514,513	88,408	-	-	89,344	180,179,596	12,171	-	-	132,990
Contract asset	11,814,842	-	-	-	-	1,630,646	-	-	-	-
Subtotal	256,209,355	88,408	-	-	89,344	297,590,242	12,171	-	-	132,990
Liability										
Borrowings	21,760,000	-	-	-	-	11,578,000	-	-	-	-
Accounts payable and other payables	35,663,842	175,310	308	4,450,768	60,290	2,347,447	229,693	22,530	2,324	105,546
Subtotal	57,423,842	175,310	308	4,450,768	60,290	13,925,447	229,693	22,530	2,324	105,546
Total	198,785,513	(86,902)	(308)	(4,450,768)	29,054	283,664,795	(217,522)	(22,530)	(2,324)	27,444

(*) Swap-covered borrowings are excluded as they are not exposed to currency risk.

② Exchange rate applied during 2020 and 2019 is as follows:

(Unit: won)

Description	2020		2019	
	Average	End	Average	End
USD	1,180.05	1,088.00	1,165.65	1,157.80
EUR	1,345.99	1,338.24	1,304.81	1,297.43
CHF	1,257.34	1,234.33	1,173.43	1,195.52
JPY(100¥)	1,105.07	1,054.26	1,069.76	1,063.47
GBP	1,513.05	1,482.40	1,487.83	1,518.69

③ Sensitivity analysis

The Company regularly estimates the foreign exchange risk for fluctuations in KRW exchange rates. The impact of fluctuations in exchange rates on income before income taxes when KRW exchange rates changes by 10% to each foreign currency as of the end of 2020 and 2019 are as follows:

(Unit: thousand won)

Category	End of 2020		End of 2019	
	Increase of 10%	Decrease of 10%	Increase of 10%	Decrease of 10%
USD	19,878,551	(19,878,551)	28,366,479	(28,366,479)
EUR	(8,690)	8,690	(21,752)	21,752
CHF	(31)	31	(2,253)	2,253
JPY	(445,077)	445,077	(232)	232
GBP	2,905	(2,905)	2,744	(2,744)
Total	19,427,658	(19,427,658)	28,344,986	(28,344,986)

E. Interest rates risk

Out of the Company's financial instruments, variable interest rate-bearing deposits and borrowings are affected by change in market interest rates. The impact of a 0.5% change in the interest rates as of the end of 2020 and 2019 on earnings before taxes is as follows:

(Unit: thousand won)

Description	End of 2020		End of 2019	
	Increase of 0.5%	Decrease of 0.5%	Increase of 0.5%	Decrease of, 0.5%
Decrease(Increase) in Interest expense	(306,020)	306,020	(1,201,400)	1,201,400

F. Capital management

The Company's capital management is aimed to maximize the interest of shareholders by maintaining a sound capital structure, and provides appropriate plans to improve a financial structure if needed by monitoring financial ratio including debt ratio and net borrowing ratio to achieve the optimal capital structure.

Debt ratio as of the end of 2020 and 2019 are as follows:

(Unit: thousand won)

Description	End of 2020	End of 2019
Liabilities(A)	1,825,417,993	1,557,172,767
Capital(B)	4,598,783,172	4,354,453,745
Debt ratio(A/B)	39.69%	35.76%

8. Transaction Status, such as Financial derivatives and Put back options

The Company made a contract about financial derivatives for foreign currency borrowings for the purpose of hedging exchange rate risk of foreign currency receivables/debts and interest rate, and the details are listed below.

(1) Currency Interest Swap Contract

Classification	Category	Financial institution	Contract Amount	Contract Date	Maturity Date	Currency (*)		Committed exchange rate	Interest rate(%)	
						Sell	Buy		Received	Paid
Trading	Currency interest swap	Hana bank	USD 30,000,000	2018.05.31	2023.05.31	USD	KRW	1,080.00	Libor(3M) + 1.70	3.70

(*) The details have been prepared based on the date of borrowing.

(2) Interest Swap Contract

Classification	Category	Financial institution	Contract Amount	Contract Date	Maturity Date	Interest rate(%)	
						Received	Paid
Trading	Interest swap	Woori bank	KRW 50,000,000,000	2020.09.28	2023.10.02	CD(91Days) + 1.23	2.25

(3) Gain and loss on valuation

Classification	Gain on valuation	Loss on valuation	Accumulated other comprehensive income
Currency Interest swap	-	KRW 2,135,606,193	-
Interest swap	-	KRW 132,396,157	-

9. Major contracts for business management

A. License-Out Contracts

- Not applicable

B. License-In Contracts

- Not applicable

C. Other Contracts

(1) Biogen's call option exercise

Biogen Therapeutics Inc. exercised the right to purchase up to 50%-1 shares of Samsung Bioepis Co., Ltd., a major subsidiary of Samsung Biologics, under the shareholder's agreement with Samsung Biologics on June 29, 2018. On November 7, 2018, all procedures for trading and trading of shares were finalized. As a result, the stake held in the call option exercise was transferred to Biogen Therapeutics Inc., and the sale price was 759.5 billion won.

(2) Purchase of Samsung Bioepis Real Estate


The Company decided to purchase the building (located on 107, Cheomdan-daero, Yeonsu-gu, Incheon, Republic of Korea) from Samsung Bioepis Co., Ltd. on April 24, 2019 to expand the office space and CDO / CRO Lab, and purchased it on May 23, 2019. The purchase amount is about 20.2 billion won.

10. R&D activities

A. R&D organization

(1) Outline

The Company has R&D divisions such as a DS1/2 MSAT team (Manufacturing Science and Technology Team), DS3 MSAT team and a CDO team (Contract Development Organization R&D Team) which are in charge of providing technical support for the production of client's products, research, and developing a cell-line process.



[R&D Organizational chart]

[Job description]

Category	Details
Technological support to manufacturing customer products	1) Study to enhance the productivity of a customer product 2) Technology transfer - Jointly conduct a R&D project with a customer for the manufacturing process of products to be produced in the Company's manufacturing facilities - Get technology transfer from a customer or develop technology
R&D for cell lines & process	1) Cell line development service (develop high-productivity cell lines) 2) Process development service (improve the productivity through process development) - R&D by combining process conditions and culture medium to improve a time when culturing cells - R&D for the process to improve target protein refining yield - R&D related to quality analysis

(2) R&D manpower status

As of the reporting date on December 31, 2020, the Company has 331 staff members assigned to research and development activities, with 48 of holding doctorate degrees and 159 holding master's degrees. The details are as follows:

(Unit: person)

Team	Ph.D	M.S.	Other	Total
DS1/2 MSAT Team	12	57	45	114
DS3 MSAT Team	10	36	28	74
CDO R&D Team	23	66	51	143
Total	45	159	124	331

(3) R&D key personnel

Name	Position	Tasks	Careers	R&D performance
Lee Kyusung	Executive Vice President	General manufacturing technology	- Center Leader, Samsung Biologics CMO1 Center (2018.05~) - Center Leader, Samsung Biologics Clients Satisfaction Center (2017.04~2018.04) - Manufacturing Division, Samsung Biologics Co., Ltd. (2011.04~2017.03) - A. Director, Technology Business, BMS Global (2005.05~2010.10) - Leader, Production Team, Merck Bio (1995.10~2005.04) - Purdue Univ., Doctor of Chemical Engineering	[Theses] - Kinetic Modeling and Reactor Simulation for Methanol Synthesis from Hydrogen and Carbon Monoxide on Copper- Base Catalyst (1984, KJChE) - Utilization of a Paraboloidal Solar Reflector as a High Temperature Source (1985, Engineering Report) - Analysis of Yeast and E. coli Fermentation with Unequal Specific Uptake Rates of α - and β - Glucose (1990, Asia- Pacific Biochemical Engineering Conference '90) - Pilot Fermentation and Downstream Processing of a Yeast Derived Recombinant Peptide(1992, Ninth International Biotechnology Symposium) - Pilot- Scale Recovery of a Yeast- Derived Recombinant Peptide by Multi- Stage Separations(1992, Annual AIChE Meeting)
Ahn Yongho	Vice President	Process Technology	- CDO R&D Team Leader, Samsung Biologics Co., Ltd (2018.12~) - R&D executive, Archigen Biotech (2015.01~2018.11) - R&D executive, Hanwha Chemical (2007.01~2015.01) - KAIST, Doctor of Biology	[Theses] - Phase III study with RA(HD203) (2016, Ann Rheum Dis.)

B. R&D expenses

(Unit: thousand won, %)

		2020	2019	2018
Type of expenses	Raw material expenses	19,256,537	11,347,154	5,057,275
	Labor expenses	35,711,736	24,761,503	13,237,550
	Depreciation expenses	10,475,256	5,644,472	3,153,938
	Outsourcing expenses	-	-	-
	etc.	13,121,038	6,754,445	3,013,382
	Total R&D expenses	78,564,567	48,507,574	24,462,145
Accounting classification	SG & A expenses	5,105,829	-	-
	Manufacturing expenses	73,458,738	48,507,574	24,462,145
	Development expenses (Intangible Assets)	-	-	-
	Total R&D expenses	78,564,567	48,507,574	24,462,145
R&D expenses/ Sales Ratio [Total R&D expenses / Sales*100]		6.7%	6.9%	4.6%

Note 1) Consolidated basis in accordance with K-IFRS.

Note 2) The Company is not applicable to government subsidies.

C. R&D performance

(1) R&D progress status and future plan

The Company provides Contract Manufacturing Organization(CMO) service and Contract Development Organization(CDO) service. R&D divisions are in charge of providing technical support for the production of client's products and researching and developing a cell-line process. There is no pipeline currently under R&D.

The Company has MSAT team, P3 MSAT team, and CDO R&D team in charge of technological support for manufacturing customer products and R&D for cell line process and to expand R&D agency area for cell line process. Based on this, the Company will become a CMO/CDO/CRO company by expanding its business areas even to the contract development of medicines.

(2) R&D completion performance

There is no pipeline that has been developed.

11. Other matters required for investment decision-making

A. Laws and regulations affecting business operation

Laws	Details
Pharmaceutical Affairs Act	<ul style="list-style-type: none">- Regulate overall matters concerning medicine manufacturing business such as quality control and manufacturer designation- Obtain a manufacturing license according to the Act- Impose administrative measures (revocation of license) or criminal punishments (imprisonment or punishment of a fine)
Unfair Competition and Prevention and Trade Secret Protection Act	<ul style="list-style-type: none">- Regulate the act of unjustifiably using or disclosing trade secrets of clients
Act on the Registration and Evaluation, Etc. of Chemical Substances, Toxic Chemicals Control Act	<ul style="list-style-type: none">- Regulate the registration, evaluation, and management of chemical substances that are not controlled as drug and quasi-drug by the Pharmaceutical Affairs Act- Registration and evaluation requires cost and time to import the drug substances that fall under chemical substances subject to the Act
Transboundary Movement, Etc. of Living Modified Organisms Act	<ul style="list-style-type: none">- Inspect the risks posed by living modified organisms- Regulate the import of living modified organisms and registration of the research facility
Fair Trade Act	<ul style="list-style-type: none">- Regulate unfair trading practices and unfair collective practices across the entire business area including winning an order for CDMO project, building manufacturing facilities, and purchasing materials- Impose corrective measures, penalty, fine, etc. if related matters are violated

B. Business-related important intellectual property rights

The Company has put a significant emphasis in research and development activities since 2017, and is increasing the scope of such activities. As the result of constant research and development activities, the Company applied for 2 domestic patents in 2020.

The patents are related to biopharmaceutical production and manufacturing facilities. These patents will play a role in providing strategic services as the business operates. In addition, the Company aims to license the patents to create revenue in the future.

The Company has also been focusing on securing trademark rights to protect its trademarks, which represent its brands, products and services, and slogans. Throughout the year, the Company applied for 53 trademarks in the domestic market, as well as global markets including the U.S., Europe, and China. Among 53 trademarks applied, 17 of those have been officially registered.

C. Environmental regulations

With an environmental policy putting environmental contaminant reduction and green values at the top of its priorities, the company commits itself to do all it can to prevent undesired environmental events and make utmost efforts to lead the sustainable future.

To put this into practice, the company strives to achieve compliance with environmental regulations and reduce contaminant generation in addition to actively being engaged in chemical accident prevention

by implementing a life cycle management system for all chemicals handled in its business sites. In addition, the company follows regulatory requirements for contaminant emission standards, reports the amount of greenhouse-gas emission and energy usage and transparently discloses relevant information to its stakeholders in order to meet the government's low-carbon growth policies and responses to climate change.

(Business site management, compliance with environmental regulations and contaminant reduction)

The company has installed and is operating various facilities for water pollution prevention, air pollution prevention, waste storage, noise control, etc. to minimize emission of contaminants generated from biomedicine manufacturing processes so that impact on the surrounding social environment can be minimized. For business site environment management, regular self-inspections in addition to management and supervision of relevant authorities have been carried out. As such, the company's excellent environment control capability was acknowledged by being selected as the Best Company for Environment Management by the City of Incheon twice, in 2015 and 2018.

The company discloses transparent information on environmental emission performance and operational status each year and is making efforts for regulatory compliance and contaminant reduction through continued investment.

TMS System Operation	- The Company has built a continuous monitoring system for basic environmental facilities to monitor contaminant emission standards and is making constant efforts to prevent environmental pollution accidents.
Waste Resource Circulation	- The Company is striving to reduce waste through various activities including garbage separation and recycling systems for the wastes discharged from its business sites. While the Company keeps an eye on the entire process from waste emission to final disposal, it also carries out regular inspections/ evaluations on outsourced waste disposal companies on annual basis.
Investment on Environmental Improvement	- The company is making continuous investment on basic environmental facilities for the sake of preventing and improving environmental pollution of its business sites and local community.

(Chemical substance management)

The Company has built an integrated chemical substance management system in order to comply with the Chemical Substances Control Act and the Act on Registration, Evaluation, etc. of Chemicals.

The Company is working actively to prevent chemical accidents by having all chemical substances go through pre-evaluation before warehousing and managed throughout the process up to disposal.

Regular training is performed for those handling chemical substances, and safety management

activities are thoroughly executed by conducting training sessions on protective equipment wearing, emergency response drilling, etc.

Integrated Chemical Substance Management System	- The company is making efforts to prevent chemical accidents across the company by managing the lifecycle (entire process) of chemical substances using the chemical substance management system.
Management of Hazardous Chemical Substance Handling Facilities	- In an effort to manage and improve chemical substance handling facilities, the Company has installed double piping, sensors, emergency shutdown facilities, etc. to prevent accidents from these facilities and regular inspections on these installations are performed annually by specialized agencies.
All-time Monitoring System	- The Company is operating and managing the 24-hour operated emergency response center (CCR: Central Control Room) for real-time monitoring of abnormal signs and immediate emergency response.

(Response to Climate Change)

In accordance with Article 8 of the Act on the Allocation and Trading of Greenhouse-Gas Emission Permits, the Company has followed relevant regulatory standards since 2017. The Company also reports to the government its greenhouse-gas emission and energy use after 3rd party verification and transparently discloses the report to its stakeholders.

In addition, the Company is reinforcing its management on unexpected risks including climate change, natural disasters, etc. through certification of the international standard for Business Continuity Management System (ISO 22301).

Greenhouse-Gas Emission Control	- Each year, the Company manages and discloses greenhouse-gas emission monitoring plans and statements through 3rd party verification.
Total Air Pollution Load Management	- The Company is making efforts to reduce emission of contaminants including nitrogen oxides, dusts, etc. that can impact climate warming through monitoring on air contaminant emission sources and operating highly efficient reduction systems.
Energy Use Reduction	- The Company is making investments to introduce and improve highly efficient facilities for sustained energy/greenhouse-gas reduction activities and is also taking the lead in making efforts to reduce greenhouse-gas emission through regular energy diagnosis from external agencies.

The Company has been a business entity eligible for allocation of emission permits since 2017 according to Article 8 (Designation of Business Entities Eligible for Allocation) of the Act on the Allocation and Trading of Greenhouse-gas Emission. Greenhouse-gas emission and energy use reported to the government for the recent 5 years are as follows:

Year	Annual Greenhouse Gas Emissions (Ton)			Annual Energy Consumption (TJ)			
	Direct	Indirect	Total	Gas	Electricity	Steam	Total
2016	22,361	46,118	68,479	437	950	-	1,387
2017	29,587	55,727	85,314	579	1,147	-	1,726
2018	40,967	75,612	116,579	803	1,557	-	2,360
2019	40,166	79,625	119,791	788	1,639	-	2,427
2020	41,793	83,014	124,807	820	1,709	-	2,529

※ The subjects are our plant, shuttle bus, rental building, etc.

※ The amount of Greenhouse Gas Emissions and Energy Consumption above is the data submitted to the National Greenhouse Gas Management System.

※ For the matters concerning green management, refer to J. Green management in 3. Other matters including current restrictions under XI. Other Matters Required for Investor Protection.

IV. Directors' Management Discussion & Analysis

1. Notes to forecasts

This annual report includes forward-looking statements that relate to future events. The statements can be generally identified by phrases containing words such as 'forecast', 'predict', 'plan', 'anticipate' or other words or phrases of similar meaning.

Forward-looking statements involve uncertain events that could positively or negatively affect the Company's management condition and financial performance include, but are not limited to:

- Trends of domestic/international financial markets including changes in exchange rate and interest rate
- The Company's strategic decision-making including business acquisition or disposal
- Unexpected sudden change of conditions in the Company's core business areas
- Other domestic/international changes that may affect management status and financial performance

Please note that because of such uncertainties, the Company's actual future performance may be materially different from the statements expressed or implied in forecasts. The Company is not liable to disclose a corrective report that modifies the details of forecasts to reflect risks or uncertainties that may occur after the forecasts were created.

2. Overview

The year 2020 is a meaningful year for Samsung Biologics in that our preemptive investments and innovative challenges came to fruition.

Following the full operation of Plants 1 and 2, the contract rate of Plant 3 greatly exceeded its initial target and is on the threshold of achieving a goal of 100%. The number of orders per annum was 47 which amounted to KRW 1,850.0 billion, the highest performance since its establishment. With the aim to proactively respond to rapidly changing market supply and demand, we have begun construction of a fourth plant and successfully opened the Global CDO R&D Center. In the midst of the COVID-19 pandemic, Samsung Biologics delivered Eli Lilly's first COVID-19 antibody treatment, Bamlanivimab, within three months, enabling us to demonstrate our competitiveness in the global market. In addition, Samsung Biologics has obtained 76 approvals from regulatory agencies through a quick response to the changing environment, for instance by supporting due diligence and inspection by global regulatory agencies via a non-face-to-face real-time virtual tour technology.

This year, we will be committed to the efficient and stable operation of manufacturing facilities while

focusing on winning preorders for Plant 4 to be opened at the end of 2022. The current trend in the pharmaceutical industry is outsourced manufacturing, and the biotechnology sector is rapidly growing. The global pharmaceutical industry is also becoming increasingly aware of the need for manufacturing bases for COVID-19 medicine which require urgent and large-scale production. In such a favorable market environment, Samsung Biologics is expected to maintain a similar growth rate in 2021 as in 2020.

The One-Stop Service that quickly offers high-quality services in overall areas from CRO/CDO to CMO provides clear competitive differentiation. By further expanding a business area to the rapidly growing DP (Drug Product) market, we will improve the satisfaction of existing CMO clients and attract new customers. As for biosimilars, we will continue holding a dominant position in the European market while accelerating the penetration in other major global markets such as the United States at the same time expanding the biosimilar pipelines for new diseases.

3. Financial status & Sales Performance

A. Financial status

(Unit: million won)

	2020	2019	Increase & Decrease	Change(%)
Assets				
I . Current assets	1,751,347	1,356,262	395,085	29.13%
Cash and cash equivalent	28,850	125,101	-96,251	-76.94%
Shot-term financial Instrument	300,000	320,000	-20,000	-6.25%
Financial assets at fair value through profit or loss	500,046	210,040	290,006	138.07%
Trade and other receivables	217,932	187,118	30,814	16.47%
Inventories	645,960	452,470	193,490	42.76%
Other current financial assets	23,556	34,782	-11,226	-32.28%
Other current assets	7,138	5,938	1,200	20.21%
Contract assets	27,865	20,813	7,052	33.88%
II. Non-current assets	4,672,854	4,555,365	117,489	2.58%
Long-term financial instruments	174	7	167	2,385.71%
Investments in associates and joint ventures	2,634,428	2,652,732	-18,304	-0.69%
Investment properties	20,248	20,761	-513	-2.47%
Property, plant and equipment	1,736,567	1,702,792	33,775	1.98%
Intangible assets	23,345	21,827	1,518	6.95%
Right-of-use asset	24,160	16,119	8,041	49.89%

	2020	2019	Increase & Decrease	Change(%)
Trade and other receivables	28,672	-	28,672	-
Defined benefit asset	11,900	-	11,900	-
Other non-current financial assets	23,184	9,499	13,685	144.07%
Other non-current assets	1,284	957	327	34.17%
Contract assets	168,892	130,671	38,221	29.25%
Total assets	6,424,201	5,911,627	512,574	8.67%
Liabilities				
I . Current liabilities	589,301	690,505	-101,204	-14.66%
II. Non-current liabilities	1,236,117	866,668	369,449	42.63%
Total liabilities	1,825,418	1,557,173	268,245	17.23%
Total equity	4,598,783	4,354,454	244,329	5.61%
Total liabilities and equity	6,424,201	5,911,627	512,574	8.67%

※ Consolidated financial statements of 2020 pending the authorization from the Annual General Meeting.

The Company will publish amendment reports, presenting summaries and explanations, if any items regarding the financial statements get rejected or amended at the Annual General Meeting.

- The Company's total assets in 2020 were KRW 6.42 trillion, an increase of KRW 512.6 billion (8.67%) from the previous year.

Current assets were KRW 1.75 trillion, increased by KRW 395.1 billion (29.13%). Quick assets increased by KRW 201.6 billion, impacted by sales growth and financing for Plant#4 construction. Operating ratio of Plant#3 increased which resulted in an increase of KRW 193.5 billion in inventories. Non-current assets were KRW 4.67 trillion in 2020, an increase of KRW 117.5 billion (2.58%). The company entered into multiple new contracts which resulted in an increase of KRW 38.2 billion in contract assets. In addition, the business expansion resulted in an acquisition of property, plant and equipment, resulting in an increase of KRW 33.8 billion.

- The Company's total liabilities rose by KRW 268.2 billion (17.23%) to KRW 1.83 trillion from the previous year.

Current liabilities decreased by KRW 101.2 billion (14.66%) from the previous year. This includes a decrease of KRW 360.7 billion in borrowings. Short-term bonds increased by KRW 149.9 billion, impacted by the replacement with long-term bonds. In addition, operating costs increased, which resulted in an increase in account payables and other payables of KRW 87.9 billion.

Non-current liabilities increased by KRW 369.4 billion (42.63%). The changes are attributable to a KRW 485.1 billion increase due to renewals of debentures and a KRW 149.9 billion decrease due to replacements of short-term bonds with long-term bonds.

- Equity increased to KRW 4.60 trillion, up KRW 244.3 billion (5.61%) year-on-year.

The major impact is an increase in net profit, as operating profit rose.

B. Sales Performance

(Unit: million won)

	2020	2019	Increase & Decrease	Rate of Increase & Decrease
I. Revenue	1,164,777	701,592	463,185	66.02%
II. Cost of revenue	748,608	509,858	239,023	46.91%
III. Gross profit	416,169	192,007	224,162	116.75%
IV. Selling, general and administrative expense	123,382	100,265	23,117	23.06%
V. Operating profit(loss)	292,787	91,742	201,045	219.14%
VI. Non-operating profit(loss)	-26,795	63,693	-90,488	-142.07%
VII. Profit(loss) before income tax	265,992	155,435	110,557	71.13%
VIII. Income tax expense(benefit)	-25,017	47,469	-72,486	-152.70%
IX. Net profit(loss) for the period	240,975	202,904	38,071	18.76%

※ Consolidated financial statements of 2020 pending the authorization from the Annual General Meeting.

The Company will publish amendment reports, presenting summaries and explanations, if any items regarding the financial statements get rejected or amended at the Annual General Meeting.

※ Samsung Biologics has a single business area.

- Revenue increased by KRW 463.2 billion (66.02%) to KRW 1.16 trillion, and gross profit increased by KRW 224.2 billion (116.75%) to KRW 416.2 billion. An increase in operation ratio resulted in such improvements.

※ Samsung Biologics provides biologics CMO (Contract Manufacturing Organization) services for biopharmaceuticals, therefore sales are changed according to the production schedule of each plant for the volume of orders from clients.

- Selling, general and administrative expense increased by KRW 23.1 billion (23.06%) from the previous year. The change is attributable to an increase in labor cost due to a rise in employee number and an increase in ordinary research and development expense due to expanded research and development activities.

- Operating profit was KRW 292.8 billion in 2020, an increase of KRW 201.0 billion (219.14%), resulting from improved sales and manufacturing activities.

- In 2020, all major financial ratios showed significant improvements as follows: Operating profit ratio of 25.1% (13.1% in 2019), EBITDA of 37.5% (32.0% in 2019), and Interest coverage ratio of 18.2 times (3.6 times in 2019).

C. New Business

The Company is expanding its business portfolio from CMO (Contract Manufacturing Organization) oriented business to CDO (Contract Development Organization) business to become a global No.1 CMO/CDO/CRO company.

CDO services provide cell line development and process development for small and medium-sized pharmaceutical companies which do not possess a capacity for cell line development and process development. The CDO business is expected to see a 10% annual growth rate with an increase in small

biotech companies and biosimilar antibody pipelines. The Company opened its first global CDO R&D center in the renowned San Francisco BioPharma Cluster, and consequently aims to expand its footage in Boston, Europe, and China.

Meanwhile, CRO (Contract Research Organization) business based on the capabilities of the existing quality analysis laboratory is underway, and related business capabilities are being strengthened.

D. Reorganization

- Not applicable

E. Currency risk

- Exposure to foreign exchange risk

The Company's level of exposure to foreign exchange risk is as follows:

(Unit: thousand won)										
Description	End of 2020					End of 2019				
	USD	EUR	CHF	JPY	GBP	USD	EUR	CHF	JPY	GBP
Assets:										
Cashable asset	10,880,000	-	-	-	-	115,780,000	-	-	-	-
Accounts receivable and other receivables	233,514,513	88,408	-	-	89,344	180,179,596	12,171	-	-	132,990
Contract asset	11,814,842	-	-	-	-	1,630,646	-	-	-	-
Subtotal	256,209,355	88,408	-	-	89,344	297,590,242	12,171	-	-	132,990
Liability										
Borrowings	21,760,000	-	-	-	-	11,578,000	-	-	-	-
Accounts payable and other payables	35,663,842	175,310	308	4,450,768	60,290	2,347,447	229,693	22,530	2,324	105,546
Subtotal	57,423,842	175,310	308	4,450,768	60,290	13,925,447	229,693	22,530	2,324	105,546
Total	198,785,513	(86,902)	(308)	(4,450,768)	29,054	283,664,795	(217,522)	(22,530)	(2,324)	27,444

(*) Swap-covered foreign currency loans are excluded as they are not exposed to exchange risks.

- Sensitivity analysis

The Company regularly estimates the foreign exchange risk for fluctuations in KRW exchange rates. The impact of fluctuations in exchange rates on income before income taxes when KRW exchange rates changes by 10% to each foreign currency as of the end of 2020 and 2019 are as follows:

(Unit: thousand won)				
Category	End of 2020		End of 2019	
	Increase of 10%	Decrease of 10%	Increase of 10%	Decrease of 10%
USD	19,878,551	(19,878,551)	28,366,479	(28,366,479)
EUR	(8,690)	8,690	(21,752)	21,752
CHF	(31)	31	(2,253)	2,253
JPY	(445,077)	445,077	(232)	232
GBP	2,905	(2,905)	2,744	(2,744)
Total	19,427,658	(19,427,658)	28,344,986	(28,344,986)

4. Liquidity, financing, and expenditures

A. Liquidity aggregates

The Company's liquidity is as follows:

(Unit: million won)

	2020	2019
Cash equivalents	28,850	125,101
Short-term financial instruments	300,000	320,000
Financial assets at fair value through profit or loss	500,046	210,040
Total	828,896	655,141

The Company's liquid funds were KRW 828.9 billion, an increase of KRW 173.8 billion from KRW 655.1 billion at the end of the previous year. The change is attributable to an inflow of KRW 202.1 billion in cash flows from operating activities, KRW 127.2 billion in acquisition of borrowings, and an outflow of KRW 148.6 billion in acquisition of tangible assets.

B. Financing and redemption plan

As of the end of 2020, the Company's total borrowings amounted to KRW 762.5 billion, an increase of KRW 127.2 billion from KRW 635.3 billion at the end of 2019. In addition, net borrowing, which deducts liquidity funds that can repay borrowings, is △KRW 66.4 billion, down KRW 49.4 billion from the end of 2019.

The Company's financing details for 2020 are as follows:

(Unit: million won)

		Financial institution	Issuance date	Maturity date	Interest rate(%)	Amount
Loans	Korean currency borrowings	Mizuho Bank	2020.07.30	2022.07.29	1.57%	10,880
Loans for equipment	Korean currency borrowings	Shinhan Bank	2020.09.28	2022.09.28	CD(91days)+1.39%	70,000
Loans for equipment	Korean currency borrowings	Woori Bank	2020.09.28	2023.10.02	CD(91days)+1.43%	70,000
Loans for equipment	Korean currency borrowings	Mizuho Bank	2020.09.28	2022.09.28	CD(91days)+0.85%	28,000
Loans for equipment	Korean currency borrowings	Woori Bank	2020.09.28	2023.10.02	2.25%	50,000
Loans for equipment	Korean currency borrowings	Hana Bank	2020.11.14	2023.11.14	CD(91days)+1.40%	50,000
Loans for equipment	Korean currency borrowings	Mizuho Bank	2020.12.18	2023.12.18	1.50%	70,000
Loans for equipment	Korean currency	Woori Bank	2020.12.28	2023.12.28	CD(91days)+1.43%	50,000

		Financial institution	Issuance date	Maturity date	Interest rate(%)	Amount
	borrowings					
Loans for equipment	Korean currency borrowings	Mizuho Bank	2020.12.28	2023.12.28	1.51%	100,000
Loans for equipment	Korean currency borrowings	SMBC Bank	2020.12.28	2021.01.28	CD(91days)+0.55%	30,000
Total						528,880

The year-based borrowing redemption plan as of December 31, 2020 is as follows:

(Unit: million won)

	Foreign bonds	Borrowings	Foreign Borrowings	Total
2021.01.01 ~ 2020.12.31	150,000	30,000	10,980	190,980
2022.01.01 ~ 2022.12.31	-	-	108,880	108,880
2023.01.01 ~ 2023.12.31	40,000	-	422,640	462,640
2024.01.01 ~	-	-	-	-
Total	190,000	30,000	542,500	762,500

(*1) Redemption is made based on actual repayments (face value) excluding discounts on bond issuance of 1.42 million won.

5. Other matters required for investment decision

A. Important accounting policies and estimates

- For matters concerning the Company's important accounting policies and estimates, refer to the notes for use of financial information of 6. Other matters relating to finance under III. Matters relating to finance.

B. Matters relating to environment and employees

- For matters relating to environmental sanctions or administrative measures, refer to 3. Other matters including sanctions under XI. Other Information.

- There is no significant change in employees including the transfer of key human resources during 2020.

C. Matters relating to legal regulations

- For major legal regulations relating to the Company's business, refer to 3. Other matters including sanctions under XI. XI. Other Information.

D. Matters regarding derivatives & risk management policy

(1) Currency interest swap contract

Classification	Category	Financial institution	Contracted Amount	Contract Date	Maturity Date	Currency		Committed exchange rate	Interest rate(%)	
						Sell	Buy		Received	Paid
Trading	Currency interest swap	Hana Bank	USD 30,000,000	2018.05.31	2023.05.31	USD	KRW	1,080.00	Libor(3M) + 1.70	3.70

(2) Interest rate swap contract

Classification	Category	Financial institution	Contracted Amount	Contract Date	Maturity Date	Interest rate(%)	
						Received	Paid
Trading	Interest swap	Woori Bank	KRW 50,000,000,000	2020.09.28	2023.10.02	CD(91D) + 1.23	2.25

(3) Gain and loss on valuation

Classification	Gain on valuation	Loss on valuation	Accumulated other comprehensive income
Currency interest swap	-	KRW 2,135,606,193	-
Interest swap	-	KRW 132,396,157	-

V. Auditor's Report

1. Auditor's opinion, etc.

A. Auditor's name and opinion

Business year	Auditor	Auditor's opinion	Emphasis, etc.	Key Audit Matters
2020	Samil PwC	Unqualified opinion	<ul style="list-style-type: none"> - Securities & Futures Commission's ruling and administrative litigation and prosecution investigation - Initial adoption of K-IFRS in separate financial statements 	<ul style="list-style-type: none"> - Inspect investment stocks in associates and joint ventures for impairment - Appropriateness of CMO revenue recognition
2019	Samil PwC	Unqualified opinion	<ul style="list-style-type: none"> - Securities & Futures Commission's ruling and administrative litigation and prosecution investigation 	<ul style="list-style-type: none"> - Inspect investment stocks in associates and joint ventures for impairment - Appropriateness of CMO revenue recognition - Possibility of distorting financial statements due to inappropriate changes and deletions of important accounting records
2018	Samjong KPMG LLC	Unqualified opinion	<ul style="list-style-type: none"> - Exercised a call option - Securities & Futures Commission's ruling and administrative litigation 	<ul style="list-style-type: none"> - Inspect investment stocks in associates and joint ventures for impairment - Appropriateness of revenue recognition

※ Auditor's opinion for 2020 is for separate and consolidated financial statements.

<2020 Audit and Review Schedule>

Item		Date
1Q	Preliminary Audit	2020.03.16 ~ 2020.03.20
	Audit	2020.04.08 ~ 2020.05.14
2Q	Preliminary Audit	2020.06.22 ~ 2020.06.26
	Audit	2020.07.06 ~ 2020.08.07
3Q	Preliminary Audit	2020.09.21 ~ 2020.09.25
	Audit	2020.10.05 ~ 2020.11.16
Audit of IT systems and automated internal controls		2020.05.06 ~ 2021.01.08
Annual audit and Internal Accounting Control System design and assessment		2020.03.23 ~ 2020.12.24
Early substantive audit procedures		2021.01.06 ~ 2021.01.25

Audit of Financial Statement and Internal Accounting Control System assessment	2021.01.26 ~ 2021.02.19
--	-------------------------

※ The schedule above is for the audit and review of separate and consolidated financial statements and the audit of Internal Accounting Control System for the year ended on December 31, 2020.

B. Audit service contract

(Unit: thousand won, hour)

Business year	Auditor	Details	Contract Details		Performance Details	
			Audit fee	Audit hour	Audit fee	Audit hour
2020	Samil PwC	- Audit of the interim and annual separate and consolidated financial statements - Audit of Internal Accounting Control system	1,280,000	9,102	1,280,000	9,412
2019	Samil PwC	- Audit of the interim and annual separate financial statements - Audit of Internal Accounting Control system	1,250,000	8,602	1,540,000	11,364
2018	Samjong KPMG LLC	- Audit of the interim and annual separate financial statements	630,000	5,969	700,000	6,349

※ Audit fee and Audit hour does not include the amount in respect of English audit report for 2020 and 2019.

C. Status of signing audit services related to the investee under the equity method with auditors

(Unit: thousand won)

Business year	Contract date	Service details	Service period	Service fee	Remarks
2020	2020.03.31	Audit of financial information of equity method investees	2020.03 ~ 2021.02	150,000	-
2019	2019.03.29	Audit of financial information of equity method investees	2019.03 ~ 2020.02	160,000	-
2018	-	-	-	-	-

D. Non-audit service contract

(Unit: thousand won)

Business year	Contract date	Service details	Service period	Service fee	Remarks
2020	2020.01.02	Consultation on the Establishment of Overseas Corporations	2020.01~2020.12	490,000	-
2019	-	-	-	-	-
2018	2018.11.27	Review the financial statements after reflecting the measures taken by the Securities and Futures Commission	2018.11~2018.12	70,000	-

E. Contents of discussions about financial statements

	Date	Attendees	Meeting type	Contents of discussion
1	2020.01.22	Audit committee : 3 people Company : Audit team leader & 5 people Auditor : 1 Partner & 1 person	Face-to-Face	- Progress of annual accounting audit - Progress of key audit matters - Progress of audit on internal accounting control system

2	2020.01.22	Audit committee : 3 people Company : Audit team leader & 6 people Auditor : 1 Partner & 1 person Diagnostic committee : 6 external experts	Face-to-Face	- Reporting and consultation on the progress of the diagnosis committee investigation
3	2020.02.21	Audit committee : 3 people Company : Audit team leader & 6 people Auditor : 1 Partner & 3 people Diagnostic committee : 5 external experts	Face-to-Face	- Progress of annual accounting audit - Progress of audit on internal accounting control System - Progress of the diagnosis committee investigation
4	2020.02.28	Audit committee : 3 people Company : Audit team leader & 2 people Auditor : 1 Partner & 1 person Diagnostic committee : 2 external experts	Face-to-Face	- Progress of annual accounting audit - Progress of key audit matters - Progress of audit on internal accounting control system
5	2020.02.28	Audit committee : 3 people Company : Audit team leader & 6 people Auditor : 1 Partner & 1 person Diagnostic committee : 5 external experts	Face-to-Face	- Conclusion of management and governing body based on the results of the diagnosis committee's investigation - Final report on the diagnosis committee
6	2020.03.03	Audit committee : 3 people Auditor : 1 Partner & 3 people	Written	- Progress of key audit matters - Results of audit of internal accounting control system - Other essential communications at the end of the audit
7	2020.04.20	Audit committee : 3 people Company : Audit team leader & 5 people Auditor : 1 Partner & 1 person	Face-to-Face	- Plan of annual accounting audit - Key matters from 1Q Review
8	2020.07.21	Audit committee : 3 people & 3 external expert Company : Audit team leader & 7 people Auditor : 1 Partner & 2 people	Face-to-Face	- Key matters from 2Q Review - Results & plan of key audit matters - Progress of annual accounting audit - Progress of audit on internal accounting control system
9	2020.09.09	Audit committee : 3 people Independent director : 1 person Diagnostic committee : 2 external experts Company : Audit team leader & 3 people Auditor : 1 Partner	Face-to-Face	- Report on the launch of a diagnosis committee on prosecution
10	2020.10.07	Audit committee : 3 people Independent director : 1 person Diagnostic committee : 7 external experts Company : Audit team leader & 7 people Auditor : 1 Partner & 2 people	Face-to-Face	- Progress and interim reports of diagnosis by the Diagnostic Committee
11	2020.10.21	Audit committee : 3 people & 3 external expert Independent director : 1 person Company : Audit team leader & 7 people Auditor : 1 Partner & 2 people	Face-to-Face	- Key matters from 3Q Review - Results & plan of key audit matters - Progress of annual accounting audit - Progress of audit on internal accounting control system
12	2020.10.21	Audit committee : 3 people Independent director : 1 person Diagnostic committee : 8 external experts Company : Audit team leader & 7 people Auditor : 1 Partner & 2 people	Face-to-Face	- Progress and interim reports of diagnosis by the Diagnostic Committee
13	2020.11.13	Audit committee : 3 people Independent director : 1 person Diagnostic committee : 5 external experts Company : Audit team leader & 4 people Auditor : 1 Partner & 2 people	Face-to-Face	- Progress and interim reports of diagnosis by the Diagnostic Committee
14	2020.12.16	Audit committee : 3 people Independent director : 1 person Diagnostic committee : 5 external experts Company : Audit team leader & 4 people Auditor : 1 Partner & 2 people	Face-to-Face	- Progress and interim reports of diagnosis by the Diagnostic Committee
15	2021.01.26	Audit committee : 3 people Independent director : 1 person Company : Audit team leader & 4 people Auditor : 1 Partner & 2 people	Face-to-Face	- Results & plan of key audit matters - Progress of Year-End audit (Financial report/Internal Accounting Control System)
16	2021.01.26	Audit committee : 3 people	Face-to-	- Progress and interim reports of diagnosis by the

		Independent director : 1 person Diagnostic committee : 8 external experts Company : Audit team leader & 4 people Auditor : 1 Partner & 2 people	Face	Diagnostic Committee
17	2021.02.24	Audit committee : 3 people Independent director : 1 person Diagnostic committee : 8 external experts Company : Audit team leader & 4 people Auditor : 1 Partner & 2 people	Face-to-Face	- Conclusion of management and governing body based on the results of the Diagnosis Committee's investigation - Final report of diagnosis by the Diagnostic Committee
18	2021.02.24	Audit committee : 3 people, 3 external experts Independent director : 1 person Company : Audit team leader & 4 people Auditor : 1 Partner & 2 people	Face-to-Face	- Results of key audit matters - Year-End audit result and other essential communication factors at the completion stage of the audit

F. Changes in auditors

On July 12, 2018 and November 14, 2018, the Company was notified of the designation of auditors for 3 years as a result of actions by the Securities and Futures Commission, and concluded an audit contract with Samjong KPMG LLC and external auditor of the 7th and 8th business years, while signing a new contract with designated auditor, Hanyoung EY. The Company has appointed Samil PwC as an external auditor for two consecutive business years in line with the Audit committee's evaluation process in accordance with Audit committee's operational regulations, as the application to suspend the ruling of a request to withdraw the measure recommended by the Securities & Futures Commission has been cited.

2. Matters regarding internal control

The company's external auditor performed an audit on the Internal Accounting Control System in effect on December 31, 2020. From the audit result, the auditor's opinion was 'unqualified' which means that the Internal Accounting Control System effective as of December 31, 2020, is designed and operated effectively in terms of importance according to the 'Internal Accounting Control System Design and Operation Framework'.

VI. Matters Regarding Executive Organizations Including the Board of Directors

1. Matters regarding the board of directors

A. Overview of the Board of Directors

As of the date when the business report is submitted, the Board of Directors (BOD) consists of three Executive directors (Kim Taehan, John Rim, and Kim Dongjoong) and four Independent directors (Jeong Seekwoo, Kwon Soonjo, Heo Geunyoung, and Eunice Kim).

The BOD consists of Executive committee, Audit committee, Compensation committee, Independent director recommendation committee, and Internal transaction committee.

The Company currently separates the CEO and the Chairman position to enhance independence and transparency of the BOD. The board appointed the former CEO Kim Taehan as the Chairman, as his managerial experiences enable him to mediate different opinions of Directors and make himself most qualified to manage board activities.

The Company is undergoing a mid- and long-term review of whether to increase board members, as the scale of business continuously expands.

<Changes in independent directors>

(Unit: person)

No. of directors	No. of independent directors	Changes in independent directors		
		Appointment	Dismissal	Resignation
7	4	1	0	0

※ As of March 20, 2020, Eunice Kim was newly appointed as Independent Director.

B. Important matters for resolution

No.	Date	Agenda	Result	Director (Attendance rate)						
				Kim Tae han (82%)	John Rim (100%)	Kim Dong joong (82%)	Jeong Seek woo (100%)	Kwon Soon jo (100%)	Heo Geun nyung (100%)	Eunice Kim (100%)
1 st	2020.01.10	1. Approval of the establishment of a foreign corporation in U.S.	Approved	For	N/A	For	For	For	For	N/A
2 nd	2020.01.22	1. Approval of FY2019 financial statements and annual business report	Approved	For		For	For	For	For	
3 rd	2020.02.28	(Report) Reporting the operation status of internal accounting management system	-	-		-	-	-	-	
		(Report) Evaluation and audit report of the internal accounting management system	-	-		-	-	-	-	
		(Report) Evaluation and report of compliance	-	-		-	-	-	-	
		(Report) Report of major facility supplementary investment	-	-		-	-	-	-	
4 th	2020.03.20	1. Decision to convene the AGM	Approved	For	For For	For	For	For	For	For For
		(Report) 2020 Incentive payment report	-	-		-	-	-	-	
		(Report) Report of new facility Investment	-	-		-	-	-	-	
		1. Appointment of CEO & director 2. Appointment of Chairman of BOD	Approved Approved	For For		For For	For For	For For	For For	

No	Date	Agenda	Result	Director (Attendance rate)						
				Kim Tae han (82%)	John Rim (100%)	Kim Dong joong (82%)	Jeong Seok woo (100%)	Kwon Soon jo (100%)	Heo Geun nyung (100%)	Eunice Kim (100%)
		3. Appointment of members of committees 4. Setting the remuneration of Directors 5. Approval of large-scale internal transactions	Approved Approved Approved	For For For	For For For	For For For	For For For	For For For	For For For	For For For
5 th	2020.04.20	(Report) FY2020 1 st quarter earnings report	Approved	For	For	For	For	For	For	For
6 th	2020.07.21	(Report) FY2020 2 nd quarter earnings report	-	-	-	-	-	-	-	-
		(Report) FY2020 1H company's evaluation result	-	-	-	-	-	-	-	-
		(Report) Report on management issue	-	-	-	-	-	-	-	-
		(Report) FY2020 July executive appointment	-	-	-	-	-	-	-	-
		1. Approval of transactions with major shareholder (Samsung Electronics) 2. Approval of financial instrument with Samsung Securities Co., Ltd.	Approved Approved	For For	For For	For For	For For	For For	For For	For For
7 th	2020.08.11	1. Approval of investment in Plant#4	Approved	For	For	For	For	For	For	For
8 th	2020.09.25	(Report) Report on progress regarding prosecution of executive	-	Absent	-	Absent	-	-	-	-
9 th	2020.10.21	(Report) FY2020 3 rd quarter earnings report	-	-	-	-	-	-	-	-
		1. Approval of transactions with major shareholder	Approved	For	For	For	For	For	For	For
		2. Approval of transactions with related parties	Approved	For	For	For	For	For	For	For
		3. Amendment of Internal Accounting Control System regulations and instructions	Approved	For	For	For	For	For	For	For
		4. Appointment of compliance manager	Approved	For	For	For	For	For	For	For
10 th	2020.12.16	(Report) FY2021 business plan report	Approved	For	For	For	For	For	For	For
		(Report) FY2020 Incentive payment plan report	Approved	For	For	For	For	For	For	For
		1. Approval of transactions with major shareholder	Approved	For	For	For	For	For	For	For
		2. Approval of transactions with related parties	Approved	For	For	For	For	For	For	For
		3. Joining a financial instrument of Samsung Securities	Approved	For	For	For	For	For	For	For
		4. Payment of retirement pension	Approved	For	For	For	For	For	For	For
11 th	2020.12.29	5. Charitable contributions	Approved	For	For	For	For	For	For	For
		6. Appointment of Chief Executive Officer	Approved	For	For	For	For	For	For	For
		(Report) Report on operational improvement plan by compensation committee	-	-	-	-	-	-	-	-
		1. Approval of legal fee payment for a lawsuit against management	Deferred	Absent	-	Absent	-	-	-	-
		2. Amendment of the Board of Directors operation regulations (Introduction and operation of support staffs)	Approved	Absent	For	Absent	For	For	For	For

※ As of March 20, 2020, Executive director Kim Tae han was re-elected; John Rim was newly appointed as Executive director; and Eunice Kim was newly appointed as Independent director.

※ Details of “Approval of large-scale internal transactions” (Mar 20, 2020)

- Content : Short-term financial instrument with Samsung Securities Co., Ltd.
- Limit amount : KRW 50 billion
- Period : Apr 1, 2020 ~ Jun 30, 2020

※ Details of “Approval of transactions with major shareholder” (Jul 21, 2020)

- Content : Drug Product Business Unit, Consulting with Samsung Electronics
- Limit amount : KRW 16,214,000
- Period : Aug 1, 2020 ~ Dec 31, 2020

※ Details of “Approval of transactions with major shareholder” (Oct 21, 2020)

- Company name: SAMOO Architects & Engineers
- Content : Design outsourcing for EDISON IV Project
- Limit amount : KRW 6.5 billion
- Period : Oct 2020 ~ Dec 2021

※ Details of “Approval of transactions with major shareholder” (Oct 21, 2020)

- Company name: Samsung Electronics
- Content : Payment of Samsung CI license fee
- Limit amount : KRW 9.8 billion
- Period : Feb 2018 ~ Jan 2021

※ Details of “Approval of transactions with major shareholder” (Oct 21, 2020)

- Company name: Samsung Engineering
- Content : Subcontract for construction of EDISON IV Project (Purchase/Construction for manufacturing site and UT facilities)
- Limit amount : KRW 709 billion
- Period : Oct 2020 ~ Dec 2023

※ Details of “Approval of transactions with major shareholder” (Dec 16, 2020)

Company name	Transaction	Contract date
Samsung Electronics	Group disclosure system	2021.01
	Disclosure system	2021.01
	Purchase training	2021.01
	Samsung CI license fee	2021.01
	Electronic equipment purchase & maintenance service	2021.01
Samsung C&T	Landscape management	2021.01
	Use of Yongin folk pavilion	2021.01
Samsung Welstory	Operation of in-house restaurant, Lease in-house café	2021.01
Samsung Research America	BD personnel service	2021.01
Samsung C&T Deutschland GmbH	Purchase of spare-parts and management of inventory	2021.01
Samsung Electronics Sales	Lease in-house mobile phone store	2021.01
	Purchase of electronic equipment	2021
Samsung Electronics Service	After service fee for electronic equipment	2021

※ Details of “Approval of transactions with related parties” (Dec 16, 2020)

Company name	Transaction	Contract date
Samsung Bioepis	CMO contract	2021
Samsung Securities	Deposit transaction	2021

C. Committees of the BOD

(1) Committees

Committee Name	Composition	Name	Purpose & authority	Remarks
Executive committee (2011.04.22)	3 Executive directors	(Chairperson) John Rim Kim Taehan Kim Dongjoong	<p>[Purpose] To deliberate the matters entrusted by the BOD out of the company's material management information, matters often entrusted by the BOD, and matters entrusted by the BOD as other material management information</p> <p>[Main authorities] ① Matters regarding management, etc. ② Matters regarding finance, etc. ③ Other matters to be referred</p>	-

Committee Name	Composition	Name	Purpose & authority	Remarks
Compensation committee (2016.08.10)	3 Independent directors 1 Executive director	(Chairperson) Kwon Soonjo Heo Geunnyung Eunice Kim Kim Dongjoong	[Purpose] To secure objectivity and transparency in determining director compensation [Main authorities] ① Matters regarding the compensation limit of registered directors ② Matters regarding the compensation system of registered directors ③ Matters entrusted by the BOD regarding director compensation	-
Internal transaction committee (2016.08.10)	3 Independent directors	(Chairperson) Heo Geunnyung Jeong Seokwoo Kwon Soonjo	[Purpose] To deliberate large-scale internal transactions in order to strength internal control over internal transactions and external control over shareholders and to enhance the efficiency of supervision over illegal support [Main authorities] ① To approve internal transactions ② To listen to the report of internal transactions ③ To order an ex-officio investigation of internal transactions ④ To suggest a corrective action against internal transactions	-

※ As of March 20, 2020, Executive director Kim Taehan was re-elected; John Rim was newly appointed as Executive director; and Eunice Kim was newly appointed as Independent director.

※ The Audit committee and the independent director recommendation committee were excluded according to the corporate disclosure preparation standards.

(2) Committee activities

※ The Audit Committee and Independent Director Recommendation Committee were excluded according to Corporate Disclosure Guidelines set forth by the Financial Supervisory Service Authority of South Korea.

① Executive committee

Date	Details of agendas	Result	Director (Attendance rate)		
			Kim Taehan (100%)	John Rim (100%)	Kim Dongjoong (100%)
2020.02.28	1. Approval of major facility supplementary investment	Approved	For	N/A	For
2020.03.19	1. Report of new facility Investment	Approved	For		For
2020.04.09	1. Approval of new contract	Approved	For	For	For
2020.04.21	1. Approval of new contract	Approved	For	For	For
2020.05.08	1. Extending the due dates of maximum limits of loans with respect to Wooribank	Approved	For	For	For
	2. Extending the due dates of maximum limits of loans with respect to Shinhanbank	Approved	For	For	For
	3. Extending the due dates of maximum limits of loans with respect to KEBhanabank	Approved	For	For	For
2020.05.21	1. Approval of new contract	Approved	For	For	For

	2. Approval of new contract	Approved	For	For	For
2020.06.05	1. Approval of new contract	Approved	For	For	For
2020.06.23	1. Approval of new contract	Approved	For	For	For
2020.07.16	1. Extending the due dates of maximum limits of loans with respect to Kookminbank	Approved	For	For	For
	2. Setting a new credit limit with Mizuhobank	Approved	For	For	For
2020.07.28	1. Approval of new contract	Approved	For	For	For
2020.08.05	1. Approval of new contract	Approved	For	For	For
2020.08.20	1. Approval of investment in DP, Pre-filled Syringe line	Approved	For	For	For
2020.09.22	1. Approval of new contract	Approved	For	For	For
	2. Approval of new contract	Approved	For	For	For
2020.09.25	1. Extending the due dates of maximum limits of loans with respect to Wooribank	Approved	For	For	For
	2. Setting a new credit limit with Wooribank	Approved	For	For	For
	3. Extending the due dates of maximum limits of loans with respect to Shinhanbank	Approved	For	For	For
	4. Setting a new credit limit with Mizuhobank	Approved	For	For	For
2020.10.06	1. Approval of new contract	Approved	For	For	For
2020.11.02	1. Approval of new contract	Approved	For	For	For
2020.11.06	1. Approval of new contract	Approved	For	For	For
2020.11.12	1. Extending the due dates of maximum limits of loans with respect to Hanabank	Approved	For	For	For
2020.12.15	1. Extending the due dates of maximum limits of loans with respect to Mizuhobank	Approved	For	For	For
	2. Setting a new credit limit with Wooribank	Approved	For	For	For
	3. Setting a new credit limit with Mizuhobank	Approved	For	For	For
	4. Extending the due dates of maximum limits of loans with respect to SMBC Bank	Approved	For	For	For

※ As of March 20, 2020, John Rim was newly appointed as Executive Director.

② Compensation committee

Date	Details of agendas	Result	Director (Attendance rate)			
			Kwon Soonjo (100%)	Heo Geun-nyung (100%)	Eunice Kim (-)	Kim Dong-joong (100%)
2020.02.28	1. Approval of annual salary of Executive directors	Approved	For	For	N/A	For
	2. Preliminary reviews of the remuneration of directors	Approved	For	For		For
2020.12.16	1. Report of remuneration of directors for 2020	-	-	-	-	-

※ As of March 20, Eunice Kim was newly appointed as Independent Director.

③ Internal transaction committee

Date	Details of agendas	Result	Director (Attendance rate)		
			Heo Geun-nyung (100%)	Jeong Seokwoo (100%)	Kwon Soonjo (100%)
2020.03.20	1. Purchasing financial instrument of Samsung securities Co., Ltd.	Approved	For	For	For
2020.07.21	1. Purchasing financial instrument of Samsung Securities Co., Ltd.	Approved	For	For	For
2020.10.21	1. Design subcontract with SAMWOO Architects & Engineers	Approved	For	For	For

	2. Payment of Samsung CI license fee	Approved	For	For	For
	3. Joining property insurance with Samsung Fire & Marine Insurance Co., Ltd.	Approved	For	For	For
	1. Payment of retirement pension	Approved	For	For	For
2020.12.16	2. Purchasing financial instrument	Approved	For	For	For
	3. Operation of In-house restaurant	Approved	For	For	For

※ Details of agendas “Approval of large-scale internal transactions” (Mar 20, 2020)

- Content : Purchasing financial instrument(Money Market Trust) of Samsung securities Co., Ltd.
- Limit amount : KRW 50 billion
- Period : Apr 1, 2020 ~ Jun 30, 2020

※ Details of “Approval of large-scale internal transactions” (Jul 21, 2020)

- Content : Purchasing financial instrument(Money Market Trust) of Samsung securities Co., Ltd.
- Limit amount : KRW 70 billion
- Period : Oct 1, 2020 ~ Dec 31, 2020

※ Details of “Approval of large-scale internal transactions” (Oct 21, 2020)

- ① Design subcontract with SAMWOO Architects & Engineers
 - Limit amount : KRW 6.5 billion
 - Period : Oct 1, 2020 ~ Sep 30, 2021
- ② Payment of Samsung CI license fee
 - Limit amount : KRW 9.8 billion
 - Period : Feb 1, 2018 ~ Jan 31, 2021
- ③ Joining property insurance with Samsung Fire & Marine Insurance Co., Ltd.
 - Limit amount : KRW 3.4 billion
 - Period : Dec 1, 2020 ~ Nov 30, 2021

※ Details of “Approval of large-scale internal transactions” (Dec 16, 2020)

- ① Payment of retirement pension
 - Content: Annual payment of retirement pension to Samsung Fire & Marine Insurance, Samsung Life Insurance and Samsung Securities
 - Limit amount : KRW 37.7 billion
- ② Purchasing financial instrument
 - Content : Purchasing financial instrument(Money Market Trust) of Samsung securities Co., Ltd
 - Limit amount : KRW 50 billion
 - Period : Jan 1, 2021 ~ Mar 31, 2021
- ③ Operation of In-house restaurant
 - Content : Contract for operation of In-house restaurant with Samsung Welstory
 - Limit amount : KRW 12.4 billion
 - Period : Jan 1, 2021 ~ Dec 21, 2021

D. Independence of directors

(1) Independence of directors

Directors are appointed at the general meeting of stockholders, and director candidates to be appointed

by the general meeting of stockholders are recommended by the Board of Directors, which is decided as a bill to be submitted to the general meeting of stockholders. The Company ensures directors' independence to make them objectively oversee the company business.

Name	Termination of term	Consecutive terms (No.)	Appointment background	Recommendation	Tasks
Kim Taehan	2023 AGM	O (3)	<ul style="list-style-type: none"> - A professional enterpriser who has been working as the CEO since the foundation of the Company and has been improving the Company by making important decisions with a long-term view - Representative of South Korea's bio industry with high awareness and reliability in relation to global pharmaceutical companies - The company expects to lead the company's future contracts and new business projects 	BOD	Executive Director, Chair of BOD
John Rim	2023 AGM	X	<ul style="list-style-type: none"> - Served as CFO through sales / marketing, production / RM / SCM at global biopharmaceutical companies Genentech, Roche, etc., and the possesses world's best global network and expertise - Based on a high understanding of the industry as a whole, he is expected to contribute to strengthening business capabilities and competitiveness and expanding new orders. 	BOD	CEO, Chair of Executive committee
Kim Dongjoong	2022 AGM	O (1)	<ul style="list-style-type: none"> - Contributed to the transplantation of advanced company management system to the company based on past experience of working for Samsung Electronics - Expected to contribute to the company's continued growth by overseeing HR, IT, Finance, Business planning and Business Innovation departments, which are the company's key management functions. 	BOD	Executive Director, CFO

Name	Termination of term	Consecutive terms (No.)	Appointment background	Recommendation	Tasks
Jeong Seokwoo	2022 AGM	O (1)	<ul style="list-style-type: none"> - As an accounting expert (KICPA) and a professor of business administration, he served as a non-executive member of the Korea Accounting Institute - Expected to contribute to stable accounting standards that is suitable for global business. 	Independent director recommendation committee	Independent director, Chairman of Audit committee
Kwon Soonjo	2022 AGM	O (1)	<ul style="list-style-type: none"> - As an expert in bioengineering, he served as a professor at Utah State University - Expected to contribute to the management of the latest technology and trends in bioengineering 	Independent director recommendation committee	Independent director, Chairman of Compensation committee, Chairman of Independent director recommendation committee
Heo Geunnyung	2022 AGM	X	<ul style="list-style-type: none"> - As a legal expert (lawyer), Served as presiding judge at the Seoul Central District Court and a professor at the Judicial Research and Training institute - As a legal expert with considerable experience in legal practice and academic fields, the Company looks forward to the inspection and reinforcement of existing legal system 	Independent director recommendation committee	Independent director, Chairman of Internal transaction committee
Eunice Kim	2023 AGM	X	<ul style="list-style-type: none"> - Global leader with good legal knowledge and communication skills based on her experience as an in-house lawyer, an inside and independent director in a number of financial companies - In the process of collaborating with global pharmaceutical companies, communication skills and legal knowledge will be a great asset, and she is expected to reflect diversity in the operation of the board of directors as outside directors of women. 	Independent director recommendation committee	Independent director

※ As of March 20, 2020, Executive Director Kim Taehan was re-elected; John Rim was newly appointed as Executive Director; and Eunice Kim was newly appointed as Independent director.

(2) Independent director recommendation committee

The Company has created the independent director recommendation committee on August 10, 2016 for the recommendation of independent director candidates, and the committee will review their

competence and recommend qualified persons. The independent director recommendation committee is composed of three directors including Executive director Kim Taehan and Independent directors Kwon Soonjo, Jeong Seokwoo, and Eunice Kim.

Date	Details of agendas	Result	Director (Attendance rate)			
			Kwon Soonjo (100%)	Jeong Seokwoo (100%)	Eunice Kim (-)	Kim Taehan (100%)
2020.02.28	1. Recommendation of independent directors	Approved	For	For	N/A	For

E. Expertise of independent directors

The Company provides the independent directors with access to support staff so they are able to perform their duties professionally in the BOD and the Board committees. The support staff provides the Directors with reference materials corresponding to the meeting agendas well in advance so Directors will have the ample opportunity thoroughly review the topics to be discussed before the Board and committee meetings. If necessary, the Directors are provided with separate information sessions on any item on the agenda and they are also frequently provided updates on other key management issues

- Secretariat of the Board of Directors

Name	Department/Position	Task
Kim Yongsin	Global Client Satisfaction Center/ Vice President	General Management
Cho Sunghwan	General Affair Part / Part Leader	Operation
Lee Eunwon	General Affair Part / Pro	
Jung Dasom	General Affair Part / Pro	

- Education of Independent directors

Date	Educator	Attendant	Reasons for absence	Contents of Education
2020.01.07	PwC	Jeong Seokwoo	-	- Attend PwC Corporate Directors Exchange (~01.08)
2020.01.13	JP Morgan	Jeong Seokwoo Kwon Soonjo Heo Geunnyung	-	- Attend JP Morgan healthcare conference (~01.17)
2020.05.18	Korea Health Industry Promotion Agency	Jeong Seokwoo Kwon Soonjo Heo Geunnyung Eunice Kim	-	- Attend BIO KOREA 2019 conference and exhibition(Online)(~05.23)
2020.07.07	Audit Committee Forum	Jeong Seokwoo	-	- 2020 1 st Regular Forum for Auditors and Auditors
2020.07.24	SamjongKPMG	Jeong Seokwoo	-	- SamjongKPMG : A Case Study on the Activities of the Audit Committee through Video Drama

2. Matters regarding an audit system

A. Profile of the member of the Audit committee

Name	Career	Accounting and Finance expertise		
		Applicable status	Expert type	Related experience
Jeong Seok woo	<ul style="list-style-type: none"> - Prof., Business School, Korea University (1997~present) - Chairman, Korea Accounting Association(2019~present) - Independent Director, SK Networks(2019~present) - Non-executive member, Korea Accounting Institute (2016~2019) - Independent Director, SGI Seoul Guarantee Insurance (2016~2018) - Non-executive member, Securities & Futures commission (2013~2016) - Member, International Commission of Inquiry (2009~2011) - State Univ. of New York, Buffalo, Doctor in business administration (1996) - Korea Univ. Master of Business (1986) - Korea Univ., Bachelor of Business (1984) 	Yes	② Degree holder in the field of accounting & finance (Type 2)	<ul style="list-style-type: none"> - Basic qualifications: Acquisition of a master's degree or higher related to accounting &finance · State Univ. of New York, Buffalo, Doctor in Business Administration (1996) · Korea Univ., Master of Business (1986) - Work experience requirement: Over five years of overall work experience as a researcher or assistant professor in accounting or finance fields at a research institute or a university · Prof. in Business School, Korea University (1997~present)
Kwon Soon jo	<ul style="list-style-type: none"> - Prof. in Biological Engineering, Inha University (2013~present) - Chairman, International Cooperation Committee, the American Institute of Biological Engineering (2011~2013) - Prof., Utah State University (2006~2013) - Prof., Florida State University (2002~2006) 	-	-	-
Heo Geun nyung	<ul style="list-style-type: none"> - Representative Lawyer, Pyeongan Law Firm (2016~) - Lawyer, GILDO Law Firm (2011~2016) - Senior Judge, Seoul Central District Court (2004~2007) - Prof., Judicial Research and Training Institute (2001~2004) - Chief Judge, Cheongju District Court (1999~2001) - Juridical researcher, Supreme Court (1997~1999) - Judge, Seoul High Court (1996~1997) 	-	-	-

B. Independence of Audit committee members

Name	Appointment Background	Recommendation	Term	Reappointment (No.)	Relationship with the company	Relationship with the largest/major shareholder
Jeong Seok woo	<ul style="list-style-type: none"> - As an accounting expert (KICPA) and a professor of business administration, he served as a non-executive member of the Korea Accounting Institute - Expected to contribute to stable accounting standards that is suitable for global business. 	Independent director recommendation committee	2019.03~2022.03	O (1)	-	Affiliate Executive (SBL)
Kwon Soon jo	<ul style="list-style-type: none"> - As an expert in bioengineering, he served as a professor at Utah State University - Expected to contribute to the management of the latest technology and trends in bioengineering 	Independent director recommendation committee	2019.03~2022.03	O (1)	-	Affiliate Executive (SBL)
Heo Geun nyung	<ul style="list-style-type: none"> - As a legal expert (lawyer), Served as presiding judge at the Seoul Central District Court and a professor at the Judicial Research and Training institute - As a legal expert with considerable experience in legal practice and academic fields, the Company looks forward to the inspection and reinforcement of existing legal system 	Independent director recommendation committee	2019.03~2022.03	X	-	Affiliate Executive (SBL)

※ Independent Director Jung Seokwoo and Kwon Soonjo were recommended by the Board of Directors at the time of their initial appointment (August 2016) for reasons that no Independent director recommendation committee was installed.

The Company's Audit committee is created in accordance with Article 542-11 of the Commercial Act,

and three independent directors who constitute the Audit committee as stated above meet eligibility requirements both for Independent directors and Audit committee members.

Provision	Details	Remarks
Article 415-2	- Consists of more than 3 directors with more than 2/3 of independent directors	- 3 Independent directors
Article 542-11	- Meets Article 415-2 - More than one member must be an accounting or financial specialist prescribed by Presidential Decree. - Representative of Audit committee must be an independent director.	- 3 Independent directors - Jeong Seokwoo (Prof. of Business Dept./CPA) - Chairperson: Jeong Seokwoo
Article 542-12	- Elect directors at the shareholder's meeting and appoint Audit committee members among the elected directors	- Elect three independent directors at general shareholders' meeting and appoint them as an Audit committee member

Meanwhile, the Audit committee is eligible to request directors to report company business or investigate the company's business operation and financial status for effective auditing.

C. Activities of Audit committee

Date	Details of agendas	Result	Directors		
			Jeong Seok woo (100% attendance)	Kwon Soon jo (100% attendance)	Heo Geun nyung (100% attendance)
2020.01.22	1. Report on 2019 financial statements and annual business report 2. Report on the results of the information asset implementation inspection 3. Report on progress of accounting audit	- - -	- - -	- - -	- - -
2020.01.22	[Resolution Item] 1. Evaluation of the department responsible for internal audit [Report Item] 1. Report on results of the Audit committee's work and independence assessment 2. Report on the 4 th result of the assessment committee	Approved - -	For - -	For - -	For - -
2020.02.21	1. Report on progress of internal accounting evaluation by the dedicated organization 2. Report on progress of internal accounting evaluation by law firms/PA 3. Report on progress of internal accounting evaluation by External auditor	- - -	- - -	- - -	- - -
2020.02.28	[Resolution Item] 1. Approval of the agenda for the AGM [Report Item] 1. Report on Internal Accounting Control System 2. Report on progress of annual audit	Approved - -	For - -	For - -	For - -
2020.02.28	1. Final report by of the assessment committee 2. Report on annual activity plan of Audit committee 3. Report on annual activity plan in-house audit team	- - -	- - -	- - -	- - -
2020.04.20	1. Report on 2020 1Q financial statements 2. Report on 2020 Plan of the internal accounting management system 3. Report on 2020 audit plan of external auditor 4. Progress of 2020 1Q audit	- - - -	- - - -	- - - -	- - - -
2020.07.21	1. Report on 2020 2Q financial statements 2. Report on audit results for the 1 st half of 2020 and audit plans for the 2 nd half of 2020 3. Report on 2020 internal accounting management system design evaluation 4. Review of PA's internal accounting management system design assessment report 5. Introduction of Digital Analytic Tool 6. Progress of Accounting Review in the 1 st Half of 2020 7. Progress of internal accounting management system audit	- - - - - - -	- - - - - - -	- - - - - - -	- - - - - - -
2020.09.09	1. Report on the launch of the 2 nd diagnostic committee	-	-	-	-
2020.10.07	1. Report on the 1 st result of the 2 nd diagnostic committee	-	-	-	-
2020.10.21	[Resolution Item] 1. Amendment of Internal Accounting Control System regulation and instruction [Report Item] 1. Report on 2020 3Q financial statements	Approved - -	For - -	For - -	For - -

	2. Report on 2020 half year Internal Accounting Control System evaluation	-	-	-	-
2020.10.21	1. Report on the 2 nd result of the 2 nd diagnostic committee	-	-	-	-
	2. Progress of 2020 3Q audit	-	-	-	-
	3. Progress of internal accounting management system audit	-	-	-	-
2020.11.13	1. Report on the 3 rd result of the 2 nd diagnostic committee	-	-	-	-
2020.12.16	1. Report on appointment of new legal compliance team leader	-	-	-	-
	2. Report on the 4 th result of the 2 nd diagnostic committee	-	-	-	-

D. Education plan & status of Audit committee

(1) 2020 Education plan of Audit committee

	Education plan	
	Name of education	Educator
2020.01	- PwC CORPORATE DIRECTORS EXCHANGE	PwC
2020.01	- JP Morgan healthcare conference	JP Morgan
2020.05	- BIO KOREA 2020	Korea Health Industry Promotion Agency
2020.06	- Seminar by Board of Audit of Listed Companies	Board of Audit of Listed Companies
2020.07	- Seminar inviting outside experts	Internal Control Operation Part
2020.09	- Seminar on accounting and audit issues	Audit Committee Forum
2020.10	- A breakfast lecture at the Board of Audit of Listed Companies	Board of Audit of Listed Companies
2020.11	- Seminar by Board of Audit of Listed Companies	Board of Audit of Listed Companies
2020.12	- Seminar on accounting and audit issues	Audit Committee Forum

※ It is subject to change according to our circumstances.

(2) 2020 Education status of Audit committee

Date	Educator	Attendant	Reasons for absence	Contents of Education
2020.01.07	PwC	Jeong Seokwoo	-	- Attend PwC CORPORATE DIRECTORS EXCHANGE(~1.8)
2020.01.13	JP Morgan	Jeong Seokwoo Kwon Soonjo Heo Geunnyung	-	- Attend JP Morgan healthcare conference (~1.17)
2020.05.18	Korea Health Industry Promotion Agency	Jeong Seokwoo Kwon Soonjo Heo Geunnyung	-	- Attend BIO KOREA 2019 conference and exhibition(Online)(~05.23)

Date	Educator	Attendant	Reasons for absence	Contents of Education
2020.07.07	Audit Committee Forum	Jeong Seokwoo	-	- 2020 1 st Regular Forum for Auditors and Auditors
2020.07.24	SamjongKPMG	Jeong Seokwoo	-	- SamjongKPMG : A Case Study on the Activities of the Audit Committee through Video Drama

※ In order to enhance the Audit committee's understanding of internal accounting and business through communication with the Audit committee, the company has been delivering various information to the auditors in the form of news clip since March 2020, including biweekly work, trends related to internal accounting, and the status of the company and pharmaceutical industry.

E. Audit committee support department

Department	No.	Position(Service Period)	Details
Internal Control Operation Part	5	1 Part Leader, 4 Pros (1.4years)	- Design and operation of internal accounting control system - Operation and education of Audit committee
Audit Team	2	1 Team leader, 1 Pro (0.6years)	- Audit committee Support - Internal control process regular inspection

※ On October 1, 2019, Audit Team was established under the Audit Committee to actively support the work requested by the Audit Committee.

※ Service Period is based on the period of responsibility for support work.

※ On December 16, 2020, the new Audit Team leader was appointed.

F. Compliance officer

Name	Career	Qualification
Moon Hyung Woo	- Master degree in Laws, Seoul National University - Lawyer, Law firm KIM CHANG & LEE (2006~2017) - Team leader, Legal Compliance Team, Samsung Biologics Co., Ltd. (2017~present)	Qualified (Article 542-13 Clause 5 No. 1 of Commercial Act)

G. Major activity details of compliance officer

The company conducts regular/non-regular compliance activities at the workplace, and based on the results of the activities, the company is effectively supporting compliance activities so that the company and its employees can comply with all laws and regulations by reflecting the issues that need improvement.

	Major Inspection & Activity details
2020.02	- Regular report to BOD on compliance activity - Reorganization of compliance organization
2020.03	- Compliance education for new employee
2020.05	- Compliance education(Subcontracting Act)
2020.06	- CEO compliance letter - Compliance education for experienced employee
2020.07	- Compliance education for experienced employee

2020.08	- Compliance education for new/experienced employee & intern
2020.09	- CP PR (Security of trade secrets, Capital Markets Act, etc.)
2020.10	- Compliance education for all employee
2020.11	- Compliance inspection(Authorization)

H. Compliance officer support team

Department	No.	Position (Service Period)	Details
Legal Compliance Team	11	8 Lawyers (2.8 years) 3 Pros (3.9 years)	- Inspection and education of CPs such as fair trade and anti-graft law - Reviewing transaction contracts and in-house regulations

※ Service Period refers to time performing work relevant to support activity.

3. Matters regarding the exercise of shareholders' voting rights

A. Voting system

On February 26, 2021, the Company's board of Directors approved an electronic voting system to enhance convenience in exercising voting rights for shareholders. The Company will implement the electronic voting system at its 10th annual shareholder meeting, held on March 19, 2021.

The Company has not adopted a cumulative voting system and voting in writing.

B. Minority shareholders' rights

No minority shareholder rights were exercised during the reporting period.

C. Competition over management rights

No competition over management rights occurred during the reporting system.

VII. Matters Regarding Shareholders

1. Stocks held by the largest shareholder and related parties

A. Stocks held by the largest shareholder and related parties

(As of Dec 31, 2020)

(Unit: Share, %)

Name	Relationship	Class of stock	Share number and ratio				Remarks
			Beginning of the year		Ending of the year		
			No. of shares	Share ratio	No. of shares	Share ratio	
Samsung C&T Corporation	Largest shareholder	Common stock	28,742,466	43.44	28,742,466	43.44	-
Samsung Electronics Co., Ltd.	Related party	Common stock	20,836,832	31.49	20,836,832	31.49	-
Samsung Life Insurance Co., Ltd. (special account)	Related party	Common stock	34,381	0.05	48,700	0.07	Trading
Kim Taehan	Related party	Common stock	45,500	0.07	45,000	0.07	Gift
Kim Dongjoong	Related party	Common stock	4,300	0.01	4,300	0.01	-
Total		Common stock	49,663,479	75.06	49,677,298	75.08	-
		Preferred stock	-	-	-	-	-

B. Overview of the largest shareholder

(1) Corporation Information

Name	Number of Investors (Number of persons)	Chief Executive Officer (Representative Member)		Business Executive (Business Member)		Largest Shareholder (Largest Investor)	
		Name	Share(%)	Name	Share(%)	Name	Share(%)
Samsung C&T Corporation	165,305	Lee Young Ho	-	-	-	JY Lee, etc.	33.42
		Koh Jung Suk	-	-	-	-	-
		Chung Keum Yong	-	-	-	-	-

※ The number of investors above is the number of common stock shareholders of Samsung C&T Corporation recorded up to the latest shareholder list closure date which is December 31, 2020. The shares of Chief Executive Officer, Business Executive, and Largest Shareholder are recorded up to the disclosure date which is December 31, 2020.

- Changes in Chief Executive Officer, Business Executive, and Largest Shareholder

Date of change	Chief Executive Officer (Representative Member)		Business Executive (Business Member)		Largest Shareholder (Largest Investor)	
	Name	Share(%)	Name	Share(%)	Name	Share(%)
2016.02.18	Yoon Ju Hwa	-	-	-	-	-
2018.03.22	Choi Chi Hun	-	-	-	-	-
2018.03.22	Kim Shin	-	-	-	-	-
2018.03.22	Kim Bong Yung	-	-	-	-	-
2018.03.22	Lee Young Ho	-	-	-	-	-
2018.03.22	Koh Jung Suk	-	-	-	-	-
2018.03.22	Chung Keum Yong	-	-	-	-	-

※ The date of change above is the day when Yoon Ju hwa, Choi Chi Hun, Kim Shin and Kim Bong Yung resigned, and when Lee Young Ho, Koh Jung Suk and Chung Keum Yong were inaugurated.

※ For changes in the share ownership status during the period of public disclosure, changes in ownership and statement by dates are separately disclosed in the electronic disclosure system, so please refer to the "2020 Annual report" by Samsung C&T Corporation.

(2) Financial status

(Unit: million won)

Samsung C&T Corporation	
Total assets	54,331,740
Total liabilities	21,386,258
Total stockholder's equity	32,945,482
Sales	30,216,119
Operating income	857,080
Current net income	1,160,651

※ The values above are based on the consolidated financial statements.

(3) Business status

Samsung C&T Corporation, the largest shareholder of Samsung Biologics Co., Ltd., is located in 26, Sangil-ro 6-gil, Gangdong-gu, Seoul, Republic of Korea, and engages mainly in business areas at home and abroad: the engineering & construction sector including building, civil infrastructure, plant, and housing; the trading & investment sector including natural resources, steel, chemical & industrial materials, and living industrial; the fashion sector including apparel products manufacturing, sales business and textile processing; the resort sector including landscaping and Everland (drier park), Caribbean Bay (water park), golf club, and catering (Samsung Welstory) and the biopharmaceutical outsourcing & biosimilar sector.

※ For details of the largest shareholder, refer to Samsung C&T Corporation's 2020 Annual Report for published in the DART (Data Analysis, Retrieval, and Transfer System).

2. Changes of the largest shareholder

Changes of the largest shareholder during the time period subject to disclosure are as follows:

(As of Dec 31, 2020)

(Unit: share, %)

Date	Largest shareholder	No. of stocks held	Share ratio	Cause of Change	Remarks
2011.04.22	(Old) Cheil Industries Inc.	600,000	40,00%	Establishment	-
2011.04.22	Samsung Electronics Co., Ltd.	600,000	40.00%	Establishment	-
2015.09.02	Samsung C&T Corporation	14,069,833	51.04%	Note1)	Note2)

Note1) Samsung C&T Corporation is the sole largest shareholder, as Cheil Industries Inc., a survival corporation after merger between Samsung C&T Corporation and (old) Cheil Industries Inc. which was the largest shareholder was renamed to Samsung C&T Corporation.

Note2) Currently, the largest shareholder Samsung C&T Corporation has 28,742,466 shares which is 43.44% stake.

3. Distribution of shares

A. Shareholders with over 5% ownership and stocks held by the Employee Share Ownership Association

(As of Dec 31, 2020)

(Unit: share)

Category	Name of shareholders	No. of shares	Share ratio	Remarks
Shareholders with over 5% ownership	Samsung C&T Corporation	28,742,466	43.44%	-
	Samsung Electronics Co., Ltd.	20,836,832	31.49%	-
Employees Share Ownership Association		33,293	0.05%	-

B. Status of Minority shareholders

(As of Dec 31, 2020)

(Unit: share)

Category	Shareholders			Shares owned			Remarks
	No. of Minority shareholders	No. of total shareholders	Ratio	No. of Minority shares	No. of total shares	Ratio	
Minority shareholders	141,199	141,232	99.98%	14,259,488	66,165,000	21.55%	Shareholders holding stocks below 1/100 of total stocks issued

4. Shareholders service

Details of stock warrants in the articles of incorporation	<p>Article 11 (Issuance and allocation of shares)</p> <p>① Issuance of new shares by the Company by a resolution of the Board of Directors shall be in accordance with the following:</p> <p>2. To the extent not exceeding 30/100 of the total number of shares issued and outstanding shares, by granting the preemptive rights to subscribe for the new shares to certain persons by a means other than as prescribed by the Subsection (1) above (including the Company's existing shareholders) if necessary for improvement of the Company's financials, introduction of new knowledge, protection of control, and fulfillment of managerial purpose of the Company toward foreign and domestic financial institutions, investors, partners, etc.</p> <p>3. To the extent not exceeding 50/100 of the total number of shares issued and outstanding shares, by granting the preemptive rights to subscribe for the new shares to public (including the Company's existing shareholders) by a means other than as prescribe by the Subsection (1) above, for the purpose of listing or other financing pursuant to Financial Investment Services and Capital Markets Act.</p> <p>② If the shares are issued pursuant to the Section (1) Subsection (3) above, the Company shall issue the new shares as follows by a resolution of the Board of Directors:</p> <p>1. By offering new shares to public, without setting any criterion for eligibility to subscribe</p> <p>2. By offering new shares to members of the Employees Share Ownership Association, and by granting right to subscribe the shares not subscribed by the members of the Employees Share Ownership Association to public;</p> <p>3. By granting the preemptive rights to subscribe for the new shares to the Company's existing shareholders, and by granting the rights to subscribe for the new shares to public if there are unsubscribed shares; or</p> <p>4. By granting the rights to subscribe for the new shares to certain types of persons pursuant to reasonable criterion prescribed by the relevant law, including a forecast of demand by an investment trader of an investment broker as an underwriter or an agent</p> <p>③ If new shares are issued under the Section (1) Subsection (2) and (3) above, the Company shall notify the existing shareholders, or give public notice of the information as required under the Article 416 (1) (2), (2-2), (3), and (4) of the Korean Commercial Code (the "KCC") two (2) weeks prior to the payment date; provided that public disclosure of a material fact report with the Financial Services Commission and the Exchange pursuant to Article 165-9 of the Financial Investment Services and Capital Markets Act may be made in lieu of the notification and public notice above.</p> <p>④ If shares are issued under each Subsection of Section (1) above, the class, number and issue price of the shares shall be determined by a resolution of the Board of Directors.</p> <p>⑤ In case where the Company issues new shares and there are shares not subscribed for or paid for, the terms of their disposition such as the appropriate issue price shall be determined by a resolution of the Board of Directors pursuant to the relevant laws.</p> <p>⑥ In case where the Company issues new shares and there are fractional shares, the terms of their disposition shall be determined by a resolution of the Board of Directors</p> <p>⑦ If new shares are issued under the Section (1) Subsection (1), the Company shall issue the preemptive right certificates to the shareholders.</p>		
Closing date	December 31	General Shareholders' Meeting	Within 3 months after the business year ends
Closure of stockholders' list	From January 1 to January 31		
Type of share certificates	-		
Transfer agent	Korea Securities Depository		
Privileges of shareholders	Not Applicable		
Public notice	<p>Homepage (https://www.samsungbiologics.com)</p> <p>But, publish in Korea Joongang Daily in the event of computer problems or other unavoidable circumstances</p>		

5. Share price and stock trading performance

(Unit: won, share)

Class			2020.12	2020.11	2020.10	2020.09	2020.08	2020.07
Common stock	Share price	Highest	880,000	812,000	723,000	781,000	843,000	790,000
		Lowest	789,000	698,000	630,000	673,000	735,000	730,000
		Average	812,381	772,190	684,421	745,857	793,550	749,783
	Trading volume	Highest (day)	507,215	447,218	301,106	199,488	761,446	371,837
		Lowest (day)	66,994	72,329	46,859	59,316	100,079	93,656
		Monthly (Thousand)	3,554	3,559	2,188	2,384	5,099	4,429

※ The Company was listed on the stock market as of November 10, 2016.

VIII. Matters Regarding Executives and Employees

1. Executives and employees

A. Registered executives

(As of Dec 31, 2020)

(Unit: share)

Name	Gender	Date of birth	Position	Registration status	Employment status	Tasks	Career	No. of shares held		Term of service	Termination of term
								With voting rights	Without voting rights		
Kim Taehan	M	1957.11	Executive director	Registered	Full-time	Chairman of Board of Directors	<ul style="list-style-type: none"> - Chairman, Samsung Biologics Co., Ltd. (2020.12~) - CEO, Samsung Biologics Co., Ltd. (2011.04~2020.12) - Samsung New business project team (2008.05~2011.04) - Univ. of Texas, Austin, Doctor in Chemical engineering 	45,000	-	9 years 8 months	2023.03.20
John Rim	M	1961.10	Chief Executive Officer	Registered	Full-time	Chief Executive Officer	<ul style="list-style-type: none"> - CEO, Samsung Biologics Co., Ltd. (2020.12~) - CMO2 Leader, Samsung Biologics CMO2 Center (2018.10~2020.12) - Northwestern Univ., MBA 	-	-	2 year 4 month	2023.03.20
Kim Dongjoong	M	1965.02	Executive director	Registered	Full-time	General management support	<ul style="list-style-type: none"> - Senior Vice President & CFO, Business Resources Innovation Center, Samsung Biologics, Co., Ltd. (2017.04~) - Vice President & CFO, Corporate Management Office, Samsung Biologics, Co., Ltd. (2014.12~2017.03) - Head of Planning Support Team, Samsung Electronics Mechatronics & Manufacturing Technology Center, Samsung Electronics Co., Ltd. (2013.12~2014.11) - Ajou Univ., Master of Business Administration 	4,300	-	6 years	2022.03.21
Jeong Seokwoo	M	1962.07	Independent director	Registered	Part-time	Independent director (Chairman of Audit committee)	<ul style="list-style-type: none"> - Prof. in Business School, Korea University (1997.03~) - Chairman, Korea Accounting Association(2019~2020) - State Univ. of New York, Buffalo, 	-	-	4 years 5 months	2022.03.21

							Doctor in business administration				
Kwon Soonjo	M	1965.06	Independent director	Registered	Part-time	Independent director (Auditor)	<ul style="list-style-type: none"> - Prof. in Biological Engineering, Inha University (2013.03~) - Prof. Utah State University (2006~2013) - Univ. of California, Irvine, Doctor of Biotechnology 	-	-	4 years 5 months	2022.03.21
Heo Geunnyung	M	1956.01	Independent director	Registered	Part-time	Independent director (Auditor)	<ul style="list-style-type: none"> - Representative Lawyer, PyeongAn law firm (2020~) - Senior Judge, Seoul Central District Court (2004~2007) - Master of Law at Seoul National University 	-	-	1 year 10 month	2022.03.21
Eunice Kim	W	1959.03	Independent director	Registered	Part-time	Independent director	<ul style="list-style-type: none"> - Prof. in Law school, Ewha W. University (2010~) - Vice chairman, International Association of Korean Lawyers (2008~) - Vice president, Hana Financial Group Inc. (2008~2010) - Yale University Law School J.D. 	-	-	10 month	2023.03.20

※ As of March 20, 2020, Executive director Kim Taehan was re-elected; John Rim was newly appointed as Executive Director; and Eunice Kim was newly appointed as Independent Director.

B. Unregistered executives

(As of Dec 31, 2020)

(Unit: share)

Name	Gender	Date of birth	Position	Registration status	Employment status	Tasks	Career	No. of shares held		Term of service
								With voting rights	Without voting rights	
Yun Gwanghun	M	1956.07	Executive Vice President	Unregistered	Full-time	General plant construction/ infrastructure	- Center Leader, Samsung Biologics EPCV Center (2018.10~) - CMO2 Leader, Samsung Biologics CMO2 (2018.05~2018.09) - Swiss Federal Institute, Doctor of Chemical engineering	900	-	8 years
Lee Kyusung	M	1960.10	Executive Vice President	Unregistered	Full-time	General manufacturing technology	- Center Leader, Samsung Biologics CMO1 Center (2018.05~) - Center Leader, Samsung Biologics Client Satisfaction Center (2017.04~2018.04) - Purdue Univ., Doctor of Chemical engineering	13,000	-	9 years 8 months
Kim Ingyu	M	1965.07	Senior Vice President	Unregistered	Full-time	Facility operation	- Team Leader, Samsung Biologics Plant Technology Team (2020.06~) - BU Leader, Samsung Biologics P3 BU (2018.05~2020.06) - Yonsei Univ., Master of Economics	-	-	4 years 11 months
James Park	M	1966.04	Senior Vice President	Unregistered	Full-time	Contract strategy planning/ Marketing	- Center Leader, Samsung Biologics Global BD Center (2018.03~) - Team Leader, Samsung Biologics Global BD 2Team (2017.04~2018.02) - Columbia Univ., Master of Industrial engineering	1,900	-	5 years 1 months
Sam MacHour	M	1963.03	Senior Vice President	Unregistered	Full-time	Quality assurance	- Center Leader, Samsung Biologics Quality Center (2019.07~) - Quality Executive, Lonza (2015.09~2018.11) - Concordia Univ., Master of Atomic Nucleophysics	-	-	1 year 7 month
Yoon Hoyeol	M	1963.08	Senior Vice President	Unregistered	Full-time	Business planning/ operation support	- Center Leader, Samsung Biologics CSC Center (2017.04~) - Operation, Samsung Biologics Corporate Business Operation (2015.02~2017.03) - State Univ. of New York, Stony Brook, Master of Technology Management	2,240	-	9 years
James Choi	M	1967.08	Senior Vice President	Unregistered	Full-time	IT / Marketing / Global PR / IR	- Center Leader, Samsung Biologics GIM Center (2020.06~) - CIO, Samsung Biologics GIO Team (2014.08~2020.06) - Univ. of Southern California, MBA	711	-	6 years 4 month

Daniel Slone	M	1951.01	Vice President	Unregistered	Full-time	Production process	- BU Leader, Samsung Biologics DS 1/2 BU (2018.11~) - Team Leader, Samsung Biologics Purification Team (2014.01~2018.10) - Florida International Univ., Bachelor of Biology	-	-	7 years
Kim Yongsin	M	1964.05	Vice President	Unregistered	Full-time	HR / SHE / Information Security	- Center Leader, Samsung Biologics Global Client Satisfaction Center (2020.02~) - Team Leader, Samsung Biologics Global Employee Satisfaction Team(HR) (2014.12~2020.02) - Kyung Hee Univ., Russian Language & Literature	1,030	-	5 years
Ahn Yongho	M	1968.04	Vice President	Unregistered	Full-time	CDO R&D	- Team Leader, Samsung Biologics CDO R&D Team (2018.12~) - R&D executive, Archigen Biotech (2015.01~2018.11) - KAIST, Doctor of Biology	-	-	2 year 1 months
Hwang Wangoo	M	1972.02	Vice President	Unregistered	Full-time	CRO Business	- Team Leader, Samsung Biologics CRO Business Team (2019.07~) - Team Leader, Samsung Biologics P3 QC Team (2018.05~2019.07) - Seoul National Univ., Doctor of Chemistry	190	-	3 years 1 months
Lee Chungwoo	M	1969.12	Vice President	Unregistered	Full-time	Facility Operation	- Team Leader, Samsung Biologics Facility Technology Team (2017.04~) - Team Leader, Samsung Biologics Facility Maintenance Team (2015.12~2017.03) - Hanyang Univ., Bachelor of Electrical engineering	-	-	3 years 7 months
Shim Byunghwa	M	1968.01	Vice President	Unregistered	Full-time	Business Innovation	- Team Leader, Samsung Biologics Business Innovation Team (2018.03~) - Team Leader, Samsung Biologics Finance Team (2014.12~2018.02) - Sogang Univ., Bachelor of Economics	300	-	2 years 10 months
Kim Kijoong	M	1969.08	Vice President	Unregistered	Full-time	Information Security	- Executive, Samsung Biologics ISA Team (2020.02~) - Group Leader, Samsung Electronics Information Security Group(Mobile) (2017.11~2019.12) - Kyoungbuk National Univ., Bachelor of Inorganic material engineering	20	-	1 year 1 Months
Yang Eunyoung	W	1974.12	Vice President	Unregistered	Full-time	CDO Business	- Team Leader, Samsung Biologics CDO Business Team (2018.03~) - Part Leader, Samsung biologics BD Strategy Part (2015.11~2018.02) - Seoul National Univ., Bachelor of Pharmacy	-	-	11 months

Park Segang	M	1973.12	Vice President	Unregistered	Full-time	Manufacturing Operation	- Team Leader, Samsung biologics DS3 Cell Culture Team(2020.06~) - Team Leader, Samsung biologics Plant Technology Team (2020.02~2020.06) - Inha Univ., Bachelor of Chemical engineering	330	-	11 months
Jin Yonghwan	M	1966.10	Vice President	Unregistered	Full-time	Manufacturing Technology	- Team Leader, Samsung biologics DS3 MSAT Team (2018.12~) - Team Leader, Samsung biologics CDO R&D Team (2017.03~2018.11) - Seoul National Univ., Doctor of Molecular Biology	171	-	11 months
Regina Choi	W	1970.08	Vice President	Unregistered	Full-time	sCMO Business	- BU Leader, Samsung biologics sCMO BU (2019.10~) - Team Leader, Samsung biologics PM Team (2017.04~2019.09) - Cooper Union, Master of Chemical engineering	1,200	-	6 months
Moon Hyungwoo	M	1970.01	Vice President	Unregistered	Full-time	Legal Compliance	- Team Leader, Samsung biologics Legal Compliance Team (2017.07~) - Lawyer, Kim Chang & Lee Law Firm (2006.02~2017.05) - Seoul National Univ., Master of Law	-	-	1 month
Seo Sangwon	M	1979.01	Vice President	Unregistered	Full-time	Corporate Engineering	- Team Leader, Samsung biologics Corporate Engineering Team (2018.05~) - Team Leader, Samsung biologics Engineering Technology Team (2015.02~2018.04) - POSTECH, Master of Biological science	700	-	1 month
Lim Heekyun	M	1975.06	Vice President	Unregistered	Full-time	Business Operation	- Team Leader, Samsung biologics Business Operation Team (2020.12~) - Group Leader, Samsung Advanced Institute of Technology Open Innovation Group (2019.03~2020.12) - POSTECH, Bachelor of Biological science	-	-	1month
Lim Kyoungsim	W	1974.01	Vice President	Unregistered	Full-time	Supply Chain Management	- Team Leader, Samsung biologics Supply Chain Management Team (2018.03~) - Team Leader, Samsung biologics Operational Procurement Team (2015.12~2018.02) - Chungnam Univ., Bachelor of Chemistry	1,000	-	1 month

※ Number of shares held by executives is as of December 31, 2020. For subsequent changes, refer to the ownership report of executives and major shareholders at the DART (Data Analysis, Retrieval and Transfer System).

C. Interlocking executive

Interlocking executive		Interlocking company	
Name	Position	Name	Position
John Rim	Executive Director(CEO)	Samsung Bioepis	Other non-executive director
Jeong Seokwoo	Independent director	SK Networks	Independent director
Eunice Kim	Independent director	U-young Industrial CO.,LTD.	Executive director

D. Changes of unregistered executives after disclosure reference date

Classification	Position	Name	Date of birth	Gender	Tasks	Reason
Retirement	Senior Vice President	Kim Ingyu	1965.07	M	Facility operation	Termination of Contract

E. Employees

(As of Dec 31, 2020)

(Unit: million won)

Employee									Non-Employee				
Business unit	Gender	No. of employees				Total	Average length of service	Gross annual salary	Per capita average salary	M	W	Total	Remarks
		Regular workers		Fixed-term workers									
		All	(Part-time worker)	All	(Part-time worker)								
Manufacturing	M	830	-	42	-	872	3.9	-	-	281	224	505	-
Manufacturing	F	360	-	23	-	383	3.8	-	-				-
Research	M	468	-	39	-	507	3.4	-	-				-
Research	F	554	-	11	-	565	3.5	-	-				-
Support	M	348	-	24	-	362	3.6	-	-				-
Support	F	178	-	9	-	187	3.5	-	-				-
Total no. of employees	M	1,646	-	105	-	1,751	3.6	148,555	88				-
	F	1,092	-	43	-	1,135	3.6	79,349	74				-
Total		2,738	-	148	-	2,886	3.6	227,904	83				-

※ Gross annual salary is based on gross salary in the statement of earned income payments to be submitted to a competent tax office in accordance with Article 20 of the Income Tax Act.

※ The number of employees above is based on headquarters and registered executives (7 members) are excluded.
The number of employees was recorded including those on leave of absence.

※ The average annual salary amount for one person was calculated based on the average number of employees of a year which is 2,757 employees (1,690 men and 1,067 women).

F. Compensation of unregistered executives

(As of Dec 31, 2020)

(Unit: million won)

	No.	Gross annual salary	Per capita average salary	Remarks
Unregistered executives	24	9,652	402	-

※ In Gross annual salary, the compensation of unregistered executives, who were appointed during 2020, only includes the amount paid after their appointment.

2. Executive compensation

<Compensation of directors and auditors>

1. Compensation approved by Annual General Meeting of shareholders

(Unit: million won)

Category	No.	Amount approved	Remarks
Executive directors	3	-	-
Independent directors	1	-	-
Members of Audit committee	3	-	-
Total	7	11,000	-

2. Compensation paid

2-1. Compensation paid for directors and auditors

(Unit: million won)

Number of persons	Total compensation	Average compensation per person	Remarks
7	4,851	693	-

※ In total compensation, the compensation for Executive director John Rim before his appointment as registered director is not included.

2-2. Compensation paid, by Director type

(Unit: million won)

Category	Number of persons	Total compensation	Avg. compensation per person	Remarks
Executive directors	3	4,537	1,512	-
Independent directors	1	65	65	-
Members of Audit committee	3	249	83	-
Auditors	-	-	-	-

※ The Audit committee consists of three independent directors.

※ The number of persons is as of the date when the business report is prepared.

※ Total compensation is the amount of income paid based on the Income Tax Act to registered directors in office or retired, independent directors, and members of Audit committee as the status of registered executive during the business year in accordance with Article 159 of the Financial Investment Services and Capital Market Act and Article 168 of the Enforcement Decree of the Act.

※ In total compensation, the compensation for Executive director John Rim before his appointment as registered director is not included.

※ Average compensation per person is calculated by dividing total compensation by number of persons.

3. Criteria for compensation

- As for criteria for compensation of registered directors (3 Executive directors and 4 Independent directors), the limit of compensation is determined by a resolution of the Board of Directors pursuant to Article 40 of the Company's Articles of Incorporation.
- Total compensation is the amount exclusive of labor costs for appropriation. Average compensation

per capital is calculated by dividing total compensation by number of persons.

<Compensation for Executive Directors and Auditors (KRW 500 million or more)>

1. Individual compensation paid

(Unit: million won)

Name	Position	Total compensation	Compensation not included in total compensation
Kim Taehan	Chairman	2,783	-
John Rim	CEO	995	-
Kim Dongjoong	Senior Vice President	759	-

※ Compensation for Executive director John Rim does not include the amount paid before his appointment as Registered director.

2. Calculation criteria and method

(Unit: million won)

Name	Type of compensation		Total amount	Calculation criteria and method
Kim Taehan	Earned income	Gross payroll	789	In accordance with internal regulation for executive treatment (Board resolution), compensation is determined based on his position (CEO), responsibilities, and performance results. He was paid KRW 65.8 million on a monthly basis.
		Bonus	1,927	<ul style="list-style-type: none"> - Traditional holiday bonus: 100% of monthly wage - Target incentive: Decided by CEO based on the level of target attainment by division; and paid twice a year to the extent of 0~200% of monthly wage (vary depending on organization's performance) - Performance incentive: Decided by CEO and funded with 20% of profits if revenues exceed the break-even point; and paid once a year to the extent of 0~50% of annual base salary (vary depending on individual performance). - Long-term performance incentive: Calculated to the extent of compensation limit set by the General Shareholders' Meeting based on three-year average annual salary by evaluating ROE, PER, pre-tax profit ratio, etc.; and paid over the course of 3 years. <p>※ Incentive calculated based on the fact that the Company successfully obtained sufficient contracts to accomplish full operation of all three plants. In addition, he contributed to improvement of business performance by advanced implementation of new business areas such as DP/CDO/CRO.</p>
		Stock option execution profit	-	-
		Other earned income	67	- Fringe benefits: Treatment is offered in line the executive treatment rules
		Retirement income	-	-
		Other income	-	-
John Rim	Earned income	Gross payroll	421	In accordance with separate service contract, compensation is determined based on his position (Executive Vice President), responsibilities, and performance results. He was paid USD 35,000 on a monthly basis.

		Bonus	481	<ul style="list-style-type: none"> - Long-term performance incentive: Calculated using KPI achievement rate, paid twice a year - Personal Performance incentive: Paid once a year within 0% to 50% of the base salary based on individual performance - Sign on Bonus: Split payment within the contract period after joining the company according to the terms of the contract <p>※ Incentive calculated based on the fact that he contributed to securing production volume through order support using global network, and its contribution to timely production process and organizational capacity improvement of CMO2 Center.</p>
		Stock option execution profit	-	-
		Other earned income	93	- Fringe benefits: Treatment is offered in line with the separate service contract.
		Retirement income	-	-
		Other income	-	-
Kim Dongjoong	Earned income	Gross payroll	296	In accordance with internal regulation for executive treatment (Board resolution), compensation is determined by based on his position (Senior Vice President), responsibilities, and performance results. He was paid KRW 23.9 million on a monthly basis.
		Bonus	386	<ul style="list-style-type: none"> - Traditional holiday bonus: 100% of monthly wage - Target incentive: Decided by CEO based on the level of target attainment by division; and paid twice a year to the extent of 0~200% of monthly wage (vary depending on organization's performance) - Personal Performance incentive: Paid once a year within 0% to 50% of the base salary based on individual performance - Long-term performance incentive: Calculated to the extent of compensation limit set by the General Shareholders' Meeting based on three-year average annual salary by evaluating ROE, PER, pre-tax profit ratio, etc.; and paid in installments for three years <p>※ Incentive calculated based on the fact that he contributed to improving business performance by increasing revenue and reducing operation costs</p>
		Stock option execution profit	-	-
		Other earned income	77	- Fringe benefits: Treatment is offered in line the executive treatment rules
		Retirement income	-	-
		Other income	-	-

<Compensation for 5-highest paid individuals (KRW 500 million or more)>

1. Individual compensation

(Unit: million won)

Name	Title	Total compensation	Compensation not included in total amount
Kim Taehan	Chairman	2,783	-
John Rim	CEO	1,285	-
Yoon kwanghun	Executive Vice President	985	-

Sam MacHour	Senior Vice President	982	-
Lee Kyusung	Executive Vice President	930	-

2. Calculation criteria and method

(Unit: million won)

Name	Type of compensation		Total amount	Calculation criteria and method
Kim Taehan	Earned income	Gross payroll	789	In accordance with internal regulation for executive treatment (Board resolution), compensation is determined by based on his position (CEO), responsibilities, and performance results. He was paid KRW 65.8 million on a monthly basis.
		Bonus	1,927	<ul style="list-style-type: none"> - Traditional holiday bonus: 100% of monthly wage - Target incentive: Decided by CEO based on the level of target attainment by division; and paid twice a year to the extent of 0~200% of monthly wage (vary depending on organization's performance) - Performance incentive: Decided by CEO and funded with 20% of profits if revenues exceed the break-even point; and paid once a year to the extent of 0~50% of annual base salary (vary depending on individual performance). - Long-term performance incentive: Calculated to the extent of compensation limit set by the General Shareholders' Meeting based on three-year average annual salary by evaluating ROE, PER, pre-tax profit ratio, etc.; and paid in installments for three years <p>※ Incentive calculated based on the fact that the Company successfully obtained sufficient contracts to accomplish full operation of all three plants. In addition, he contributed to improvement of business performance by advanced implementation of new business areas such as DP/CDO/CRO.</p>
		Stock option execution profit	-	
		Other earned income	67	- Fringe benefits: Treatment is offered in line the executive treatment rules
		Retirement income	-	-
		Other income	-	-
John Rim	Earned income	Gross payroll	506	In accordance with separate service contract, compensation is determined based on his position (Executive Vice President), responsibilities, and performance results. He was paid USD 35,000 on a monthly basis.
		Bonus	686	<ul style="list-style-type: none"> - Long-term performance incentive: Calculated using KPI achievement rate, paid twice a year - Personal Performance incentive: Paid once a year within 0% to 50% of the base salary based on individual performance - Sign on Bonus: Split payment within the contract period after joining the company according to the terms of the contract <p>※ Incentive calculated based on the fact that he contributed to securing production volume through order support using global network, and its contribution to timely production process and organizational capacity improvement of CMO2 Center.</p>
		Stock option	-	-

		execution profit		
		Other earned income	93	- Fringe benefits: Treatment is offered in line with the separate service contract.
		Retirement income	-	-
		Other income	-	-
Yoon Kwanghun	Earned income	Gross payroll	613	In accordance with separate service contract, compensation is determined based on his position (Executive Vice President), responsibilities, and performance results. He was paid KRW 51.1 million on a monthly basis.
		Bonus	342	- Traditional holiday bonus: 100% of monthly wage - Long Term Incentive: Calculated using KPI achievement rate, paid twice a year - Personal Performance incentive: Pay once a year within 0% to 30% of the base salary based on individual performance ※ Incentive calculated based on the fact that he successfully accomplished maintenance and facility management of three plants, and improving profitability through continuous engineering innovation activities
		Stock option execution profit	-	-
		Other earned income	30	- Fringe benefits: Treatment is offered in line with the separate service contract.
		Retirement income	-	-
		Other income	-	-
Sam MacHour	Earned income	Gross payroll	466	In accordance with separate service contract, compensation is determined based on his position (Senior Vice President), responsibilities, and performance results. He was paid USD 32,500 on a monthly basis.
		Bonus	447	- Long Term Incentive: Calculated using KPI achievement rate, paid twice a year - Personal Performance incentive: Pay once a year within 0% to 30% of the base salary based on individual performance - Sign on Bonus: Split payment within the contract period after joining the company according to the terms of the contract ※ Incentive calculated based on the fact that he adequately accomplished efficiency improvement and operation process optimization for CMO2 Full Operation. In addition, quantitative indicators include that he contributed to obtaining contracts using his global network.
		Stock option execution profit	-	-
		Other earned income	69	- Fringe benefits: Treatment is offered in line with the separate service contract.
		Retirement income	-	-
		Other income	-	-
Lee Kyusung	Earned income	Gross payroll	533	In accordance with separate service contract, compensation is determined based on his position (Executive Vice President), responsibilities, and performance results. He was paid KRW 44.4 million on a monthly basis.
		Bonus	355	- Traditional holiday bonus: 100% of monthly wage - Long Term Incentive: Calculated using KPI achievement rate, paid twice a year - Personal Performance incentive: Pay once a year within 0% to 30% of the base salary based on individual performance

				※ Incentive calculated based on the fact that he adequately accomplished efficiency improvement and operation process optimization for CMO2 Full Operation. In addition, quantitative indicators include that he contributed to obtaining contracts using his global network.
		Stock option execution profit	-	-
		Other earned income	42	- Fringe benefits: Treatment is offered in line with the separate service contract.
		Retirement income	-	-
		Other income	-	-

< Grant and execution of stock option >

Not applicable as of the date when the annual report is submitted.

IX. Matters Regarding Affiliates

1. Affiliates

A. Overview of affiliates

(1) Overview of corporate group

- ① Name of corporate group: Samsung
- ② Controller of corporate group: Lee JY

(2) Companies to form a corporate group

(As of Dec 31, 2020)

Category	No. of companies	Name of company	Business registration no.
Listed companies	16	Samsung C&T Corporation	1101110015762
		Samsung Biologics Co., Ltd.	1201110566317
		Samsung Life Insurance Co., Ltd.	1101110005953
		Samsung SDI Co., Ltd.	1101110394174
		Samsung SDS Co., Ltd.	1101110398556
		Samsung Engineering Co., Ltd.	1101110240509
		Samsung Electro-Mechanics Co., Ltd.	1301110001626
		Samsung Electronics Co., Ltd.	1301110006246
		Samsung Heavy Industries Co., Ltd.	1101110168595
		Samsung Securities Co., Ltd.	1101110335649
		Samsung Card Co., Ltd.	1101110346901
		Samsung Fire & Marine Insurance Co., Ltd.	1101110005078
		Multicampus Corporation	1101111960792
		S-1 Corporation	1101110221939
		Cheil Worldwide Inc.	1101110139017
		Hotel Shilla Co., Ltd.	1101110145519
Unlisted companies	43	Samsung Display Co., Ltd.	1345110187812
		Samsung Medison Co., Ltd.	1346110001036
		Samsung Bioepis Co., Ltd.	1201110601501
		Samsung Venture Investment Corporation	1101111785538
		Samsung Life Service Claim Adjustment Co., Ltd.	1101111855414
		Samsung Futures Inc.	1101110894520
		Samsung Active Asset Management Co., Ltd.	1101116277382
		Samsung SRA Asset Management Co., Ltd.	1101115004322
		Samsung Welstory Co., Ltd.	1101115282077
		Samsung Asset Management Co., Ltd.	1701110139833
		Samsung Electronics Logitech Corporation	1301110046797
		Samsung Electronics Service Co., Ltd.	1301110049139
		Samsung Electronics Service CS Co., Ltd	1358110352541

		Samsung Electronics Sales Co., Ltd.	1801110210300
		Samsung Card Customer Service Co., Ltd.	1101115291656
		Samsung Corning Advanced Glass LLC.	1648110138904
		Samsung Hedge Asset Management Co., Ltd.	1101116277390
		Samsung Fire Service Co., Ltd.	1101111237703
		Samsung Claim Adjustment Service Co., Ltd.	1101111595680
		SEMES Co., Ltd.	1615110011795
		Suwon Samsung Football Club Co., Ltd.	1358110160126
		Steel Structure Technologies Co., Ltd. (STECO)	1647110003490
		Shilla Stay Co., Ltd.	1101115433927
		SD Flex Co., Ltd.	1760110039005
		SBTM Co., Ltd.	1101116536556
		S1CRM Corporation	1358110190199
		SUMaterials Co., Ltd.	1648110061337
		S-Core Co., Ltd.	1101113681031
		STM Co., Ltd.	2301110176840
		HDC Shilla Duty Free Ltd.	1101115722916
		Open Hands Co., Ltd.	1311110266146
		Cheil Fashion Retail Co., Ltd.	1101114736934
		Miracom Inc Co., Ltd.	1101111617533
		Samsung Economic Research Institute (SERI)	1101110766670
		Samsung Lions Co., Ltd.	1701110015786
		Samsung Life Financial Service Co., Ltd.	1101115714533
		Samsung Fire & Marine Financial Service Co., Ltd.	1101116002424
		Samwoo Architects & Engineers Co., Ltd.	1101115494151
		Seoul Lake Side Co., Ltd.	1101110504070
		SECUI Co., Ltd.	1101111912503
		CVnet Corporation	1101111931686
		Harman International Korea	1101113145673
		Human TSS Co., Ltd.	1101114272706
Total	59		

(3) Regulations of relevant laws, etc.

① Designation: May 1, 2020

② Summary

- Prohibition of mutual shareholding
- Prohibition of guarantee for affiliate's debt
- Restriction on financial and insurance affiliates' voting rights
- Resolution and notice by the board of directors on large-scale intragroup transactions
- Notice of important issues of unlisted affiliates
- Notice regarding the status of corporate group, etc.

(4) Shares of affiliates

① Domestic corporations

※ Percent of ownership as of December 31, 2020 based on common shares

(Unit: %)

Investor	Investee	Samsung C&T Corporation	Samsung Biologics Co., Ltd.	Samsung Life Insurance Co., Ltd.	Samsung SDI Co., Ltd.	Samsung SDS Co., Ltd.	Samsung Engineering Co., Ltd.	Samsung Electro-Mechanics Co., Ltd.	Samsung Electronics Co., Ltd.	Samsung Heavy Industries Co., Ltd.	Samsung Securities Co., Ltd.	Samsung Card Co., Ltd.	Samsung Fire & Marine Insurance Co., Ltd.	Multicampus Corporation
Samsung C&T Corporation			43.4	19.3		17.1	7.0		5.0	0.1				
Samsung Biologics Co., Ltd.														
Samsung Life Insurance Co., Ltd.		0.1	0.1		0.1	0.1	0.2	0.2	8.8	3.1	29.6	71.9	15.0	0.0
Samsung SDI Co., Ltd.							11.7			0.4				
Samsung SDS Co., Ltd.														47.2
Samsung Electro-Mechanics Co., Ltd.										2.2				
Samsung Electronics Co., Ltd.			31.5		19.6	22.6		23.7		16.0				
Samsung Heavy Industries Co., Ltd.														
Samsung Securities Co., Ltd.														
Samsung Card Co., Ltd.														
Samsung Fire & Marine Insurance Co., Ltd.							0.2		1.5					
S-1 Corporation														
Cheil Worldwide Inc.										0.1				
Hotel Shilla Co., Ltd.														
Samsung Display Co., Ltd.														
Samsung Asset Management Co., Ltd.														
Samsung Electronics Service Co., Ltd.														
Miracom INC Co., Ltd.														
Samsung Economic Research Institute (SERI)														15.2
Harman International Industries, Inc.														
Total		0.1	75.0	19.3	19.7	39.7	19.0	23.9	15.3	21.9	29.6	71.9	15.0	62.4

※ Percent of ownership as of December 31, 2020 based on common shares

(Unit: %)

Investor	S-1 Corporation	Cheil Worldwide Inc.	Hotel Shilla Co., Ltd.	Samsung Display Co., Ltd.	Samsung Medison Co., Ltd.	Samsung Bioepis Co., Ltd.	Samsung Venture Investment Corporation	Samsung Life Service Claim Adjustment Co., Ltd.	Samsung Futures Inc.	Samsung Active Asset Management Co., Ltd.	Samsung SRA Asset Management Co., Ltd.	Samsung Welstory Co., Ltd.	Samsung Asset Management Co., Ltd.
Samsung C&T Corporation							16.7					100.0	
Samsung Biologics Co., Ltd.						50.0							
Samsung Life Insurance Co., Ltd.	5.4	0.3	7.5					99.8			100.0		100.0
Samsung SDI Co., Ltd.	11.0		0.1	15.2			16.3						
Samsung SDS Co., Ltd.													
Samsung Electro-Mechanics Co., Ltd.							17.0						
Samsung Electronics Co., Ltd.		25.2	5.1	84.8	68.5		16.3						
Samsung Heavy Industries Co., Ltd.							17.0						
Samsung Securities Co., Ltd.	1.3		3.1				16.7		100.0				
Samsung Card Co., Ltd.	1.9	3.0	1.3										
Samsung Fire & Marine Insurance Co., Ltd.	1.0												
S-1 Corporation													
Cheil Worldwide Inc.													
Hotel Shilla Co., Ltd.													
Samsung Display Co., Ltd.													
Samsung Asset Management Co., Ltd.										100.0			
Samsung Electronics Service Co., Ltd.													
Miracom INC Co., Ltd.													
Samsung Economic Research Institute (SERI)													
Harman International Industries, Inc.													
Total	20.6	28.6	17.1	100.0	68.5	50.0	100.0	99.8	100.0	100.0	100.0	100.0	100.0

※ Percent of ownership as of December 31, 2020 based on common shares

(Unit: %)

Investor	Investee	Samsung Electronics Logitech Corporation	Samsung Electronics Service Co., Ltd.	Samsung Electronics Service CS Co., Ltd.	Samsung Electronics Sales Co., Ltd.	Samsung Card Customer Service Co., Ltd.	Samsung Corning Advanced Glass LLC.	Samsung Hedge Asset Management Co., Ltd.	Samsung Fire Service Co., Ltd.	Samsung Claim Adjustment Service Co., Ltd.	SEMES Co., Ltd.	Suwon Samsung Football Club Co., Ltd.	Steel Structure Technologies Co., Ltd. (STECO)
	Samsung C&T Corporation												
	Samsung Biologics Co., Ltd.												
	Samsung Life Insurance Co., Ltd.												
	Samsung SDI Co., Ltd.												
	Samsung SDS Co., Ltd.												
	Samsung Electro-Mechanics Co., Ltd.												
	Samsung Electronics Co., Ltd.	100.0	99.3		100.0						91.5		70.0
	Samsung Heavy Industries Co., Ltd.												
	Samsung Securities Co., Ltd.												
	Samsung Card Co., Ltd.					100.0							
	Samsung Fire & Marine Insurance Co., Ltd.								100.0	100.0			
	S-1 Corporation												
	Cheil Worldwide Inc.											100.0	
	Hotel Shilla Co., Ltd.												
	Samsung Display Co., Ltd.						50.0						
	Samsung Asset Management Co., Ltd.							100.0					
	Samsung Electronics Service Co., Ltd.			100.0									
	Miracom INC Co., Ltd.												
	Samsung Economic Research Institute (SERI)												
	Harman International Industries, Inc.												
	Total	100.0	99.3	100.0	100.0	100.0	50.0	100.0	100.0	100.0	91.5	100.0	70.0

※ Percent of ownership as of December 31, 2020 based on common shares

(Unit: %)

investee Investor	Shilla Stay Co., Ltd.	SD Flex Co., Ltd.	SBTM Co., Ltd.	S1CRM Corporation	SUMaterials Co., Ltd.	S-Core Co., Ltd..	STM Co., Ltd.	HDC Shilla Duty Free Ltd.	Open Hands Co., Ltd.	Cheil Fashion Retail Co., Ltd.	Miracom Inc Co., Ltd.	Samsung Economic Research Institute (SERI)
Samsung C&T Corporation										100.0		1.0
Samsung Biologics Co., Ltd.												
Samsung Life Insurance Co., Ltd.												14.8
Samsung SDI Co., Ltd.		50.0					100.0					29.6
Samsung SDS Co., Ltd.						81.8			100.0		83.6	
Samsung Electro- Mechanics Co., Ltd.												23.8
Samsung Electronics Co., Ltd.												29.8
Samsung Heavy Industries Co., Ltd.												1.0
Samsung Securities Co., Ltd.												
Samsung Card Co., Ltd.												
Samsung Fire & Marine Insurance Co., Ltd.												
S-1 Corporation				100.0		0.6					0.6	
Cheil Worldwide Inc.						5.2					5.4	
Hotel Shilla Co., Ltd.	100.0		100.0					50.0				
Samsung Display Co.,					50.0							
Samsung Asset Management Co., Ltd.												
Samsung Electronics Service Co., Ltd.												
Miracom INC Co., Ltd.						0.5						
Samsung Economic Research Institute (SERI)												
Harman International Industries, Inc.												
Total	100.0	50.0	100.0	100.0	50.0	88.1	100.0	50.0	100.0	100.0	89.6	100.0

※ Percent of ownership as of December 31, 2020 based on common shares

(Unit: %)

Investor	Investee	Samsung Lions Co., Ltd.	Samsung Life Financial Service Co., Ltd.	Samsung Fire & Marine Financial Service Co., Ltd.	Samwoo Architects & Engineers Co., Ltd.	Seoul Lake Side Co., Ltd.	SECUI Co., Ltd.	CVnet Corporation	Harman International Korea	Human TSS Co., Ltd.
	Samsung C&T Corporation				100.0	100.0	8.7	40.1		
	Samsung Biologics Co., Ltd.									
	Samsung Life Insurance Co., Ltd.		100.0							
	Samsung SDI Co., Ltd.									
	Samsung SDS Co., Ltd.						56.5	9.4		
	Samsung Electro-Mechanics Co., Ltd.									
	Samsung Electronics Co., Ltd.									
	Samsung Heavy Industries Co., Ltd.									
	Samsung Securities Co., Ltd.									
	Samsung Card Co., Ltd.									
	Samsung Fire & Marine Insurance Co., Ltd.			100.0						
	S-1 Corporation									100.0
	Cheil Worldwide Inc.	67.5								
	Hotel Shilla Co., Ltd.									
	Samsung Display Co., Ltd.									
	Samsung Asset Management Co., Ltd.									
	Samsung Electronics Service Co., Ltd.									
	Miracom INC Co., Ltd.									
	Samsung Economic Research Institute (SERI)									
	Harman International Industries, Inc.								100.0	
	Total	67.5	100.0	100.0	100.0	100.0	65.2	49.5	100.0	100.0

② Overseas corporations

※ Percent of ownership as of December 31, 2020 based on common shares

Investor	Investee	Share Ratio(%)
Samwoo Architects & Engineers Co., Ltd.	SAMOO HU Designer and Engineering Services Limited	100.0
Samwoo Architects & Engineers Co., Ltd.	SAMOO DESIGNERS & ENGINEERS INDIA PRIVATE LIMITED	100.0
Samwoo Architects & Engineers Co., Ltd.	SAMOO (KL) SDN. BHD.	100.0
Samsung C&T America Inc.	Meadowland Distribution	100.0
Samsung C&T America Inc.	Samsung Green repower, LLC	100.0
Samsung C&T America Inc.	Samsung Solar Construction Inc.	100.0
Samsung C&T America Inc.	QSSC, S.A. de C.V.	20.0
Samsung C&T America Inc.	Samsung Solar Energy LLC	100.0
Samsung C&T America Inc.	Equipment Trading Solutions Group, LLC	70.0
Samsung C&T America Inc.	S-print Inc	24.0
Samsung Renewable Energy Inc.	SP Arrow Wind Ontario LP	50.0
Samsung Renewable Energy Inc.	SRE GRW EPC GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE GRW EPC LP	100.0
Samsung Renewable Energy Inc.	SRE SKW EPC GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE SKW EPC LP	100.0
Samsung Renewable Energy Inc.	SRE WIND PA GP INC.	100.0
Samsung Renewable Energy Inc.	SRE WIND PA LP	100.0
Samsung Renewable Energy Inc.	SRE GRS Holdings GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE GRS Holdings LP	100.0
Samsung Renewable Energy Inc.	SRE K2 EPC GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE K2 EPC LP	100.0
Samsung Renewable Energy Inc.	SRE KS HOLDINGS GP INC.	100.0
Samsung Renewable Energy Inc.	SRE KS HOLDINGS LP	100.0
Samsung Renewable Energy Inc.	SP Belle River Wind LP	42.5
Samsung Renewable Energy Inc.	SRE Arrow EPC GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE Arrow EPC LP	100.0
Samsung Renewable Energy Inc.	North Kent Wind 1 LP	35.0
Samsung Renewable Energy Inc.	SRE Wind GP Holding Inc.	100.0
Samsung Renewable Energy Inc.	South Kent Wind LP Inc.	50.0
Samsung Renewable Energy Inc.	Grand Renewable Wind LP Inc.	45.0
Samsung Renewable Energy Inc.	SRE North Kent 2 LP Holdings LP	100.0
Samsung Renewable Energy Inc.	SRE Solar Development GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE Solar Development LP	100.0
Samsung Renewable Energy Inc.	SRE Windsor Holdings GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE Southgate Holdings GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE Solar Construction Management GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE Solar Construction Management LP	100.0
Samsung Renewable Energy Inc.	SRE DEVELOPMENT GP INC.	100.0
Samsung Renewable Energy Inc.	SRE DEVELOPMENT LP	100.0
Samsung Renewable Energy Inc.	SRE BRW EPC GP INC.	100.0
Samsung Renewable Energy Inc.	SRE BRW EPC LP	100.0
Samsung Renewable Energy Inc.	SRE North Kent 1 GP Holdings Inc	100.0
Samsung Renewable Energy Inc.	SRE North Kent 2 GP Holdings Inc	100.0
Samsung Renewable Energy Inc.	SRE Belle River GP Holdings Inc	100.0
Samsung Renewable Energy Inc.	SRE NK1 EPC GP Inc	100.0
Samsung Renewable Energy Inc.	SRE NK1 EPC LP	100.0
Samsung Renewable Energy Inc.	SRE Summerside Construction GP Inc.	100.0
Samsung Renewable Energy Inc.	SRE Summerside Construction LP	100.0
Samsung Renewable Energy Inc.	Kneehill Solar GP	100.0
Samsung Renewable Energy Inc.	Kneehill Solar LP	100.0
Samsung Renewable Energy Inc.	Michichi Solar GP Inc.	100.0
Samsung Renewable Energy Inc.	Michichi Solar LP	100.0
Samsung Green repower, LLC	SOLAR PROJECTS SOLUTIONS,LLC	50.0
Samsung Green repower, LLC	Monument Power, LLC	100.0
SP Arrow Wind Ontario GP Inc	SP Arrow Wind Ontario LP	0.0
Samsung C&T Oil & Gas Parallel Corp.	PLL Holdings LLC	83.6
Samsung C&T Oil & Gas Parallel Corp.	PLL E&P LLC	90.0
SRE GRW EPC GP Inc.	SRE GRW EPC LP	0.0
SRE SKW EPC GP Inc.	SRE SKW EPC LP	0.0
PLL Holdings LLC	Parallel Petroleum LLC	61.0
SRE WIND PA GP INC.	SRE WIND PA LP	0.0
SRE GRS Holdings GP Inc.	Grand Renewable Solar GP Inc.	50.0
SRE GRS Holdings GP Inc.	SRE GRS Holdings LP	0.0
SRE K2 EPC GP Inc.	SRE K2 EPC LP	0.0
SRE KS HOLDINGS GP INC.	KINGSTON SOLAR GP INC.	50.0
SRE KS HOLDINGS GP INC.	SRE KS HOLDINGS LP	0.0

Investor	Investee	Share Ratio(%)
SP Belle River Wind GP Inc	SP Belle River Wind LP	0.0
SRE Armow EPC GP Inc.	SRE Armow EPC LP	0.0
SRE Wind GP Holding Inc.	SP Armow Wind Ontario GP Inc	50.0
SRE Wind GP Holding Inc.	South Kent Wind GP Inc.	50.0
SRE Wind GP Holding Inc.	Grand Renewable Wind GP Inc.	50.0
South Kent Wind GP Inc.	South Kent Wind LP Inc.	0.0
Grand Renewable Wind GP Inc.	Grand Renewable Wind LP Inc.	0.0
North Kent Wind 1 GP Inc	North Kent Wind 1 LP	0.0
SRE Solar Development GP Inc.	SRE Solar Development LP	0.0
SRE Solar Construction Management GP Inc.	SRE Solar Construction Management LP	0.0
SRE DEVELOPMENT GP INC.	SRE DEVELOPMENT LP	0.0
SRE BRW EPC GP INC.	SRE BRW EPC LP	0.0
SRE North Kent 1 GP Holdings Inc	North Kent Wind 1 GP Inc	50.0
SRE North Kent 2 GP Holdings Inc	SRE North Kent 2 LP Holdings LP	0.0
SRE Belle River GP Holdings Inc	SP Belle River Wind GP Inc	50.0
SRE NK1 EPC GP Inc	SRE NK1 EPC LP	0.0
SRE Summerside Construction GP Inc.	SRE Summerside Construction LP	0.0
Samsung Solar Energy LLC	Samsung Solar Energy 1 LLC	100.0
Samsung Solar Energy LLC	Samsung Solar Energy 2 LLC	100.0
Samsung Solar Energy LLC	Samsung Solar Energy 3, LLC	100.0
Samsung Solar Energy 1 LLC	CS SOLAR LLC	50.0
Kneehill Solar GP	Kneehill Solar LP	0.0
Samsung Solar Energy 3, LLC	SST SOLAR, LLC	50.0
Michichi Solar GP Inc.	Michichi Solar LP	0.0
Samsung C&T Deutschland GmbH	POSS-SLPC, S.R.O	20.0
Samsung C&T Deutschland GmbH	Solluce Romania 1 B.V.	20.0
Samsung C&T Deutschland GmbH	S.C. Otellinox S.A	99.7
Solluce Romania 1 B.V.	LJG GREEN SOURCE ENERGY ALPHA S.R.L.	78.0
Samsung C&T Malaysia SDN. BHD	WARIS GIGIH ENGINEERING AND TECHNOLOGY SDN. BHD.	70.0
Samsung C&T Singapore Pte., Ltd.	Samsung Chemtech Vina LLC	48.3
Samsung C&T Singapore Pte., Ltd.	S-print Inc	16.0
Samsung C&T Singapore Pte., Ltd.	Samsung C&T Thailand Co., Ltd	0.2
Samsung C&T Singapore Pte., Ltd.	PT. INSAM BATUBARA ENERGY	10.0
Samsung C&T Singapore Pte., Ltd.	Malaysia Samsung Steel Center Sdn.Bhd	30.0
Samsung C&T Singapore Pte., Ltd.	S&G Biofuel PTE.LTD	12.6
S&G Biofuel PTE.LTD	PT. Gandaerah Hendana	95.0
S&G Biofuel PTE.LTD	PT. Inecda	95.0
Samsung C&T Hongkong Ltd.	Samsung C&T Thailand Co., Ltd	6.8
Samsung C&T Hongkong Ltd.	SAMSUNG TRADING (SHANGHAI) CO., LTD	100.0
Samsung C&T Hongkong Ltd.	Samsung Precision Stainless Steel(pinghu) Co.,Ltd.	45.0
Samsung Electronics Co., Ltd.	Samsung Japan Corporation	100.0
Samsung Electronics Co., Ltd.	Samsung R&D Institute Japan Co. Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics America, Inc.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Canada, Inc.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Mexico S.A. De C.V.	63.6
Samsung Electronics Co., Ltd.	Samsung Electronics Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics (UK) Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Holding GmbH	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Iberia, S.A.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics France S.A.S	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Hungarian Private Co. Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Italia S.P.A.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Europe Logistics B.V.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Benelux B.V.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Overseas B.V.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Polska, SP.Zo.o	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Portuguesa S.A.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Nordic Aktiebolag	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Austria GmbH	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Slovakia s.r.o	55.7
Samsung Electronics Co., Ltd.	Samsung Electronics Europe Holding Cooperatief U.A.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Display (M) Sdn. Bhd.	75.0
Samsung Electronics Co., Ltd.	Samsung Electronics (M) Sdn. Bhd.	100.0
Samsung Electronics Co., Ltd.	Samsung Vina Electronics Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Asia Private Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung India Electronics Private Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung R&D Institute India-Bangalore Private Limited	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Australia Pty. Ltd.	100.0
Samsung Electronics Co., Ltd.	PT Samsung Electronics Indonesia	100.0
Samsung Electronics Co., Ltd.	Thai Samsung Electronics Co., Ltd.	91.8
Samsung Electronics Co., Ltd.	Samsung Malaysia Electronics (SME) Sdn. Bhd.	100.0

Investor	Investee	Share Ratio(%)
Samsung Electronics Co., Ltd.	Samsung Electronics Hong Kong Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Suzhou Samsung Electronics Co., Ltd.	69.1
Samsung Electronics Co., Ltd.	Samsung (CHINA) Investment Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Suzhou Semiconductor Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Huizhou Co., Ltd.	89.6
Samsung Electronics Co., Ltd.	Tianjin Samsung Electronics Co., Ltd.	48.2
Samsung Electronics Co., Ltd.	Samsung Electronics Taiwan Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Tianjin Samsung Telecom Technology Co., Ltd.	90.0
Samsung Electronics Co., Ltd.	Shanghai Samsung Semiconductor Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Suzhou Computer Co., Ltd.	73.7
Samsung Electronics Co., Ltd.	Shenzhen Samsung Electronics Telecommunication Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Semiconductor (China) R&D Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung (China) Semiconductor Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung SemiConductor Xian Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Gulf Electronics Co., Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Egypt S.A.E	0.1
Samsung Electronics Co., Ltd.	Samsung Electronics South Africa(Pty) Ltd.	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Latinoamerica(Zona Libre), S. A.	100.0
Samsung Electronics Co., Ltd.	Samsung Eletronica da Amazonia Ltda.	87.0
Samsung Electronics Co., Ltd.	Samsung Electronics Argentina S.A.	98.0
Samsung Electronics Co., Ltd.	Samsung Electronics Chile Limitada	4.1
Samsung Electronics Co., Ltd.	Samsung Electronics Rus Company LLC	100.0
Samsung Electronics Co., Ltd.	Samsung Electronics Rus Kaluga LLC	100.0
Samsung Electronics Co., Ltd.	Tianjin Samsung LED Co., Ltd.	100.0
Samsung Biologics Co., Ltd.	Samsung Biologics America, Inc.	100.0
Samsung Bioepis Co., Ltd.	SAMSUNG BIOEPIS UK LIMITED	100.0
Samsung Bioepis Co., Ltd.	Samsung Bioepis NL B.V.	100.0
Samsung Bioepis Co., Ltd.	Samsung Bioepis CH GmbH	100.0
Samsung Bioepis Co., Ltd.	Samsung Bioepis PL Sp z o.o.	100.0
Samsung Bioepis Co., Ltd.	SAMSUNG BIOEPIS AU PTY LTD	100.0
Samsung Bioepis Co., Ltd.	SAMSUNG BIOEPIS NZ LIMITED	100.0
Samsung Bioepis Co., Ltd.	SAMSUNG BIOEPIS TW Limited	100.0
Samsung Bioepis Co., Ltd.	Samsung Bioepis HK Limited	100.0
Samsung Bioepis Co., Ltd.	SAMSUNG BIOEPIS IL LTD	100.0
Samsung Bioepis Co., Ltd.	SAMSUNG BIOEPIS BR PHARMACEUTICAL LTDA	100.0
Samsung Display Co., Ltd.	Intellectual Keystone Technology LLC	41.9
Samsung Display Co., Ltd.	Samsung Display Slovakia, s.r.o.	100.0
Samsung Display Co., Ltd.	Samsung Display Vietnam Co., Ltd.	100.0
Samsung Display Co., Ltd.	Samsung Display Noida Private Limited	100.0
Samsung Display Co., Ltd.	Samsung Suzhou Module Co., Ltd.	100.0
Samsung Display Co., Ltd.	Samsung Suzhou LCD Co., Ltd.	60.0
Samsung Display Co., Ltd.	Samsung Display Dongguan Co., Ltd.	100.0
Samsung Display Co., Ltd.	Samsung Display Tianjin Co., Ltd.	95.0
Samsung Display Co., Ltd.	Novald GmbH	9.9
SEMES Co., Ltd.	SEMES America, Inc.	100.0
SEMES Co., Ltd.	SEMES (XIAN) Co., Ltd.	100.0
Samsung Electronics America, Inc.	NeuroLogica Corp.	100.0
Samsung Electronics America, Inc.	Dacor Holdings, Inc.	100.0
Samsung Electronics America, Inc.	Samsung HVAC America, LLC	100.0
Samsung Electronics America, Inc.	SmartThings, Inc.	100.0
Samsung Electronics America, Inc.	Samsung Oak Holdings, Inc.	100.0
Samsung Electronics America, Inc.	Joyent, Inc.	100.0
Samsung Electronics America, Inc.	TeleWorld Solutions, Inc.	100.0
Samsung Electronics America, Inc.	Prismview, LLC	100.0
Samsung Electronics America, Inc.	Samsung Semiconductor, Inc.	100.0
Samsung Electronics America, Inc.	Samsung Research America, Inc	100.0
Samsung Electronics America, Inc.	Samsung Electronics Home Appliances America, LLC	100.0
Samsung Electronics America, Inc.	Samsung International, Inc.	100.0
Samsung Electronics America, Inc.	Harman International Industries, Inc.	100.0
Dacor Holdings, Inc.	Dacor, Inc.	100.0
Dacor, Inc.	Dacor Canada Co.	100.0
Samsung Oak Holdings, Inc.	Stellus Technologies, Inc.	100.0
TeleWorld Solutions, Inc.	TWS LATAM B, LLC	100.0
TeleWorld Solutions, Inc.	TWS LATAM S, LLC	100.0
TWS LATAM B, LLC	SNB Technologies, Inc. Mexico S.A. de. C.V	50.0
TWS LATAM S, LLC	SNB Technologies, Inc. Mexico S.A. de. C.V	50.0
Samsung Semiconductor, Inc.	Samsung Austin Semiconductor LLC.	100.0
Samsung Electronics Canada, Inc.	AdGear Technologies Inc.	100.0
Samsung Electronics Canada, Inc.	SigMast Communications Inc.	100.0
Samsung Research America, Inc	SAMSUNG NEXT LLC	100.0
Samsung Research America, Inc	Viv Labs, Inc.	100.0
SAMSUNG NEXT LLC	SAMSUNG NEXT FUND LLC	100.0

Investor	Investee	Share Ratio(%)
Samsung International, Inc.	Samsung Mexicana S.A. de C.V	100.0
Samsung Electronics Mexico S.A. De C.V.	Samsung Electronics Digital Appliance Mexico, SA de CV	100.0
Harman International Industries, Inc.	Harman International Japan Co., Ltd.	100.0
Harman International Industries, Inc.	Harman International Industries Canada Ltd.	100.0
Harman International Industries, Inc.	Harman Becker Automotive Systems, Inc.	100.0
Harman International Industries, Inc.	Harman Professional, Inc.	100.0
Harman International Industries, Inc.	Harman Connected Services, Inc.	100.0
Harman International Industries, Inc.	Harman Financial Group LLC	100.0
Harman International Industries, Inc.	Harman Belgium SA	100.0
Harman International Industries, Inc.	Harman France SNC	100.0
Harman International Industries, Inc.	Red Bend Software SAS	100.0
Harman International Industries, Inc.	Harman Inc. & Co. KG	66.0
Harman International Industries, Inc.	Harman KG Holding, LLC	100.0
Harman International Industries, Inc.	Harman Becker Automotive Systems Italy S.R.L.	100.0
Harman International Industries, Inc.	Harman Finance International, SCA	100.0
Harman International Industries, Inc.	Harman Finance International GP S.a.r.l	100.0
Harman International Industries, Inc.	Harman Industries Holdings Mauritius Ltd.	100.0
Harman International Industries, Inc.	Harman International Mexico, S. de R.L. de C.V.	99.9
Harman Becker Automotive Systems, Inc.	Harman International Estonia OU	100.0
Harman Professional, Inc.	AMX UK Limited	100.0
Harman Professional, Inc.	Harman Singapore Pte. Ltd.	100.0
Harman Professional, Inc.	Harman da Amazonia Industria Eletronica e Participacoes Ltda.	0.0
Harman Professional, Inc.	Harman do Brasil Industria Eletronica e Participacoes Ltda.	0.0
Harman Connected Services, Inc.	Harman Connected Services Engineering Corp.	100.0
Harman Connected Services, Inc.	Harman Connected Services AB.	100.0
Harman Connected Services, Inc.	Harman Connected Services UK Ltd.	100.0
Harman Connected Services, Inc.	Harman Connected Services Corp. India Pvt. Ltd.	1.6
Harman Connected Services, Inc.	Global Symphony Technology Group Private Ltd.	100.0
Harman Financial Group LLC	Harman International (India) Private Limited	0.0
Harman Financial Group LLC	Harman International Mexico, S. de R.L. de C.V.	0.1
Harman Financial Group LLC	Harman de Mexico, S. de R.L. de C.V.	0.0
Samsung Electronics (UK) Ltd.	Samsung Semiconductor Europe Limited	100.0
Samsung Electronics Holding GmbH	Samsung Semiconductor Europe GmbH	100.0
Samsung Electronics Holding GmbH	Samsung Electronics GmbH	100.0
Samsung Electronics Hungarian Private Co. Ltd.	Samsung Electronics Czech and Slovak s.r.o.	31.4
Samsung Electronics Hungarian Private Co. Ltd.	Samsung Electronics Slovakia s.r.o	44.3
Samsung Electronics Benelux B.V.	Samsung Electronics Mexico S.A. De C.V.	36.4
Samsung Electronics Benelux B.V.	SAMSUNG ELECTRONICS BALTICS SIA	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics West Africa Ltd.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics East Africa Ltd.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Saudi Arabia Ltd.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Egypt S.A.E	99.9
Samsung Electronics Benelux B.V.	Samsung Electronics Israel Ltd.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Tunisia S.A.R.L	99.0
Samsung Electronics Benelux B.V.	Samsung Electronics Pakistan(Private) Ltd.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics South Africa Production (pty) Ltd.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Turkey	100.0
Samsung Electronics Benelux B.V.	Samsung Semiconductor Israel R&D Center, Ltd.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Levant Co.,Ltd.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Maghreb Arab	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Venezuela, C.A.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronica da Amazonia Ltda.	13.0
Samsung Electronics Benelux B.V.	Samsung Electronics Chile Limitada	95.9
Samsung Electronics Benelux B.V.	Samsung Electronics Peru S.A.C.	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Ukraine Company LLC	100.0
Samsung Electronics Benelux B.V.	Samsung R&D Institute Rus LLC	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Central Eurasia LLP	100.0
Samsung Electronics Benelux B.V.	Samsung Electronics Caucasus Co. Ltd	100.0
Samsung Electronics Benelux B.V.	Corephotonics Ltd.	100.0
Zhilabs, S.L.	Zhilabs Inc.	100.0
Samsung Electronics Nordic Aktiebolag	Samsung Nanoradio Design Center	100.0
AKG Acoustics GmbH	Harman Professional Denmark ApS	100.0
AKG Acoustics GmbH	Studer Professional Audio GmbH	100.0
Harman Professional Denmark ApS	Martin Professional Japan Ltd.	40.0
Harman Professional Denmark ApS	Harman International s.r.o	100.0
Harman Becker Automotive Systems GmbH	Harman International Romania SRL	0.0
Harman Holding GmbH & Co. KG	Harman Becker Automotive Systems GmbH	100.0
Harman Holding GmbH & Co. KG	Harman Deutschland GmbH	100.0
Harman Holding GmbH & Co. KG	Harman Becker Automotive Systems Manufacturing Kft	100.0
Harman Holding GmbH & Co. KG	Harman RUS CIS LLC	100.0

Investor	Investee	Share Ratio(%)
Harman Inc. & Co. KG	Harman Holding GmbH & Co. KG	100.0
Harman Inc. & Co. KG	Harman Management GmbH	100.0
Harman Inc. & Co. KG	Harman Hungary Financing Ltd.	100.0
Harman Connected Services GmbH	Harman Connected Services OOO	100.0
Harman KG Holding, LLC	Harman Inc. & Co. KG	34.0
Harman Becker Automotive Systems Manufacturing Kft	Harman Professional Kft	100.0
Harman Becker Automotive Systems Manufacturing Kft	Harman Consumer Nederland B.V.	100.0
Harman Becker Automotive Systems Manufacturing Kft	Harman International Romania SRL	100.0
Harman Becker Automotive Systems Manufacturing Kft	Red Bend Ltd.	100.0
Harman Becker Automotive Systems Manufacturing Kft	Harman do Brasil Industria Eletronica e Participacoes Ltda.	100.0
Harman Hungary Financing Ltd.	Harman International Industries Limited	100.0
Harman Finance International GP S.a.r.l	Harman Finance International, SCA	0.0
Harman Consumer Nederland B.V.	AKG Acoustics GmbH	100.0
Harman Consumer Nederland B.V.	Harman Audio Iberia Espana Sociedad Limitada	100.0
Harman Consumer Nederland B.V.	Harman Holding Limited	100.0
Harman Audio Iberia Espana Sociedad Limitada	Harman France SNC	0.0
Harman Connected Services AB.	Harman Finland Oy	100.0
Harman Connected Services AB.	Harman Connected Services GmbH	100.0
Harman Connected Services AB.	Harman Connected Services Poland Sp.zoo	100.0
Harman Connected Services AB.	Harman Connected Services Solutions (Chengdu) Co., Ltd.	100.0
Harman International Industries Limited	Harman Automotive UK Limited	100.0
Harman International Industries Limited	Martin Manufacturing (UK) Ltd	100.0
Harman International Industries Limited	Harman Connected Services Limited	100.0
Harman International Industries Limited	Arcam Limited	100.0
Harman International Industries Limited	Harman International Industries PTY Ltd.	100.0
Harman International Industries Limited	Harman de Mexico, S. de R.L. de C.V.	100.0
Harman Connected Services UK Ltd.	Harman Connected Services Morocco	100.0
Arcam Limited	A&R Cambridge Limited	100.0
Samsung Electronics Austria GmbH	Samsung Electronics Switzerland GmbH	100.0
Samsung Electronics Europe Holding Cooperatief U.A.	Samsung Electronics Czech and Slovak s.r.o.	68.6
Samsung Electronics Europe Holding Cooperatief U.A.	Samsung Electronics Romania LLC	100.0
Samsung Electronics Europe Holding Cooperatief U.A.	Zhilabs, S.L.	100.0
Samsung Electronics Europe Holding Cooperatief U.A.	Porta Nuova Varesine Building 2 S.r.l.	49.0
Samsung Electronics Europe Holding Cooperatief U.A.	Samsung Electronics Poland Manufacturing SP.Zo.o	100.0
Samsung Electronics Europe Holding Cooperatief U.A.	Samsung Electronics Greece S.M.S.A	100.0
Samsung Electronics Europe Holding Cooperatief U.A.	Samsung Electronics Air Conditioner Europe B.V.	100.0
Samsung Electronics Europe Holding Cooperatief U.A.	FOODIENT LTD.	100.0
Samsung Electronics Europe Holding Cooperatief U.A.	Samsung Denmark Research Center ApS	100.0
Samsung Electronics Europe Holding Cooperatief U.A.	Samsung Cambridge Solution Centre Limited	100.0
Samsung Electronics Europe Holding Cooperatief U.A.	Novald GmbH	40.0
Samsung Asia Private Ltd.	Samsung Electronics Japan Co., Ltd.	100.0
Samsung Asia Private Ltd.	Samsung Electronics Display (M) Sdn. Bhd.	25.0
Samsung Asia Private Ltd.	Samsung Electronics Singapore Pte. Ltd.	100.0
Samsung Asia Private Ltd.	Samsung Electronics New Zealand Limited	100.0
Samsung Asia Private Ltd.	Samsung Electronics Philippines Corporation	100.0
Samsung Asia Private Ltd.	Samsung R&D Institute BanglaDesh Limited	100.0
Samsung Asia Private Ltd.	Samsung Electronics Vietnam Co., Ltd.	100.0
Samsung Asia Private Ltd.	Samsung Electronics Vietnam THAINGUYEN Co., Ltd.	100.0
Samsung Asia Private Ltd.	Samsung Electronics HCMC CE Complex Co., Ltd.	100.0
Samsung Asia Private Ltd.	Samsung Electro-Mechanics(Thailand) Co., Ltd.	25.0
Samsung Asia Private Ltd.	iMarket Asia Co., Ltd.	11.4
Samsung India Electronics Private Ltd.	Samsung Nepal Services Pvt, Ltd	100.0
PT Samsung Electronics Indonesia	PT Samsung Telecommunications Indonesia	100.0
Thai Samsung Electronics Co., Ltd.	Laos Samsung Electronics Sole Co., Ltd	100.0
Samsung Electronics Hong Kong Co., Ltd.	iMarket Asia Co., Ltd.	11.3
Suzhou Samsung Electronics Co., Ltd.	Samsung Suzhou Electronics Export Co., Ltd.	100.0
Samsung (CHINA) Investment Co., Ltd.	Suzhou Samsung Electronics Co., Ltd.	19.2
Samsung (CHINA) Investment Co., Ltd.	Samsung Mobile R&D Center China-Guangzhou	100.0
Samsung (CHINA) Investment Co., Ltd.	Samsung R&D Institute China-Shenzhen	100.0
Samsung (CHINA) Investment Co., Ltd.	Samsung Electronics Huizhou Co., Ltd.	10.4
Samsung (CHINA) Investment Co., Ltd.	Tianjin Samsung Electronics Co., Ltd.	43.1
Samsung (CHINA) Investment Co., Ltd.	Beijing Samsung Telecom R&D Center	100.0
Samsung (CHINA) Investment Co., Ltd.	Samsung Electronics Suzhou Computer Co., Ltd.	26.3
Samsung (CHINA) Investment Co., Ltd.	Samsung Electronics China R&D Center	100.0
Harman International (China) Holdings Co., Ltd.	Harman (Suzhou) Audio and Infotainment Systems Co., Ltd.	100.0
Harman International (China) Holdings Co., Ltd.	Harman Technology (Shenzhen) Co., Ltd.	100.0
Harman International (China) Holdings Co., Ltd.	Harman (China) Technologies Co., Ltd.	100.0
Harman Holding Limited	Harman Commercial (Shanghai) Co., Ltd.	100.0
Harman Holding Limited	Harman International (China) Holdings Co., Ltd.	100.0

Investor	Investee	Share Ratio(%)
Harman Holding Limited	Harman Automotive Electronic Systems (Suzhou) Co., Ltd.	100.0
Samsung Gulf Electronics Co., Ltd.	Samsung Electronics Egypt S.A.E	0.1
Samsung Electronics Maghreb Arab	Samsung Electronics Tunisia S.A.R.L	1.0
Harman Industries Holdings Mauritius Ltd.	Harman International (India) Private Limited	100.0
Global Symphony Technology Group Private Ltd.	Harman Connected Services Corp. India Pvt. Ltd.	98.4
Red Bend Ltd.	Red Bend Software Ltd.	100.0
Samsung Electronics Latinoamerica(Zona Libre), S. A.	Samsung Electronics Latinoamerica Miami, Inc.	100.0
Samsung Electronics Latinoamerica(Zona Libre), S. A.	Samsung Electronica Colombia S.A.	100.0
Samsung Electronics Latinoamerica(Zona Libre), S. A.	Samsung Electronics Panama. S.A.	100.0
Samsung Eletronica da Amazonia Ltda.	Samsung Electronics Argentina S.A.	2.0
Harman do Brasil Industria Eletronica e Participacoes Ltda.	Harman da Amazonia Industria Eletronica e Participacoes Ltda.	100.0
Samsung Electronics Central Eurasia LLP	Samsung Electronics Caucasus Co. Ltd	0.0
Samsung SDI Co., Ltd.	Intellectual Keystone Technology LLC	41.0
Samsung SDI Co., Ltd.	Samsung SDI Japan Co., Ltd.	89.2
Samsung SDI Co., Ltd.	Samsung SDI America, Inc.	91.7
Samsung SDI Co., Ltd.	Samsung SDI Hungary., Zrt.	100.0
Samsung SDI Co., Ltd.	Samsung SDI Europe GmbH	100.0
Samsung SDI Co., Ltd.	Samsung SDI Battery Systems GmbH	100.0
Samsung SDI Co., Ltd.	Samsung SDI Vietnam Co., Ltd.	100.0
Samsung SDI Co., Ltd.	Samsung SDI Energy Malaysia Sdn, Bhd.	100.0
Samsung SDI Co., Ltd.	Samsung SDI India Private Limited	100.0
Samsung SDI Co., Ltd.	Samsung SDI(Hong Kong) Ltd.	97.6
Samsung SDI Co., Ltd.	Samsung SDI China Co., Ltd.	100.0
Samsung SDI Co., Ltd.	Samsung SDI-ARN (Xi'An) Power Battery Co., Ltd.	65.0
Samsung SDI Co., Ltd.	Samsung SDI (Changchun) Power Battery Co., Ltd.	50.0
Samsung SDI Co., Ltd.	Samsung SDI (Tianjin) Battery Co.,Ltd.	80.0
Samsung SDI Co., Ltd.	Novald GmbH	50.1
Samsung SDI Co., Ltd.	SAMSUNG SDI WUXI CO.,LTD.	100.0
Samsung SDI Co., Ltd.	Samsung SDI(Wuxi) Battery Systems Co., Ltd.	50.0
Samsung SDI Co., Ltd.	iMarket Asia Co., Ltd.	8.7
Samsung SDI(Hong Kong) Ltd.	Samsung SDI India Private Limited	0.0
Samsung SDI(Hong Kong) Ltd.	Tianjin Samsung SDI Co., Ltd.	80.0
Samsung Electro-Mechanics Co., Ltd.	Samsung Electro-Mechanics Japan Co., Ltd.	100.0
Samsung Electro-Mechanics Co., Ltd.	Samsung Electro-Mechanics America, Inc.	100.0
Samsung Electro-Mechanics Co., Ltd.	Samsung Electro-Mechanics GmbH	100.0
Samsung Electro-Mechanics Co., Ltd.	Samsung Electro-Mechanics(Thailand) Co., Ltd.	75.0
Samsung Electro-Mechanics Co., Ltd.	Samsung Electro-Mechanics Philippines, Corp.	100.0
Samsung Electro-Mechanics Co., Ltd.	Calamba Premier Realty Corporation	39.8
Samsung Electro-Mechanics Co., Ltd.	Samsung Electro-Mechanics Pte Ltd.	100.0
Samsung Electro-Mechanics Co., Ltd.	Samsung Electro-Mechanics Vietnam Co., Ltd.	100.0
Samsung Electro-Mechanics Co., Ltd.	Samsung Electro-Mechanics Software India Bangalore Private Limited	99.9
Samsung Electro-Mechanics Co., Ltd.	Dongguan Samsung Electro-Mechanics Co., Ltd.	100.0
Samsung Electro-Mechanics Co., Ltd.	Tianjin Samsung Electro-Mechanics Co., Ltd.	81.8
Samsung Electro-Mechanics Co., Ltd.	Samsung High-Tech Electro-Mechanics(Tianjin) Co., Ltd.	95.0
Samsung Electro-Mechanics Co., Ltd.	Samsung Electro-Mechanics (Shenzhen) Co., Ltd.	100.0
Samsung Electro-Mechanics Co., Ltd.	Kunshan Samsung Electro-Mechanics Co., Ltd.	100.0
Samsung Electro-Mechanics Co., Ltd.	iMarket Asia Co., Ltd.	8.7
Calamba Premier Realty Corporation	Batino Realty Corporation	100.0
Samsung Electro-Mechanics Pte Ltd.	Samsung Electro-Mechanics Software India Bangalore Private Limited	0.1
Samsung Fire & Marine Insurance Co., Ltd.	Samsung Fire & Marine Management Corporation	100.0
Samsung Fire & Marine Insurance Co., Ltd.	SAMSUNG FIRE & MARINE INSURANCE COMPANY OF EUROPE LTD.	100.0
Samsung Fire & Marine Insurance Co., Ltd.	PT. Asuransi Samsung Tugu	70.0
Samsung Fire & Marine Insurance Co., Ltd.	SAMSUNG VINA INSURANCE COMPANY LIMITED	75.0
Samsung Fire & Marine Insurance Co., Ltd.	Samsung Reinsurance Pte. Ltd.	100.0
Samsung Fire & Marine Insurance Co., Ltd.	삼성재산보험 (중국) 유한공사	100.0
Samsung Fire & Marine Insurance Co., Ltd.	Samsung Fire & Marine Insurance Management Middle East Limited	100.0
Samsung Heavy Industries Co., Ltd	Camellia Consulting Corporation	100.0
Samsung Heavy Industries Co., Ltd	Samsung Heavy Industries India Pvt.Ltd.	100.0
Samsung Heavy Industries Co., Ltd	SAMSUNG HEAVY INDUSTRIES (M) SDN.BHD	100.0
Samsung Heavy Industries Co., Ltd	삼성중공업(영파)유한공사	100.0
Samsung Heavy Industries Co., Ltd	삼성중공업(영성)유한공사	100.0
Samsung Heavy Industries Co., Ltd	영성가야선업유한공사	100.0
Samsung Heavy Industries Co., Ltd	SAMSUNG HEAVY INDUSTRIES NIGERIA LIMITED	100.0
Samsung Heavy Industries Co., Ltd	Samsung Heavy Industries Mozambique LDA	100.0

Investor	Investee	Share Ratio(%)
SAMSUNG HEAVY INDUSTRIES NIGERIA LIMITED	SHI - MCI FZE	70.0
Samsung Life Insurance Co., Ltd.	Porta Nuova Varesine Building 2 S.r.l.	51.0
Samsung Life Insurance Co., Ltd.	THAI SAMSUNG LIFE INSURANCE CO., LTD.	48.9
Samsung Life Insurance Co., Ltd.	Beijing Samsung Real Estate Co., Ltd	90.0
Samsung Asset Management Co., Ltd.	Samsung Asset Management (New York), Inc.	100.0
Samsung Asset Management Co., Ltd.	Samsung Global SME Private Equity Manager Fund Co., Ltd.	100.0
Samsung Asset Management Co., Ltd.	Samsung Asset Management(London) Ltd.	100.0
Samsung Asset Management Co., Ltd.	Samsung Private Equity Manager I Co., Ltd.	100.0
Samsung Asset Management Co., Ltd.	Samsung Asset Management (Hong Kong) Ltd.	100.0
Samsung Asset Management (Hong Kong) Ltd.	Samsung Asset Management (Beijing) Ltd.	100.0
CHEIL INDUSTRIES ITALY SRL	COLOMBO VIA DELLA SPIGA S.R.L	100.0
Samsung C&T Corporation	MYODO METAL CO., LTD.	100.0
Samsung C&T Corporation	Samsung C&T Japan Corporation	100.0
Samsung C&T Corporation	Samsung C&T America Inc.	100.0
Samsung C&T Corporation	Samsung E&C America, INC.	100.0
Samsung C&T Corporation	Samsung Renewable Energy Inc.	100.0
Samsung C&T Corporation	QSSC, S.A. de C.V.	60.0
Samsung C&T Corporation	Samsung C&T Oil & Gas Parallel Corp.	100.0
Samsung C&T Corporation	Samsung C&T Lima S.A.C.	100.0
Samsung C&T Corporation	Samsung C&T Deutschland GmbH	100.0
Samsung C&T Corporation	Samsung C&T U.K. Ltd.	100.0
Samsung C&T Corporation	Samsung C&T ECUK Limited	100.0
Samsung C&T Corporation	Whesoe engineering Limited	100.0
Samsung C&T Corporation	POSS-SLPC, S.R.O	50.0
Samsung C&T Corporation	Solluce Romania 1 B.V.	80.0
Samsung C&T Corporation	SAM investment Manzanilo.B.V	53.3
Samsung C&T Corporation	Samsung C&T (KL) Sdn.,Bhd.	100.0
Samsung C&T Corporation	Samsung C&T Malaysia SDN. BHD	100.0
Samsung C&T Corporation	Erdsam Co., Ltd.	100.0
Samsung C&T Corporation	Samsung Chemtech Vina LLC	51.7
Samsung C&T Corporation	S-print Inc	40.0
Samsung C&T Corporation	Samsung C&T Thailand Co., Ltd	93.0
Samsung C&T Corporation	PT. INSAM BATUBARA ENERGY	90.0
Samsung C&T Corporation	Samsung E&C India Private Limited	100.0
Samsung C&T Corporation	Samsung C&T Corporation India Private Limited	100.0
Samsung C&T Corporation	Malaysia Samsung Steel Center Sdn.Bhd	70.0
Samsung C&T Corporation	Samsung C&T Singapore Pte., Ltd.	100.0
Samsung C&T Corporation	S&G Biofuel PTE.LTD	50.5
Samsung C&T Corporation	SAMSUNG C&T Mongolia LLC.	70.0
Samsung C&T Corporation	Samsung C&T Eng.&Const. Mongolia LLC.	100.0
Samsung C&T Corporation	S&WOO CONSTRUCTION PHILIPPINES,INC.	100.0
Samsung C&T Corporation	Samsung C&T Hongkong Ltd.	100.0
Samsung C&T Corporation	Samsung C&T Taiwan Co., Ltd.	100.0
Samsung C&T Corporation	Samsung Precision Stainless Steel(pinghu) Co.,Ltd.	55.0
Samsung C&T Corporation	SAMSUNG C&T (SHANGHAI) CO., LTD.	100.0
Samsung C&T Corporation	Samsung C&T (Xi'an) Co., Ltd.	100.0
Samsung C&T Corporation	WARIS GIGIH ENGINEERING AND TECHNOLOGY SDN. BHD.	30.0
Samsung C&T Corporation	SAMSUNG C&T CORPORATION SAUDI ARABIA	100.0
Samsung C&T Corporation	SAM Gulf Investment Limited	100.0
Samsung C&T Corporation	Samsung C&T Chile Copper SpA	100.0
Samsung C&T Corporation	SCNT Power Kelar Inversiones Limitada	100.0
Samsung C&T Corporation	Samsung C&T Corporation Rus LLC	100.0
Samsung C&T Corporation	Samsung SDI America, Inc.	8.3
Samsung C&T Corporation	Samsung SDI(Hong Kong) Ltd.	2.4
Samsung C&T Corporation	Beijing Samsung Real Estate Co.. Ltd	10.0
Samsung C&T Corporation	Cheil Industries Corp., USA	100.0
Samsung C&T Corporation	CHEIL INDUSTRIES ITALY SRL	100.0
Samsung C&T Corporation	Samsung Fashion Trading Co. ,Ltd	100.0
Samsung C&T Corporation	SAMSUNG C&T CORPORATION VIETNAM CO., LTD	100.0
Samsung C&T Corporation	Samsung C&T Corporation UEM Construction JV Sdn Bhd	60.0
Samsung C&T Corporation	iMarket Asia Co., Ltd.	19.3
Samsung Welstory Co., Ltd.	WELSTORY VIETNAM COMPANY LIMITED	100.0
Samsung Welstory Co., Ltd.	Shanghai Ever-Hongjun Business Mgt Service Co.,LTD	85.0
Samsung Welstory Co., Ltd.	Shanghai Welstory Food Company Limited	81.6
Multicampus Corporation	LANGUAGE TESTING INTERNATIONAL, INC.	82.4
Pengtai Greater China Company Limited	PENGTAI CHINA CO.,LTD.	100.0
Pengtai Greater China Company Limited	PengTai Taiwan Co., Ltd.	100.0
PENGTAI CHINA CO.,LTD.	PENGTAI E-COMMERCE CO.,LTD	100.0
PENGTAI CHINA CO.,LTD.	PENGTAI MARKETING SERVICE CO.,LTD.	100.0

Investor	Investee	Share Ratio(%)
PENGTAI INTERACTIVE ADVERTISING CO.,LTD	Medialytics Inc.	100.0
PENGTAI INTERACTIVE ADVERTISING CO.,LTD	Beijing Pengtai Baozun E-commerce Co., Ltd.	51.0
iMarket Asia Co., Ltd.	iMarket China Co., Ltd.	80.0
Samsung Securities Co., Ltd.	Samsung Securities (America), Inc.	100.0
Samsung Securities Co., Ltd.	Samsung Securities (Europe) Limited.	100.0
Samsung Securities Co., Ltd.	Samsung Securities (Asia) Limited.	100.0
Samsung SDS Co., Ltd.	iMarket Asia Co., Ltd.	40.6
Samsung SDS Co., Ltd.	Samsung SDS Global SCL America, Inc.	100.0
Samsung SDS Co., Ltd.	SAMSUNG SDS GSCL Canada., Ltd.	100.0
Samsung SDS Co., Ltd.	Samsung SDS America, Inc.	100.0
Samsung SDS Co., Ltd.	Neo EXpress Transportation (NEXT), Inc.	51.0
Samsung SDS Co., Ltd.	Samsung SDS Europe, Ltd.	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Hungary, Kft.	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Slovakia, S.R.O.	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Poland Sp. Z.o.o.	100.0
Samsung SDS Co., Ltd.	Samsung GSCL Sweden AB	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL France SAS	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Greece Societe Anonyme	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Baltics, SIA	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Italy S.R.L. A Socio Unico	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global Supply Chain Logistics Spain S.L.U	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Netherlands Cooperatief U.A.	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Germany GmbH	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Austria GmbH	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Romania S.R.L	100.0
Samsung SDS Co., Ltd.	Samsung SDS Asia Pacific Pte, Ltd.	100.0
Samsung SDS Co., Ltd.	Samsung Data Systems India Private Limited	100.0
Samsung SDS Co., Ltd.	Samsung SDS India Private Limited	100.0
Samsung SDS Co., Ltd.	VASCO Supply Chain Solutions Private Limited	51.0
Samsung SDS Co., Ltd.	Samsung SDS Vietnam Co., Ltd.	100.0
Samsung SDS Co., Ltd.	PT. Samsung SDS Global SCL Indonesia	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Philippines Co., Ltd.Inc.	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Thailand Co.,Ltd	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Malaysia SDN.BHD.	100.0
Samsung SDS Co., Ltd.	SAMSUNG SDS Global SCL Australia Pty.,Ltd.	100.0
Samsung SDS Co., Ltd.	SDS-ACUTECH CO., Ltd.	50.0
Samsung SDS Co., Ltd.	ALS SDS Joint Stock Company	51.0
Samsung SDS Co., Ltd.	SDS-MP Logistics Joint Stock Company	51.0
Samsung SDS Co., Ltd.	Samsung SDS China Co., Ltd.	100.0
Samsung SDS Co., Ltd.	Samsung IT Services (Beijing) Co., Ltd.	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Hong Kong Co., Ltd.	100.0
Samsung SDS Co., Ltd.	SAMSUNG SDS Global SCL Egypt	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL South Africa (PTY) Ltd.	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Nakliyat ve Lojistik Anonim Sirketi	100.0
Samsung SDS Co., Ltd.	Samsung SDS Global Supply Chain Logistics Middle East DWC-LLC	100.0
Samsung SDS Co., Ltd.	Samsung SDS Latin America Solucoes Em Tecnologia Ltda.	99.7
Samsung SDS Co., Ltd.	SAMSUNG SDS Glogal SCL Latin America Logistica Ltda	99.7
Samsung SDS Co., Ltd.	INTE-SDS Logistics S.A. de C.V.	51.0
Samsung SDS Co., Ltd.	Samsung SDS Global SCL Rus Limited Liability Company	100.0
Miracom Inc Co., Ltd.	MIRACOM INC ASIA PACIFIC LIMITED	100.0
Samsung SDS Global SCL America, Inc.	Samsung SDS Latin America Solucoes Em Tecnologia Ltda.	0.3
Samsung SDS Global SCL America, Inc.	Samsung SDS Mexico, S.A. DE C.V.	99.0
Samsung SDS Global SCL America, Inc.	Samsung SDS Global SCL Panama S. A.	100.0
Samsung SDS Global SCL America, Inc.	Samsung SDS Global SCL Chile Limitada	100.0
Samsung SDS Global SCL America, Inc.	Samsung SDS Global SCL Peru S.A.C.	100.0
Samsung SDS Global SCL America, Inc.	Samsung SDS Global SCL Colombia S.A.S.	100.0
Samsung SDS Global SCL America, Inc.	SAMSUNG SDS Glogal SCL Latin America Logistica Ltda	0.3
Samsung SDS Europe, Ltd.	Samsung SDS Global SCL Netherlands Cooperatief U.A.	0.0
Samsung SDS Global SCL Netherlands Cooperatief U.A.	Samsung SDS Global SCL Poland Sp. Z.o.o.	0.0
Samsung SDS Global SCL Netherlands Cooperatief U.A.	Samsung SDS Global SCL Greece Societe Anonyme	0.0
Samsung SDS Global SCL Netherlands Cooperatief U.A.	Samsung SDS Global SCL Romania S.R.L	0.0
Samsung SDS Global SCL Netherlands Cooperatief U.A.	Samsung SDS Global SCL Rus Limited Liability Company	0.0

Investor	Investee	Share Ratio(%)
Samsung SDS China Co., Ltd.	Samsung SDS Global SCL Beijing Co., Ltd	100.0
Samsung IT Services (Beijing) Co., Ltd.	Samsung SDS Global Development Center Xi'an	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering America Inc.	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering Hungary Ltd.	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering Italy S.R.L.	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering (Malaysia) SDN. BHD.	100.0
Samsung Engineering Co., Ltd.	PT Samsung Engineering Indonesia Co., Ltd.	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering (Thailand) Co., Ltd.	81.0
Samsung Engineering Co., Ltd.	Samsung Engineering India Private Limited	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering Vietnam Co., Ltd.	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering Construction(Shanghai) Co., Ltd	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering Construction Xi'an Co., Ltd.	100.0
Samsung Engineering Co., Ltd.	Samsung Saudi Arabia Co., Ltd.	100.0
Samsung Engineering Co., Ltd.	Muharrag Wastewater Services Company W.L.L.	99.8
Samsung Engineering Co., Ltd.	Muharrag STP Company B.S.C.	6.6
Samsung Engineering Co., Ltd.	Muharrag Holding Company 1 Ltd.	65.0
Samsung Engineering Co., Ltd.	Samsung Ingenieria Mexico Construccion Y Operacion S.A. De C.V.	99.9
Samsung Engineering Co., Ltd.	Samsung Engineering Trinidad Co., Ltd.	100.0
Samsung Engineering Co., Ltd.	Samsung Ingenieria Manzanillo, S.A. De C.V.	99.9
Samsung Engineering Co., Ltd.	Grupo Samsung Ingenieria Mexico, S.A. De C.V.	100.0
Samsung Engineering Co., Ltd.	Samsung Ingenieria Energia S.A. De C.V.	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering Bolivia S.A	100.0
Samsung Engineering Co., Ltd.	Samsung Ingenieria DUBA S.A. de C.V.	100.0
Samsung Engineering Co., Ltd.	Samsung Engineering Kazakhstan L.L.P.	100.0
Samsung Engineering America Inc.	SEA Construction, LLC	100.0
Samsung Engineering America Inc.	SEA Louisiana Construction, L.L.C.	100.0
Samsung Engineering (Malaysia) SDN. BHD.	Muharrag Wastewater Services Company W.L.L.	0.3
Samsung Engineering India Private Limited	Samsung Saudi Arabia Co., Ltd.	0.0
Samsung Saudi Arabia Co., Ltd.	Samsung EPC Company Ltd.	75.0
Muharrag Holding Company 1 Ltd.	Muharrag Holding Company 2 Ltd.	100.0
Muharrag Holding Company 2 Ltd.	Muharrag STP Company B.S.C.	89.9
Samsung Ingenieria Manzanillo, S.A. De C.V.	Asociados Constructores DBNR, S.A. de C.V.	49.0
S-1 Corporation	S-1 CORPORATION HUNGARY LLC	100.0
S-1 Corporation	SOCM LLC	100.0
S-1 Corporation	S-1 CORPORATION VIETNAM CO., LTD	100.0
S-1 Corporation	Samsung Beijing Security Systems	100.0
Cheil Worldwide Inc.	PENGTAI INTERACTIVE ADVERTISING CO.,LTD	100.0
Cheil Worldwide Inc.	Cheil USA Inc.	100.0
Cheil Worldwide Inc.	Cheil Central America Inc.	100.0
Cheil Worldwide Inc.	Iris Worldwide Holdings Limited	100.0
Cheil Worldwide Inc.	CHEIL EUROPE LIMITED	100.0
Cheil Worldwide Inc.	Cheil Germany GmbH	100.0
Cheil Worldwide Inc.	Cheil France SAS	100.0
Cheil Worldwide Inc.	CHEIL SPAIN S.L	100.0
Cheil Worldwide Inc.	Cheil Benelux B.V.	100.0
Cheil Worldwide Inc.	Cheil Nordic AB	100.0
Cheil Worldwide Inc.	Cheil India Private Limited	100.0
Cheil Worldwide Inc.	Cheil (Thailand) Ltd.	100.0
Cheil Worldwide Inc.	Cheil Singapore Pte. Ltd.	100.0
Cheil Worldwide Inc.	CHEIL VIETNAM COMPANY LIMITED	99.0
Cheil Worldwide Inc.	Cheil Integrated Marketing Philippines, Inc.	100.0
Cheil Worldwide Inc.	CHEIL MALAYSIA SDN. BHD.	100.0
Cheil Worldwide Inc.	Cheil New Zealand Limited	100.0
Cheil Worldwide Inc.	CHEIL CHINA	100.0
Cheil Worldwide Inc.	Cheil Hong Kong Ltd.	100.0
Cheil Worldwide Inc.	Caishu (Shanghai) Business Consulting Co., Ltd	100.0
Cheil Worldwide Inc.	Cheil MEA FZ-LLC	100.0
Cheil Worldwide Inc.	Cheil South Africa (Pty) Ltd	100.0
Cheil Worldwide Inc.	CHEIL KENYA LIMITED	99.0
Cheil Worldwide Inc.	Cheil Communications Nigeria Ltd.	99.0
Cheil Worldwide Inc.	Cheil Worldwide Inc./Jordan LLC.	100.0
Cheil Worldwide Inc.	Cheil Ghana Limited	100.0
Cheil Worldwide Inc.	Cheil Egypt LLC	99.9
Cheil Worldwide Inc.	Cheil Brasil Comunicacoes Ltda.	100.0
Cheil Worldwide Inc.	Cheil Mexico, S.A. de C.V.	98.0
Cheil Worldwide Inc.	Cheil Chile SpA.	100.0
Cheil Worldwide Inc.	Cheil Peru S.A.C.	100.0
Cheil Worldwide Inc.	CHEIL ARGENTINA S.A.	98.0
Cheil Worldwide Inc.	Cheil Rus LLC	100.0
Cheil Worldwide Inc.	Cheil Ukraine LLC	100.0
Cheil Worldwide Inc.	Cheil Kazakhstan LLC	100.0

Investor	Investee	Share Ratio(%)
Hotel Shilla Co., Ltd.	Samsung Hospitality America Inc.	100.0
Hotel Shilla Co., Ltd.	Shilla Travel Retail Pte. Ltd.	100.0
Hotel Shilla Co., Ltd.	Samsung Shilla Business Service Beijing Co., Ltd.	100.0
Hotel Shilla Co., Ltd.	Shilla Travel Retail Hong Kong Limited	100.0
Hotel Shilla Co., Ltd.	Shilla Travel Retail Taiwan Limited	64.0
HDC Shilla Duty Free Ltd.	HDC SHILLA (SHANGHAI) CO., LTD	100.0
SBTM Co., Ltd.	Samsung Hospitality U.K. Inc.	100.0
SBTM Co., Ltd.	Samsung Hospitality Europe GmbH	100.0
SBTM Co., Ltd.	SAMSUNG HOSPITALITY ROMANIA SRL	100.0
SBTM Co., Ltd.	Samsung Hospitality Vietnam Co., Ltd.	99.0
SBTM Co., Ltd.	Samsung Hospitality Philippines Inc.	100.0
SBTM Co., Ltd.	Samsung Hospitality India Private Limited	100.0
Iris Americas, Inc.	Iris (USA) Inc.	100.0
Iris Americas, Inc.	Iris Atlanta, Inc.	100.0
Iris Americas, Inc.	Iris Experience, Inc.	100.0
Iris Americas, Inc.	Iris Latin America, Inc.	100.0
Iris Americas, Inc.	Iris Worldwide San Diego, Inc.	100.0
Iris Americas, Inc.	89 Degrees, Inc.	100.0
Iris Latin America, Inc.	Irisnation Latina No.2, S. de R.L. de C.V.	0.0
Iris Latin America, Inc.	Irisnation Latina, S. de R.L. de C.V.	0.0
Iris Canada Holdings Ltd	Pricing Solutions Ltd	100.0
Cheil USA Inc.	The Barbarian Group LLC	100.0
Cheil USA Inc.	McKinney Ventures LLC	100.0
Cheil USA Inc.	Cheil India Private Limited	0.0
Cheil USA Inc.	Cheil Mexico, S.A. de C.V.	2.0
Iris Worldwide Holdings Limited	Iris Nation Worldwide Limited	100.0
Iris Nation Worldwide Limited	Iris Americas, Inc.	100.0
Iris Nation Worldwide Limited	Irisnation Latina No.2, S. de R.L. de C.V.	100.0
Iris Nation Worldwide Limited	Irisnation Latina, S. de R.L. de C.V.	100.0
Iris Nation Worldwide Limited	Iris Canada Holdings Ltd	100.0
Iris Nation Worldwide Limited	Iris London Limited	100.0
Iris Nation Worldwide Limited	Iris Promotional Marketing Ltd	100.0
Iris Nation Worldwide Limited	Iris Ventures 1 Limited	98.6
Iris Nation Worldwide Limited	Founded Partners Limited	100.0
Iris Nation Worldwide Limited	Iris Products (Worldwide) Limited	100.0
Iris Nation Worldwide Limited	Iris Korea Limited	100.0
Iris Nation Worldwide Limited	Iris Digital Limited	100.0
Iris Nation Worldwide Limited	Iris Amsterdam B.V.	100.0
Iris Nation Worldwide Limited	Datalytics Limited	100.0
Iris Nation Worldwide Limited	Iris Ventures (Worldwide) Limited	100.0
Iris Nation Worldwide Limited	Iris Culture Limited	100.0
Iris Nation Worldwide Limited	Concise Consultants Limited	100.0
Iris Nation Worldwide Limited	Atom42 Ltd	100.0
Iris Nation Worldwide Limited	WDMP Limited	49.0
Iris Nation Worldwide Limited	Pricing Solutions (UK) Limited	100.0
Iris Nation Worldwide Limited	Iris Services Limited Doel Skopje	100.0
Iris Nation Worldwide Limited	Irisnation Singapore Pte. Ltd.	100.0
Iris Nation Worldwide Limited	Iris Worldwide Integrated Marketing Private Limited	100.0
Iris Nation Worldwide Limited	Iris Sydney PTY Ltd	100.0
Iris Nation Worldwide Limited	Iris Worldwide (Thailand) Limited	100.0
Iris Nation Worldwide Limited	Iris Beijing Advertising Company Limited	100.0
Iris Nation Worldwide Limited	Irisnation Hong Kong Limited	100.0
Iris London Limited	Iris Partners LLP	100.0
Iris Promotional Marketing Ltd	Holdings BR185 Limited	100.0
Iris Ventures 1 Limited	Iris Germany GmbH	100.0
Founded Partners Limited	Founded, Inc.	100.0
Iris Germany GmbH	Pepper NA, Inc.	100.0
Iris Germany GmbH	Pepper Technologies Pte. Ltd.	100.0
CHEIL EUROPE LIMITED	Beattie McGuinness Bungay Limited	100.0
CHEIL EUROPE LIMITED	Cheil Italia S.r.l	100.0
Cheil Germany GmbH	Cheil Austria GmbH	100.0
Cheil Germany GmbH	Centrade Integrated SRL	80.0
Centrade Integrated SRL	Centrade Cheil HU Kft.	100.0
Centrade Integrated SRL	Centrade Cheil Adriatic D.O.O.	100.0
Cheil India Private Limited	Experience Commerce Software Private Limited	100.0
Cheil Singapore Pte. Ltd.	Pengtai Greater China Company Limited	95.7
Cheil Singapore Pte. Ltd.	PT. CHEIL WORLDWIDE INDONESIA	100.0
Cheil Integrated Marketing Philippines, Inc.	Cheil Philippines Inc.	30.0
Cheil Hong Kong Ltd.	Pengtai Greater China Company Limited	3.1
Samsung Shilla Business Service Beijing Co., Ltd.	Tianjin Samsung International Travel Service Co., Ltd	100.0
Shilla Travel Retail Hong Kong Limited	Shilla Retail Limited	100.0
Shilla Travel Retail Hong Kong Limited	Shilla Travel Retail Duty Free HK Limited	100.0
Cheil MEA FZ-LLC	One Agency FZ-LLC	100.0

Investor	Investee	Share Ratio(%)
Cheil MEA FZ-LLC	One RX Project Management Design and Production Limited Company	0.0
Cheil MEA FZ-LLC	Cheil Egypt LLC	0.1
Cheil South Africa (Pty) Ltd	CHEIL KENYA LIMITED	1.0
Cheil South Africa (Pty) Ltd	Cheil Communications Nigeria Ltd.	1.0
One Agency FZ-LLC	One RX India Private Limited	100.0
One Agency FZ-LLC	One RX Project Management Design and Production Limited Company	100.0
One Agency FZ-LLC	ONE RX INTERIOR DECORATION L.L.C	100.0
One Agency FZ-LLC	ONE AGENCY PRINTING L.L.C	100.0
One Agency FZ-LLC	One Agency South Africa (Pty) Ltd	100.0
ONE RX INTERIOR DECORATION L.L.C	One RX India Private Limited	0.0
Holdings BR185 Limited	Brazil 185 Participacoes Ltda	100.0
Brazil 185 Participacoes Ltda	Iris Router Marketing Ltda	100.0
Cheil Brasil Comunicacoes Ltda.	CHEIL ARGENTINA S.A.	2.0

B. Investments in other companies

(As of Dec 31, 2020)

(Unit: million won, thousand shares, %)

Name of company	Acquisition date	Purpose of Investment	Acquisition cost	Beginning balance			Increase(decrease)			Ending balance			Financial status in recent business year	
				Volume	Share ratio	Book value	Acquisition (disposal)		Gain (loss) on valuation	Volume	Share ratio	Book value	Total assets	Net profit (loss)
							Volume	Amount						
Samsung Bioepis Co., Ltd. (unlisted)	2012.02.28	Joint venture	139,995	10,342	50.00	517,100	-	-	-	10,342	50.00	517,100	2,618,003	137,963
Archigen Biotech Ltd. (unlisted)	2014.06.23	Joint venture	71,372	131,000	50.00	2,766	-	-	-2,766	131,000	50.00	-	4,596	-8,133
Samsung Biologics America, Inc. (unlisted)	2020.03.09	Securing an overseas base, etc.	11,914	-	-	-	10	11,914	-	10	100.00	11,914	15,398	45
Total				-	-	519,866	-	11,914	-2,766	-	-	529,014	-	-

※ Book value is based on separate financial statements.

※ In September 2020, Samsung Biologics and AstraZeneca decided to discontinue R&D activities of Archigen Biotech Limited, a joint venture.

C. Interlocking executive

For the details of interlocking executive, refer to VIII. Matters Regarding Executives and Employees - 1. Executives and employees - C. Interlocking executive.

X. Transactions with Stakeholders (Related Party Transactions)

1. Credit offerings for affiliates and subsidiaries

A. Provisional payments and loans (incl. securities loan)

(Unit: million won)

Name (Company)	Relationship	Type of transaction	Date of transaction	Purpose of transaction	Transactions					Credit	
					Beginning of period	Increase	Decrease	End of period	Deferred interest	Maturity date	Interest
John Rim	Related Party	Loans	2020.07.20	Housing fund	-	300	-	300	6	2022.08.02	4.6%

B. Collateral provided

Not applicable

C. Debt guarantee

Not applicable

2. Acquisitions and disposals of assets with affiliates and subsidiaries

A. Acquisitions and disposals of assets

Not applicable as of the date when the Company's annual report is submitted.

B. Purchase or sale of securities

Not applicable as of the date when the Company's annual report is submitted.

C. Investment and disposal of invested shares

(Unit: million won)

Name (Company)	Relation	Type of transaction	Date of transaction	Item of transaction	Face value	Transaction amount
Samsung Biologics America, Inc.	Affiliate	Initial investment	2020.03.09	Common stocks	\$1,000	11,914 (\$10,000,000)

3. Business transactions with affiliates and subsidiaries

(Unit: billion won)

Name	Relation	Type of transaction	Contract period	Contract details	Contract amount
Samsung Bioepis Co., Ltd.	Affiliate	Sales, etc.	2020.01 ~ 2020.12	Product/raw materials etc.	261.6

※ Total contract amount is worth 5% or above of the Company's revenue in 2020

4. Transactions with stakeholders other than affiliates and subsidiaries

Not applicable as of the date when the Company's annual report is submitted.

XI. Other Information

1. Public disclosure and shareholder meetings

A. Progress and change of notices

Disclosure date	Title	Details	Progress
2016.11.16	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 291,788,251.79 - Counterpart: Cilag GmbH International - Contract period: 2016.11.15 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2017.07.04	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 55,513,715 - Counterpart: Sun Pharma Global FZE - Contract period: 2017. 7. 4 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2017.07.21	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 14,944,000 - Counterpart: Pharmaceutical company in Europe - Contract period: 2017. 7. 20 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2017.11.08	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 7,212,800 - Counterpart: Checkpoint Therapeutics, Inc., - Contract period: 2017. 11. 8 ~ 2022. 11. 9 	In progress
2017.12.21	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 41,654,000 - Counterpart: UCB - Contract period: 2017. 12. 21 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2018.02.22	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 22,443,000 - Counterpart: Pharmaceutical company in US - Contract period: 2018. 2. 21 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2018.04.30	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 381,939,752 - Counterpart: Pharmaceutical company in Swiss - Contract period: 2018. 4. 30 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress

2018.06.01	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 15,097,201 - Counterpart : Pharmaceutical company in Europe - Contract period: 2017. 9. 5 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2018.08.14	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 127,555,800 - Counterpart : Pharmaceutical company in Asia - Contract period: 2018. 8. 14 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2018.09.12	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 163,514,000 - Counterpart : Immunomedics, Inc. - Contract period: 2018. 9. 11 ~ 2025. 12. 31 	In progress
2019.04.01	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 31,274,225 - Counterpart : Cytodyn Inc. - Contract period: 2019. 4. 1 ~ 2027.12.31 	In progress
2019.04.26	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 31,985,200 - Counterpart : Pharmaceutical company in Asia - Contract period: 2019. 4. 26 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2019.04.26	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 17,142,200 - Counterpart : Pharmaceutical company in Asia - Contract period: 2019. 4. 26 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2019.05.14	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 29,769,800 - Counterpart : Pharmaceutical company in Asia - Contract period: 2019. 5. 14 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2019.05.17	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 33,829,763 - Counterpart : UCB - Contract period: 2019. 5. 17 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2019.11.28	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 19,129,700 - Counterpart : Pharmaceutical company in Asia - Contract period: 2019. 11. 28 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress

		date is reserved.	
2019.12.03	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 46,758,000 - Counterpart : Pharmaceutical company in US - Contract period: 2019. 12. 3 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2019.12.24	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 45,046,496.80 - Counterpart : Pharmaceutical company in Swiss - Contract period: 2019. 12. 24 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2020.05.22	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount : USD 231,252,125 - Counterpart: GlaxoSmithKline Trading Services Limited - Contract period: 2020. 5. 21 ~ 2027. 12 31 	In progress
2020.06.06	Material Management Information related to Judgment of Investment	<ul style="list-style-type: none"> ◦ Overview - Signed the binding letter of intent regarding outsourced drug manufacturing - Contract amount : USD 202,261,032 - Counterpart : Pharmaceutical company in Swiss - Contract period: 2020. 6. 6 ~ Contract end date ※ The disclosure of the confidential details of contract end date is reserved. 	In progress
2020.06.06	Material Management Information related to Judgment of Investment	<ul style="list-style-type: none"> ◦ Overview - Signed the binding letter of intent regarding outsourced drug manufacturing - Contract amount : USD 35,530,000 - Counterpart : Pharmaceutical company in Swiss - Contract period: 2020. 6. 6 ~ Contract end date ※ The disclosure of the confidential details of counterpart & contract end date is reserved. 	In progress
2020.07.20	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 15,990,586 - Counterpart: H. Lundbeck A/S - Contract period: 2019. 9. 27 ~ Contract end date ※ The disclosure of the confidential details of counterpart & contract end date is reserved. 	In progress
2020.07.28	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 149,999,994 - Counterpart: Pharmaceutical company in US - Contract period: 2020. 7. 21 ~ Contract end date ※ The disclosure of the confidential details of counterpart & contract end date is reserved. 	In progress

2020.08.04	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 18,864,580 - Counterpart: Pharmaceutical company in US - Contract period: 2018. 12. 18 ~ 2021. 12. 31 ※ The disclosure of the confidential details of counterpart is reserved. 	In progress
2020.08.05	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 368,136,568 - Counterpart: GlaxoSmithKline Trading Services Limited - Contract period: 2020. 4. 9 ~ 2022. 12. 31 	In progress
2020.09.22	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 314,822,300 - Counterpart: AstraZeneca UK Ltd., - Contract period: 2020. 6. 23 ~ 2028.12.31 	In progress
2020.09.22	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 16,018,000 - Counterpart: AstraZeneca UK Ltd., - Contract period: 2020. 9. 21 ~ 2023.12.31 	In progress
2020.10.06	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 19,713,000 - Counterpart: Checkpoint Therapeutics, Inc., - Contract period: 2020. 10. 02 ~ 2030. 10. 02 	In progress
2020.11.03	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 16,110,700 - Counterpart: ImmunoGen, Inc. - Contract period: 2020. 10. 28 ~ 2030.12.31 	In progress
2020.11.09	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 51,458,000 - Counterpart: FibroGen, Inc. - Contract period: 2020. 9. 18 ~ 2022.12.31 	In progress
2021.01.15	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 202,261,032 - Counterpart: F.Hoffmann-La Roche Ltd - Contract period: 2020. 6. 1 ~ 2024.12.31 	In progress
2021.01.15	Entering into Single Sales or Supply Contract	<ul style="list-style-type: none"> ◦ Overview - Contract name: Outsourced drug manufacturing - Contract amount: USD 35,530,000 - Counterpart: F.Hoffmann-La Roche Ltd - Contract period: 2020. 6. 1 ~ 2024.12.31 	In progress

B. Summary of results of shareholder meetings

Date of meeting	Agenda	Resolution
2013.02.14	- Appointment of auditors	Pass
2013.03.29	- Approval of financial statements for the 2 nd accounting period - Approval of compensation limit of directors - Adoption of the executive severance pay rules - Alteration of the articles of incorporation	Pass
2014.03.27	- Approval of financial statements for the 3 rd accounting period - Appointment of directors - Approval of the compensation limit of directors	Pass
2014.10.08	- Appointment of auditors	Pass
2015.03.27	- Approval of financial statements for the 4 th accounting period - Approval of directors - Approval of compensation limit of directors	Pass
2016.03.30	- Approval of financial statements for the 5 th accounting period - Appointment of directors - Approval of compensation limit of directors - Report the appointment of independent directors	Pass
2016.08.10	- Approval of stock split - Approval of the articles of incorporation - Appointment of directors - Appointment of the members of Audit committee	Pass
2017.03.24	- Approval of financial statements for the 6 th accounting period - Appointment of directors - Approval of compensation limit of directors	Pass
2018.03.22	- Approval of financial statements for the 7 th accounting period - Approval of compensation limit of directors	Pass
2019.03.22	- Approval of financial statements for the 8 th accounting period - Change of the articles of incorporation - Appointment of directors - Appointment of Members of Audit Committee - Approval of compensation limit of directors	Pass
2020.03.20	- Approval of financial statements for the 9 th accounting period - Appointment of directors - Approval of compensation limit of directors	Pass

2. Contingent liability, etc.

A. Important litigations

The Company's on-going litigations are as follows:

Plaintiff	Defender	Details	Status
Samsung Biologics Co., Ltd.	Securities & Futures Commission	On October 8, 2018, the Company filed administrative litigation in the Seoul Administrative Court to withdraw the measure recommended by the Securities & Futures Commission to designate an auditor to the Company for three years and dismiss the responsible officer regarding that the details of the joint venture agreement are not stated in the notes to the financial statements.	The Seoul Administrative Court ruled to cancel the Securities and Futures Commission's administrative disposition imposed on SBL on September 24th, 2020.

Plaintiff	Defender	Details	Status
Samsung Biologics Co., Ltd.	Securities & Futures Commission, Financial Services Commission	On November 28, 2018, the Company filed administrative litigation in the Seoul Administrative Court to withdraw the measure recommended by the Securities & Futures Commission to designate an auditor to the Company for three years and dismiss the responsible officer regarding that the details of the joint venture agreement are not stated in the notes to the financial statements as well as the measure ordered by the Financial Services Commission to rewrite the financial statements (2012~2018.6.30) and subsequently impose a fine of KRW 8 billion.	Legal procedures in progress after the litigation was filed in the Seoul Administrative Court on November 27, 2018.
355 people	Samsung Biologics Co., Ltd. and 4	On April 29, 2019, 355 people filed a suit in the Seoul Central District Court for damages against the company and 4 other parties.(Amount : KRW 8,449,205,474) The plaintiffs claimed that they have experienced financial losses, for the Company disclosed business reports with false information against the accounting standards.	Legal procedures in progress after a suit was filed in the Seoul Central District Court on April 29, 2019.
32 people	Samsung C&T Corporation and 19	32 people filed a suit in the Seoul Central District Court for damages against Samsung C&T Corporation and 19. (Amount: KRW 200,320,000) The plaintiffs claimed that they have experienced financial losses, for the Company concealed important information regarding its control over Samsung Bioepis Co., Ltd., and that resulted in an unfair swap ratio between Samsung C&T and Cheil Industries.	Legal procedures in progress after a suit was filed in the Seoul Central District Court on February 17, 2020.
9 people	Samsung Biologics Co., Ltd.	9 people filed a suit in the Incheon District Court for damages against the Company. (Amount: KRW 437,944,500) The plaintiffs claimed that they have experienced financial losses in form of a decline in stock price, for the Company applied equity method of accounting against the accounting standards.	Legal procedures in progress after a suit was filed in the Incheon District Court on March 4, 2020
Company Y and 18	Samsung C&T Corporation and 23	Company Y and 18 other parties filed a suit in the Seoul Central District Court for damages against Samsung C&T Corporation and 23. (Amount: KRW 209,000,000) The plaintiffs claimed that they have experienced financial losses, for the Company concealed important information regarding its control over Samsung Bioepis Co., Ltd., and that resulted in an unfair swap ratio between Samsung C&T and Cheil Industries.	Legal procedures in progress after a suit was filed in the Seoul Central District Court on January 21, 2021.

On December 17, 2020, Biogen Therapeutics Inc. ("Biogen") has requested for arbitration in the Court of International Chamber of Commerce against Samsung Biologics Co., Ltd. ("SBL") regarding interpretation of certain provision in joint venture agreement executed on 6 December 2011 by and between Biogen and SBL. It is difficult to predict the result of the arbitration, but Biogen has not claimed any damages against SBL."

B. Details of promissory note and check for guarantee

- Not applicable

C. Details of collateral provided and debt guarantee

- Not applicable

D. Debt obligation purchase agreement

- Not applicable

E. Other contingent liabilities**(1) Major agreements with financial institutions**

Loan commitments signed with financial institutions as of the end of 2020 are as follows:

(Unit: thousand won, thousand dollar)

Bank	Type	Limits		Execution amount	
		Currency	Amount	Currency	Amount
Woori Bank	Overdraft	KRW	10,000,000	KRW	-
	B2B Plus	KRW	5,760,000	KRW	-
	General purpose loan	KRW	30,000,000	KRW	
	Facility investment loan	KRW	70,000,000	KRW	70,000,000
	Facility investment loan	KRW	50,000,000	KRW	50,000,000
	Facility investment loan	KRW	200,000,000	KRW	50,000,000
KEB Hana Bank	Overdraft	KRW	10,000,000	KRW	-
	Facility investment loan	KRW	50,000,000	KRW	50,000,000
	Facility investment loan	KRW	49,300,000	KRW	100,000
	Combined limit	KRW	40,000,000	KRW	-
	Facility loans in Fcy	USD	30,000	USD	30,000
Shinhan Bank	General purpose loan	KRW	19,214,000	KRW	-
	Overdraft	KRW	10,000,000	KRW	-
	Facility investment loan	KRW	70,000,000	KRW	70,000,000
Mizuho Bank	Facility investment loan	KRW	70,000,000	KRW	70,000,000
	Facility investment loan	KRW	28,000,000	KRW	28,000,000
	Facility investment loan	KRW	100,000,000	KRW	100,000,000
	Facility investment loan	USD	10,000	USD	10,000
Sumitomo Mitsui Banking Corporation	General purpose loan	KRW	30,000,000	KRW	30,000,000
	Facility loans in Fcy	USD	10,000	USD	10,000

Details of guarantees provided from financial institutions at the end of 2020 are as follows:

(Unit: thousand won, thousand dollar)

Bank	Type	Limits		Payment guarantee	
		Currency	Amount	Currency	Amount
Woori Bank	Confirmed guarantees in Won	KRW	9,500,000	KRW	2,931,891
Shinhan Bank	Commitments on import L/C issuance	USD	10,000	USD	-
	Confirmed guarantees in Won	USD	10,000	USD	-
Kookmin Bank	Confirmed guarantees in Fcy	KRW	30,000,000	USD	-

If the Company does not comply with the commitments below, financial institutions may require an early redemption of long-term borrowings. Details of debt covenants related to long-term borrowings with financial institutions as of December 31, 2020 are as follows:

Financial institution	Remarks	Details of covenants
Sumitomo Mitsui Bank	Shareholder composition ratio	The ownership of the Samsung Group shall be over 50%, and Samsung C&T Corporation shall maintain its ownership in the Company in excess of 30%.
Mizuho Bank, Ltd	Shareholder composition ratio	The ownership of the Samsung Group (Samsung C&T Corporation and Samsung Electronics Co., Ltd.) shall be over 60% of the voting rights stock

(2) Free land use rights

The Company is exempted from all rental fees on land usage by meeting the requirements for rent reductions provided by the Public Asset Management Ordinance of Incheon Metropolitan City when the Company concluded a contract to lease the land with Incheon Metropolitan City. The Company recognized the fair value of the exempted rental fee from Incheon Metropolitan City as intangible asset, and booked the same amount as deduction of assets in the account of government grants. The free land lease period and the requirements for full exemption are as follows:

① Land lease period

Total land lease period is 50 years with the initial period of 20 years from April 28, 2011 when the land lease contract was concluded and every 10 years of renewal afterwards.

② Requirements for exemption

The Company whose foreign investment amounts to more than USD 20 million is subject to the exemption from the Common Property Management Ordinance of Incheon. After that, the Company, including foreign-invested enterprises that meet the average daily employee count of above 300, is subject to an exemption.

(3) A suit for damages from stock trading

On April 29, 2019, 354 people, including Kang, have filed a lawsuit against Samsung Bioepis investment stock accounting (see Note 35), which is currently pending, and the value of the suit is 8,449 million won.

(4) Provision for acquisition of tangible/non-tangible assets

As of the Reporting Date, provision for the acquisition of tangible/non-tangible assets amounts to KRW 1,085 billion, where KRW 720 billion is regarding contracts with related parties including Samsung Engineering.

3. Other matters including sanctions

A. Sanctions

- The company did not have safety training for people handling hazardous chemicals according to Article 33 of the Chemical Management Act. April 30, 2018 from the Korea Chemical Safety Institute the company was fined (KRW 1,440,000) and paid the above fine. The Company is making efforts to prevent any similar violations, such as reinforcing monitoring.

- On July 12, 2018, the Securities & Futures Commission("SFC") announced its ruling according to the Act on External Audit of Stock Companies against the Company for failing to disclose information regarding the joint venture agreement between Biogen Therapeutics Inc. in the public disclosure. In order to prove unfairness of the decisions and actions taken by The Securities and Futures Commission on October 10, 2018, the company filed a lawsuit for cancellation of dispositions, such as dismissal of executives on October 7, 2018. (Seoul Administration Court)

The Seoul Administrative Court ruled to cancel the Securities and Futures Commission's administrative disposition imposed on SBL and decided to suspend the above disposition until the appellate court's ruling on September 24, 2020.

- On November 14, 2018 the SFC announced its ruling according to the Act on External Audit of Stock Companies against the Company for violating accounting standards by inappropriately applying consolidated method regarding investments in Samsung Bioepis. In order to prove unfairness of the decisions and actions taken by The Securities and Futures Commission and Financial Supervisory Service, the company filed a lawsuit for cancellation of dispositions, such as rewriting of financial statements on November 27th of 2018. (Seoul Administration Court)

B. Failure in disgorgement of short-term sales margin

The Company has not been notified of the occurrence of short-term sales margin as of the date when disclosure documents for the past three business years and this business year were prepared, from the Securities and Futures Commission (Chairman of the Financial Services Commission).

C. Important matters occurred after the document preparation reference date

D. Use of direct financing funds

(1) Use of public offering funds

(As of Dec 31, 2020)

(Unit: million won)

Category	No.	Payment date	Amount paid	Fund use plan	Actual fund use	Reason for difference
-		-	-	-	-	-

(2) Use of private placement funds

The company has issued private equity bonds with no name in the name of the bearer through the resolution of the Board of Directors.

For more information, please refer to 6. Other financial matters, the details of the debt securities issue are as follows:

(As of Dec 31, 2020)

(Unit: million won)

Category	No.	Payment date	Fund use plan		Actual fund use		Reason for difference
			Fund use	Amount paid	Fund use	Amount paid	
Corporate Bond	6-1	2018.04.27	Facility fund(Plant construction & facility Purchase)	150,000	Facility fund(Plant construction & facility Purchase)	150,000	-
Corporate Bond	6-2	2018.04.27	Facility fund(Plant construction & facility Purchase)	40,000	Facility fund(Plant construction & facility Purchase)	150,000	

E. Subsidiaries of overseas holding company

- Not applicable

F. Changes in legal risks

- Not applicable

G. Matters regarding the depositor protection of financial institutions

- Not applicable

H. Satisfaction with the requirements of special purpose acquisition company

- Not applicable

I. Roles and obligations as a financial investment business of special purpose acquisition company

- Not applicable

J. Follow-up information including mergers

☐ Transfer of Samsung Bioepis investment stock (Exit date : November 7, 2018)

(1) Issuing Company

- Company Name : Samsung Bioepis Co., Ltd.
- Location : Chumdang-daero 107(Songdo-dong), Yeonsu-gu Incheon City, South Korea
- CEO : Ko Christopher Hansung

(2) Counterparty

- Company Name : Biogen Therapeutics Inc..
- Location : 225 Binney Street, Cambridge, MA 02142, United States of America
- CEO : Michel Vounatsos

(3) Contract Information

Biogen Therapeutics Inc. had a call option that allows it to purchase up to 50%-1 shares of Samsung Bioepis under an agreement between shareholders on December 6th of 2011. On June 29th of 2018, Biogen Therapeutics Inc. exercised call option, and on November of 7th, the transfer of shares and payments were completed.

- Transfer Shares : 9,226,068 Shares (44.6%)
- Transfer Purpose : Exercise of call option by Biogen Therapeutics Inc.
- Exercising Date : March 29, 2018 (Korean Time)
- Key Dates

Category	Dates
Contract Between Shareholders	2011.12.06
Evaluation of external evaluation agencies	2018.06.22 ~ 2018.06.29
Key item report submission date	2018.06.29
Transfer of shares and payment date	2018.11.07

More details on the above asset transfer transactions can be found in the “Key Items Report” released by the Company on the Financial Supervisory Service e-Disclosure website (<http://dart.fss.or.kr>).

Please refer to the footnotes on business combinations in the financial statements for other key business combinations.

K. Green management

The Company is making efforts to meet the government's green growth policy through greenhouse-gas/energy reduction activities, water reuse, waste resource circulation, environmental performance evaluation, and management in order to establish a green management system and take full responsibility as an eco-friendly company. The Company is also doing its best to preserve the environment through continued management of environmental management indicators and discloses relevant information to its stakeholders in a transparent manner.

The Company's management indicators by each environmental area for the last 3 years are listed below. The Company will report the performance in Water Resource/ Waste/ Containment Management following environmental information disclosure.

[Greenhouse Gas & Energy]

	Unit	2017	2018	2019	2020
Greenhouse Gas Emission	tCO2e	85,314	116,579	119,791	124,807
Energy Consumption	TJ	1,726	2,360	2,427	2,529

[Water Resources Management]

	Unit	2017	2018	2019
Water Usage	Ton	964,362	1,151,697	1,165,548
Wastewater Discharge	Ton	676,406	893,213	1,098,667
Water Reuse	Ton	-	3,910	3,588
Water Reuse Rate	%	-	0.34	0.31

Note 1) In December 2017, New water reuse facility installation

[Waste Management]

	Unit	2017	2018	2019
General Waste Discharge	Ton	2,893	4,288	4,713
Designated Waste Discharge	Ton	102	116	155
Water Recycling	Ton	90	3,203	3,705
Recycling Rate	%	3.01	72.72	76.09

[Contaminant Management]

	Unit	2017	2018	2019
Air Pollutant(NOx)	Ton	13,429	19,338	19,201
Water Pollutant(Note 1)	Ton	33	48	41

Hazardous Chemical Substances	Ton	1,061	1,714	2,680
-------------------------------	-----	-------	-------	-------

Note1) Water Pollutant: COD, SS, T-N, T-P

L. Government Certification and Cancellation

☐ AEO (Export Division of Excellent Import and Export Safety Management Company)

-Related laws: Article 255-2 of the 「Customs Act」 , Article 259-2 and Article 259-3 of the Enforcement Decree of the Customs Act

-Certification Department: Korea Customs Service

-Date of Certification: Oct 15, 2018

-Validity period: Oct 15, 2018 ~ Oct 14, 2023

☐ AEO (Import Division of Excellent Import and Export Safety Management Company)

-Related laws: Article 255-2 of the 「Customs Act」 , Article 259-2 and Article 259-3 of the Enforcement Decree of the Customs Act

-Certification Department: Korea Customs Service

-Date of Certification: Apr 1, 2019

-Validity period: Apr 1, 2019 ~ Mar 31, 2024

☐ Best Family Friendly Management

-Related laws: Act on Development of Family Friendly Environment

-Certification Department: Ministry of Gender Equality and Family

-Date of Certification: Dec 1, 2020

-Validity period: Dec 1, 2020 ~ Nov 30, 2023

M. Status of safe deposit of securities certificates

- Not applicable

[Confirmation by Expert]

1. Confirmation by expert

- Not applicable

2. Expert's relations

- Not applicable